Carvedilol protects doxorubicin induced cardiomyopathy
carvedilol protects dysfunction associated toxicity
doxorubicin toxicity
carvedilol protection afford minimizing limiting dysfunction cardiomyopathy
doxorubicin therapy accompanies dysfunction mitochondrial
doxorubicin therapy accompanies dysfunction
doxorubicin therapy patients cancer
carvedilol protection afford minimizing limiting dysfunction accompanies therapy patients cancer
carvedilol protection afford minimizing limiting dysfunction mitochondrial
carvedilol protection afford minimizing limiting dysfunction
indinavir therapy undergoing causing obstruction ureteric
indinavir therapy undergoing causing obstruction
indinavir receiving describe HIV
indinavir receiving patients infected
indinavir associated incidence urolithiasis
indinavir crystals caused obstruction Ureteric
indinavir crystals caused obstruction
indinavir therapy receive patients enable diagnosis stones ureteric
indinavir therapy receive patients enable diagnosis stones
indinavir therapy receive patients enable diagnosis stones or
indinavir therapy receive patients enable diagnosis stones obstruction
indinavir therapy receive patients infection HIV
indinavir therapy receive patients infection
pilsicainide received convert fibrillation atrial
pilsicainide received convert fibrillation
sodium blocker pilsicainide received convert fibrillation atrial
sodium blocker pilsicainide received convert fibrillation
sodium blocker pilsicainide received developed death sudden
sodium blocker pilsicainide received developed death cardiac
sodium blocker pilsicainide received developed death
pilsicainide effective terminate fibrillation atrial
pilsicainide effective terminate fibrillation
terbinafine metoprolol drug induced report bradycardia sinus
terbinafine metoprolol drug induced report bradycardia
metoprolol drug induced report bradycardia sinus
metoprolol drug induced report bradycardia
metoprolol 200 man mg year day prescribed onychomycosis
terbinafine mg course 90 prescribed day disease coronary
terbinafine mg course 90 prescribed day disease artery
terbinafine mg course 90 prescribed day disease
terbinafine mg course 90 prescribed onychomycosis
metoprolol 200 man mg year day disease coronary
metoprolol 200 man mg year day disease artery
metoprolol 200 man mg year day disease
terbinafine therapy day brought room decrease status confusion
terbinafine metoprolol interaction relationship indicates score 7 scale adverse
terbinafine metoprolol interaction relationship indicates score 7 scale drug
terbinafine metoprolol interaction relationship indicates score 7 scale reaction
terbinafine metoprolol interaction relationship bradycardia sinus
terbinafine metoprolol interaction relationship bradycardia
metoprolol interaction relationship indicates score 7 scale adverse
metoprolol interaction relationship indicates score 7 scale drug
metoprolol interaction relationship indicates score 7 scale reaction
metoprolol interaction relationship bradycardia sinus
metoprolol interaction relationship bradycardia
terbinafine decreased clearance leading accumulation resulted bradycardia sinus
terbinafine decreased clearance leading accumulation resulted bradycardia
metoprolol clearance leading accumulation resulted bradycardia sinus
metoprolol clearance leading accumulation resulted bradycardia
metoprolol accumulation resulted bradycardia sinus
metoprolol accumulation resulted bradycardia
creatinine levels augment affect ability induce injury acute
creatinine levels augment affect ability induce injury kidney
creatinine levels augment affect ability induce injury
urea creatinine levels augment affect ability induce injury acute
urea creatinine levels augment affect ability induce injury kidney
urea creatinine levels augment affect ability induce injury
urea creatinine levels augment affect increase score acute
urea creatinine levels augment affect increase score tubular
urea creatinine levels augment affect increase score necrosis
creatinine levels augment affect increase score acute
creatinine levels augment affect increase score tubular
creatinine levels augment affect increase score necrosis
cisplatin involved induced mediating process necrotic
cisplatin therapy induced nephrotoxicity
dexmedetomidine administration year syncope
aminoglycosides trials indicate ranges risk developing failure acute
aminoglycosides trials indicate ranges risk developing failure renal
aminoglycosides trials indicate ranges risk developing failure
aminoglycoside levels therapy disease liver
aminoglycoside levels therapy disease
creatinine clearance therapy duration increase risk nephrotoxicity
creatinine clearance therapy disease liver
creatinine clearance therapy disease
Levodopa induced improved dyskinesias
dopamine agonist challenge evaluated severity disability motor
dopamine agonist challenge evaluated severity disability
dopamine agonist challenge evaluated severity dyskinesias patients disease Parkinson
dopamine agonist challenge evaluated severity dyskinesias patients disease Parkinson '
dopamine agonist challenge evaluated severity dyskinesias patients disease s
dopamine agonist challenge evaluated severity dyskinesias patients disease
fluoxetine administration apomorphine agonist challenge evaluated severity disability motor
fluoxetine administration apomorphine agonist challenge evaluated severity disability
levodopa dyskinesias patients disease Parkinson
levodopa dyskinesias patients disease Parkinson '
levodopa dyskinesias patients disease s
levodopa dyskinesias patients disease
levodopa dyskinesias
apomorphine agonist challenge evaluated severity disability motor
apomorphine agonist challenge evaluated severity disability
dopamine agonist challenge evaluated severity dyskinesias
apomorphine agonist challenge evaluated severity dyskinesias patients disease Parkinson
apomorphine agonist challenge evaluated severity dyskinesias patients disease Parkinson '
apomorphine agonist challenge evaluated severity dyskinesias patients disease s
apomorphine agonist challenge evaluated severity dyskinesias patients disease
levodopa dyskinesias severity disability motor
levodopa dyskinesias severity disability
fluoxetine administration apomorphine agonist challenge evaluated severity dyskinesias patients disease Parkinson
fluoxetine administration apomorphine agonist challenge evaluated severity dyskinesias patients disease Parkinson '
fluoxetine administration apomorphine agonist challenge evaluated severity dyskinesias patients disease s
fluoxetine administration apomorphine agonist challenge evaluated severity dyskinesias patients disease
fluoxetine treatment was improvement apomorphine induced modification disability motor
fluoxetine treatment was improvement apomorphine induced modification disability
apomorphine induced modification disability motor
apomorphine induced modification disability
apomorphine induced modification disability parkinsonian
fluoxetine treatment was improvement apomorphine induced modification disability parkinsonian
dopamine agonist levodopa dyskinesias reduce disability motor
dopamine agonist levodopa dyskinesias reduce disability
dopamine agonist levodopa dyskinesias reduce disability parkinsonian
fluoxetine transmission reduce disability motor
fluoxetine transmission reduce disability
levodopa dyskinesias reduce disability parkinsonian
levodopa dyskinesias
dopamine agonist levodopa dyskinesias
levodopa dyskinesias reduce disability motor
levodopa dyskinesias reduce disability
fluoxetine transmission reduce disability parkinsonian
MIP inhibition replicate pilocarpine model seizures
inositol sensitive pilocarpine model seizures
lithium effects replicate pilocarpine model seizures
mefenamic acid non effect investigate designed seizures
acid non effect investigate designed seizures
indomethacin non effect investigate designed seizures
ibuprofen non effect investigate designed seizures
Indomethacin failed seizures
ibuprofen kg failed seizures
Mefenamic mg prevented seizures
acid Mefenamic mg prevented seizures
Mefenamic mg prevented seizures rats seizure
acid Mefenamic mg prevented seizures rats seizure
Mefenamic mg prevented seizures damage brain
Mefenamic mg prevented seizures damage
acid Mefenamic mg prevented seizures damage brain
acid Mefenamic mg prevented seizures damage
pilocarpine induced damage brain
pilocarpine induced damage
Niacin extended release product approved treatment hypercholesterolemia dyslipidemia
extended release product approved treatment hypercholesterolemia dyslipidemia
release product approved treatment hypercholesterolemia dyslipidemia
lovastatin product approved treatment hypercholesterolemia dyslipidemia
Niacin extended release product approved treatment hypercholesterolemia
extended release product approved treatment hypercholesterolemia
release product approved treatment hypercholesterolemia
lovastatin product approved treatment hypercholesterolemia
niacin dyslipidemia
extended lovastatin dyslipidemia
release lovastatin dyslipidemia
lovastatin dyslipidemia
creatine increase phosphokinase observed myopathy
metformin suppresses treatment left
metformin suppresses treatment left dysfunction ventricular
metformin suppresses treatment left dysfunction
metformin suppresses treatment left dysfunction infarction myocardial
metformin suppresses treatment left dysfunction infarction
AMP activation has effect infarction myocardial
AMP activation has effect infarction
metformin treatment has effect infarction myocardial
metformin treatment has effect infarction
metformin treatment effect activities infarction myocardial
metformin treatment effect activities infarction
metformin treatment dysfunction cardiac
metformin treatment dysfunction
metformin kg 25 treated groups lower dysfunction left
metformin kg 25 treated groups lower dysfunction ventricular
metformin kg 25 treated groups lower dysfunction
isoproterenol mRNA lowered myeloid 88 factor tumor
isoproterenol mRNA lowered myeloid 88 factor necrosis
metformin treatment reduces post dysfunction myocardial
metformin treatment reduces post dysfunction infarction
levodopa effect Pharmacodynamics patients parkinsonian
levodopa i effects examined patients parkinsonian
levodopa examined patients parkinsonian
Phenylalanine reduced effects hypotensive
amino acid reduced effects hypotensive
acid reduced effects hypotensive
Phenytoin induced injury hepatic
Phenytoin induced injury
FZP toxocity
FZP toxocity Signs included salivation
FZP toxocity Signs included salivation tremors muscle
FZP toxocity Signs included salivation tremors
FZP use relevant situations is excitability epilepsy
Amiodarone induced coma myxoedema
Amiodarone induced coma
amiodarone therapy fibrillation atrial
amiodarone therapy fibrillation
amiodarone cases induced coma myxoedema
amiodarone cases induced coma
amiodarone case represents significant disease thyroid
amiodarone case represents significant disease
amiodarone case represents significant coma myxoedema
amiodarone case represents significant coma
NADPH number catalepsy
nitric inhibition Sub catalepsy
oxide synthesis Sub catalepsy
NG RATIONALE induces catalepsy
nitro NG RATIONALE induces catalepsy
L RATIONALE induces catalepsy
arginine induces catalepsy
L arginine induces catalepsy
NOARG L arginine induces catalepsy
nitric inhibitor arginine induces catalepsy
oxide synthase inhibitor arginine induces catalepsy
dopamine receptors block drugs cause catalepsy
L effects investigate induced catalepsy
NOARG investigate induced catalepsy
L NOARG induced catalepsy
NOARG induced catalepsy
L tolerance produced NOARG induced catalepsy
NOARG NOARG induced catalepsy
Angiotensin used treat failure hypertension
converting used treat failure hypertension
enzyme inhibitors converting used treat failure hypertension
ACE inhibitors converting used treat failure hypertension
inhibitors converting used treat failure hypertension
Angiotensin used treat failure hypertension congestive
Angiotensin used treat failure heart
Angiotensin used treat failure
converting used treat failure hypertension congestive
converting used treat failure heart
converting used treat failure
enzyme inhibitors converting used treat failure hypertension congestive
enzyme inhibitors converting used treat failure heart
enzyme inhibitors converting used treat failure
ACE inhibitors converting used treat failure hypertension congestive
ACE inhibitors converting used treat failure heart
ACE inhibitors converting used treat failure
inhibitors converting used treat failure hypertension congestive
inhibitors converting used treat failure heart
inhibitors converting used treat failure
MK actions model epilepticus status
MK actions model epilepticus
801 actions model epilepticus status
801 actions model epilepticus
pilocarpine lithium coadministration models seizure
pilocarpine dose administration models seizure
N aspartate 801 tested rats using models seizure
methyl aspartate 801 tested rats using models seizure
D methyl aspartate 801 tested rats using models seizure
aspartate 801 tested rats using models seizure
NMDA aspartate 801 tested rats using models seizure
lithium coadministration models seizure
MK tested rats using models seizure
801 tested rats using models seizure
pilocarpine suggesting control seizures
pilocarpine treated rats pilocarpine suggesting control seizures
lithium produced 801 pretreatment pilocarpine suggesting control seizures
MK pretreatment pilocarpine suggesting control seizures
801 pretreatment pilocarpine suggesting control seizures
pilocarpine occurred periods activity seizure
lithium 801 effect pilocarpine occurred periods activity seizure
MK effect pilocarpine occurred periods activity seizure
801 effect pilocarpine occurred periods activity seizure
pilocarpine lithium induced seizures
pilocarpine lithium induced seizures block easy difficult terminate block lethality seizures
pilocarpine prior anticonvulsants administration induced seizures
pilocarpine prior anticonvulsants administration induced seizures block easy difficult terminate block lethality seizures
lithium induced seizures
lithium induced seizures block easy difficult terminate block lethality seizures
pilocarpine 30 Administration reduced activity seizure
MK Administration 30 epilepticus status
MK Administration 30 epilepticus
801 30 epilepticus status
801 30 epilepticus
MK Administration reduced activity seizure
801 30 Administration reduced activity seizure
NMDA receptors activation plays role damage brain
NMDA receptors activation plays role damage
lithium model damage brain
lithium model damage
NMDA receptors activation plays role epilepticus status
NMDA receptors activation plays role epilepticus
pilocarpine model damage brain
pilocarpine model damage
NMDA doses synergistic resulting epilepticus status
NMDA doses synergistic resulting epilepticus
Valproic acid effective treatment types epilepsy
acid effective treatment types epilepsy
VPA acid effective treatment types epilepsy
VPA therapy withdrawal showed loss weight
VPA therapy withdrawal showed loss
5 granisetron prevention nausea
hydroxytryptamine granisetron prevention nausea
5 granisetron prevention nausea vomiting
hydroxytryptamine granisetron prevention nausea vomiting
granisetron prevention nausea vomiting
granisetron prevention nausea
granisetron doses effects assess induced nausea vomiting
Kytril granisetron doses effects assess induced nausea vomiting
granisetron doses effects assess induced nausea
Kytril granisetron doses effects assess induced nausea
granisetron doses RESULTS kg recorded response < vomiting
granisetron doses RESULTS kg recorded response rescue vomiting
granisetron dose effective vomiting
granisetron dose effective vomiting % patients received prevented vomiting
H 2 O reduced prevented loss weight
H 2 O reduced prevented loss
2 O reduced prevented loss weight
2 O reduced prevented loss
O reduced prevented loss weight
O reduced prevented loss
2 O reduced prevented loss weight
2 O reduced prevented loss
acetylcholine acid injection acid accelerated mouse convulsive
5 turnover hydroxytryptamine accelerated mouse convulsive
hydroxytryptamine accelerated mouse convulsive
5 hydroxytryptamine accelerated mouse convulsive
HT 5 hydroxytryptamine accelerated mouse convulsive
gamma synthesis suppressed accelerated mouse convulsive
aminobutyric acid injection acid accelerated mouse convulsive
acid injection acid accelerated mouse convulsive
Fluoxetine improves deficits memory
Fluoxetine improves deficits
phenytoin case seizures
DPH case seizures
DPH concentration normal presented rash
DPH treatment presented rash
DPH injection had normal presented rash
DPH treatment patient alert increase seizures
DPH eliminating alert increase seizures
guanosine renin mediated nephropathy
3 guanosine renin mediated nephropathy
' 3 guanosine renin mediated nephropathy
5 excretion 3 guanosine renin mediated nephropathy
' 5 excretion 3 guanosine renin mediated nephropathy
- excretion 3 guanosine renin mediated nephropathy
cyclic excretion 3 guanosine renin mediated nephropathy
monophosphate excretion 3 guanosine renin mediated nephropathy
cGMP excretion 3 guanosine renin mediated nephropathy
DMTU reduced damage tubular
DMTU reduced damage
superoxide anions play have differ nephropathy
DMTU SOD have differ nephropathy
DMTU SOD differ nephropathy
prostaglandins role nephropathy
Salicylate nephropathy
prostaglandins development nephropathy
bilirubin deposition leading unconjugated hyperbilirubinemia
glucuronyl transferase absence unconjugated hyperbilirubinemia
aspirin damage evidence accompanied jj jJ rats incidence hematuria
aspirin jj treated p lesions increase rats incidence hematuria
prostaglandin synthesis changes accompanied evidence damage renal
prostaglandin synthesis changes accompanied evidence damage
prostaglandin synthesis changes accompanied jj jJ rats incidence hematuria
creatinine rats jJ jj accompanied evidence damage renal
creatinine rats jJ jj accompanied evidence damage
creatinine rats incidence hematuria
prostaglandin synthesis contributes lead pathological lesions deterioration
prostaglandin synthesis contributes lead pathological lesions deterioration function of
prostaglandin synthesis contributes lead pathological lesions deterioration function renal
prostaglandin synthesis contributes lead pathological lesions deterioration function
prostaglandin synthesis inhibition lead pathological lesions deterioration
prostaglandin synthesis inhibition lead pathological lesions deterioration function of
prostaglandin synthesis inhibition lead pathological lesions deterioration function renal
prostaglandin synthesis inhibition lead pathological lesions deterioration function
prostaglandin synthesis contributes lead pathological
prostaglandin synthesis contributes lead pathological lesions renal
prostaglandin synthesis contributes lead pathological lesions medullary
prostaglandin synthesis contributes lead pathological lesions
prostaglandin synthesis inhibition lead pathological
prostaglandin synthesis inhibition lead pathological lesions renal
prostaglandin synthesis inhibition lead pathological lesions medullary
prostaglandin synthesis inhibition lead pathological lesions
calcium Nissl served detect damage neuronal
calcium Nissl served detect damage
MK induced protects damage brain
MK induced protects damage
801 augments pilocarpine MK induced protects damage brain
801 augments pilocarpine MK induced protects damage
pilocarpine MK induced protects damage brain
pilocarpine MK induced protects damage
pentobarbital Scopolamine prevented development pilocarpine induced seizure
Scopolamine prevented development pilocarpine induced seizure
pentobarbital Scopolamine blocked pilocarpine seizure
pentobarbital Scopolamine blocked pilocarpine treatment augmented seizure
Scopolamine blocked pilocarpine seizure
Scopolamine blocked pilocarpine treatment augmented seizure
MK Pentobarbital 801 protected damage brain
MK Pentobarbital 801 protected damage
801 protected damage brain
801 protected damage
MK appeared protected damage brain
MK appeared protected damage
801 MK appeared protected damage brain
801 MK appeared protected damage
scopolamine Pentobarbital 801 protected damage brain
scopolamine Pentobarbital 801 protected damage
Pentobarbital 801 protected damage brain
Pentobarbital 801 protected damage
pilocarpine protected damage brain
pilocarpine protected damage
NMDA receptor cause mechanism elevation transmission propagated initiated epilepticus status
NMDA receptor cause mechanism elevation transmission propagated initiated epilepticus
NMDA receptor cause damage brain
NMDA receptor cause damage
pilocarpine induced epilepticus initiated propagated transmission elevation mechanism cause damage brain
pilocarpine induced epilepticus initiated propagated transmission elevation mechanism cause damage
cytarabine encephalopathy Acute
cytarabine encephalopathy
cytarabine treatment leukemia acute
cytarabine treatment leukemia lymphoblastic
cytarabine treatment leukemia
PEG chemotherapy encephalopathy Acute
PEG chemotherapy encephalopathy
asparaginase cytarabine encephalopathy Acute
asparaginase cytarabine encephalopathy
PEG chemotherapy encephalopathy cytarabine treatment leukemia acute
PEG chemotherapy encephalopathy cytarabine treatment leukemia lymphoblastic
PEG chemotherapy encephalopathy cytarabine treatment leukemia
asparaginase cytarabine treatment leukemia acute
asparaginase cytarabine treatment leukemia lymphoblastic
asparaginase cytarabine treatment leukemia
cytarabine administration sided encephalopathy acute
cytarabine administration sided encephalopathy
artesunate treatment anemia
artesunate described recommended drug treatment malaria
artesunate malaria
alfentanil inhibition Increase fasciculations muscle
alfentanil inhibition Increase fasciculations
alfentanil group greater incidence fasciculations muscle
alfentanil group greater incidence fasciculations
H cm O + higher pressure fasciculations muscle
H cm O + higher pressure fasciculations
2 H cm O + higher pressure fasciculations muscle
2 H cm O + higher pressure fasciculations
O + higher pressure fasciculations muscle
O + higher pressure fasciculations
H cm + higher pressure fasciculations muscle
H cm + higher pressure fasciculations
2 H cm + higher pressure fasciculations muscle
2 H cm + higher pressure fasciculations
O cm + higher pressure fasciculations muscle
O cm + higher pressure fasciculations
alfentanil group higher pressure fasciculations muscle
alfentanil group higher pressure fasciculations
Alfentanil micrograms kg fasciculations muscle
Alfentanil micrograms kg fasciculations
denopamine Improvement failure cardiac
denopamine Improvement failure
TA denopamine Improvement failure cardiac
TA denopamine Improvement failure
064 TA denopamine Improvement failure cardiac
064 TA denopamine Improvement failure
denopamine beta agonist improving failure cardiac
denopamine beta agonist improving failure
denopamine doses induced arrhythmias
denopamine trials warrant treatment failure cardiac
denopamine trials warrant treatment failure
methotrexate enhancement images patients leukoencephalopathy developed leukemia acute
methotrexate enhancement images patients leukoencephalopathy developed leukemia lymphoblastic
methotrexate enhancement images patients leukoencephalopathy developed leukemia
warfarin fibrillation atrial
warfarin fibrillation
warfarin fibrillation aged People rate hemorrhage stroke
warfarin 76 older fibrillation atrial
warfarin 76 older fibrillation
warfarin 76 aged people determine incidence hemorrhage stroke
warfarin admitted network June fibrillation atrial
warfarin admitted network June fibrillation
warfarin use obtained strokes
warfarin initiation rate stroke
warfarin rate stroke
warfarin treatment is demonstrating low rate stroke
cholecystokinin seizures
cholecystokinin seizures
cholecystokinin ester administration enhanced latency seizures
octapeptide ester administration enhanced latency seizures
CCK ester administration enhanced latency seizures
8 CCK ester administration enhanced latency seizures
cholecystokinin octapeptide ester administration enhanced latency seizures
octapeptide ester administration enhanced latency seizures
CCK ester administration enhanced latency seizures
8 CCK ester administration enhanced latency seizures
diazepam 8 seizures
Paclitaxel acid cancer breast
Paclitaxel acid cancer
folinic fluorouracil acid cancer breast
folinic fluorouracil acid cancer
acid cancer breast
acid cancer
5 Paclitaxel acid cancer breast
5 Paclitaxel acid cancer
fluorouracil acid cancer breast
fluorouracil acid cancer
paclitaxel acid Fluorouracil therapies patients breast
paclitaxel acid Fluorouracil therapies patients cancer
Taxol Bristol acid Fluorouracil therapies patients breast
Taxol Bristol acid Fluorouracil therapies patients cancer
folinic acid Fluorouracil therapies patients breast
folinic acid Fluorouracil therapies patients cancer
acid Fluorouracil therapies patients breast
acid Fluorouracil therapies patients cancer
5 therapies patients breast
5 therapies patients cancer
Fluorouracil therapies patients breast
Fluorouracil therapies patients cancer
Paclitaxel cytotoxicity
5 Paclitaxel cytotoxicity
fluorouracil have cytotoxicity
paclitaxel mg trial performed 2 cancer breast
paclitaxel mg trial performed 2 cancer
folinic mg followed day hours mg trial performed 2 cancer breast
folinic mg followed day hours mg trial performed 2 cancer
acid mg followed day hours mg trial performed 2 cancer breast
acid mg followed day hours mg trial performed 2 cancer
5 hour followed day hours mg trial performed 2 cancer breast
5 hour followed day hours mg trial performed 2 cancer
fluorouracil hour followed day hours mg trial performed 2 cancer breast
fluorouracil hour followed day hours mg trial performed 2 cancer
granulocyte colony required patients follow neutropenia
colony required patients follow neutropenia
stimulating follow neutropenia
factor stimulating follow neutropenia
granulocyte colony required patients follow stimulating neutropenia
colony required patients follow stimulating neutropenia
stimulating neutropenia
factor stimulating neutropenia
chlorpromazine induced patients schizophrenic
chlorpromazine plays EPS patients schizophrenic
chlorpromazine treated gene inpatients schizophrenic
chlorpromazine induced schizophrenia
remifentanil i anesthesia induced anesthesia maintaining reinforced sinus compare amount bleeding
propofol anesthesia induced anesthesia maintaining reinforced sinus compare amount bleeding
indinavir treated leukocyturia associated function virus human
indinavir treated leukocyturia associated function virus immunodeficiency
indinavir treated leukocyturia associated function virus
indinavir treated type
indinavir treated type 1
indinavir treated children infected
indinavir treated leukocyturia
indinavir monitor study DESIGN nephrotoxicity cohort type human
indinavir monitor study DESIGN nephrotoxicity cohort type immunodeficiency
indinavir monitor study DESIGN nephrotoxicity cohort type virus
indinavir monitor study DESIGN nephrotoxicity cohort type
indinavir monitor study DESIGN nephrotoxicity cohort type 1
indinavir monitor study DESIGN children infected
indinavir treated children DESIGN nephrotoxicity cohort type human
indinavir treated children DESIGN nephrotoxicity cohort type immunodeficiency
indinavir treated children DESIGN nephrotoxicity cohort type virus
indinavir treated children DESIGN nephrotoxicity cohort type
indinavir treated children DESIGN nephrotoxicity cohort type 1
indinavir treated children infected
creatinine ratio increase associated leukocyturia
creatinine ratio increase associated associated hematuria
creatinine levels had Children leukocyturia
creatinine levels had leukocyturia
indinavir > level h L curve found incidence leukocyturia
creatinine levels decreased disappeared leukocyturia
creatinine ratios / decreased disappeared leukocyturia
indinavir treated Children CONCLUSIONS have incidence leukocyturia
creatinine levels increase had Children leukocyturia
Indinavir monitored children factors leukocyturia
indinavir L curve area years age leukocyturia
creatinine concentration rose hypotension
creatinine concentration rose hypotension
labetalol induces tachycardia hypertension
labetalol induces tachycardia
methoxyflurane anesthesia developed syndrome hepatic
methoxyflurane anesthesia developed syndrome insufficiency
methoxyflurane anesthesia developed syndrome
methoxyflurane anesthesia operated cholecystitis acute
methoxyflurane anesthesia operated cholecystitis
methadone group patients presented torsades
methadone group patients presented torsades de
methadone group patients presented torsades pointes
methadone dose variability % analysis interactions hypokalemia
potassium contribute QT
potassium contribute QT prolongation
bisphosphonates caused Osteoporosis
biphosphonate Alendronate effective treatment osteoporosis
Alendronate effective treatment osteoporosis
bisphosphonate CONCLUSION conclude report patients osteoporosis
bisphosphonate considered ascribing osteoporosis
bisphosphonate CONCLUSION conclude report pain
bisphosphonate considered pain
DOX dose associated disarrangement cardiac
DOX dose associated disarrangement
Mannitol Cisplatin Rates Toxicity Receiving Cancer
Mannitol Cisplatin Rates Toxicity Renal
Mannitol Cisplatin Rates Toxicity
Cisplatin Rates Toxicity Receiving Cancer
Cisplatin Rates Toxicity Renal
Cisplatin Rates Toxicity
cisplatin use complications One dose limiting nephrotoxicity
mannitol use toxicity
mannitol cisplatin rates induced patients cancer
mannitol cisplatin rates induced nephrotoxicity
cisplatin rates induced patients cancer
cisplatin rates induced patients cancer
cisplatin rates induced nephrotoxicity
cisplatin rates induced nephrotoxicity
cisplatin single receiving collected patients cancer
cisplatin We RESULTS had head
cisplatin We RESULTS had head and
cisplatin We RESULTS had head neck
cisplatin We RESULTS had cancer
cisplatin We RESULTS had cancer malignancy
mannitol receive Patients likely develop nephrotoxicity
mannitol quantities available given patients risk nephrotoxicity
cisplatin schedule those hypertension
mannitol addition benefit suggests risk nephrotoxicity
mannitol addition benefit suggests risk patients receiving schedule those hypertension
cisplatin schedule receiving patients risk nephrotoxicity
amphotericin B incorporating Attenuation nanosphere nephrotoxicity
B incorporating Attenuation nanosphere nephrotoxicity
amphotericin B incorporating nanosphere 718 effective has toxicity
B incorporating nanosphere 718 effective has toxicity
Fungizone that 718 toxicity
amphotericin B study vivo compared compared toxicity
B study vivo compared compared toxicity
amphotericin B compared toxicity
B compared toxicity
sodium deoxycholate B compared toxicity
deoxycholate B compared toxicity
D deoxycholate B compared toxicity
AmB B compared toxicity
amphotericin B incorporation suggest attenuates nephrotoxicity
B incorporation suggest attenuates nephrotoxicity
amphotericin B nephrotoxicity
B nephrotoxicity
apigenin prevent amnesia
cocaine patients I Utility pain chest
cocaine patients I Utility pain
cocaine patients difficult infarction diagnosis make associated pain chest
cocaine patients difficult infarction diagnosis make associated pain
cocaine patients difficult infarction diagnosis make abnormalities associated necrosis myocardial
cocaine patients difficult infarction diagnosis make abnormalities associated necrosis
cocaine pain chest
cocaine pain
cocaine patients MB CK associated pain chest
cocaine patients MB CK associated pain
cocaine patients MB necrosis
hydrochlorothiazide therapy Comparison study therapy adults hypertensive
valsartan Comparison study therapy adults hypertensive
hydrochlorothiazide valsartan efficacy investigated study OBJECTIVE combinations patients hypertension essential
hydrochlorothiazide valsartan efficacy investigated study OBJECTIVE combinations patients hypertension
HCTZ valsartan efficacy investigated study OBJECTIVE combinations patients hypertension essential
HCTZ valsartan efficacy investigated study OBJECTIVE combinations patients hypertension
valsartan efficacy investigated study OBJECTIVE combinations patients hypertension essential
valsartan efficacy investigated study OBJECTIVE combinations patients hypertension
VAL valsartan efficacy investigated study OBJECTIVE combinations patients hypertension essential
VAL valsartan efficacy investigated study OBJECTIVE combinations patients hypertension
HCTZ 1 randomized Patients hypertension essential
HCTZ 1 randomized Patients hypertension
HCTZ 160 VAL 5 1 randomized Patients hypertension essential
HCTZ 160 VAL 5 1 randomized Patients hypertension
VAL 1 randomized Patients hypertension essential
VAL 1 randomized Patients hypertension
VAL 5 1 randomized Patients hypertension essential
VAL 5 1 randomized Patients hypertension
VAL combinations lower incidence hypokalemia
VAL HCTZ therapies associated associated hypokalemia
diltiazem Comparison induced nephropathy
sodium chloride Comparison induced nephropathy
chloride Comparison induced nephropathy
contrast Comparison induced nephropathy
Contrast INTRODUCTION increases nephropathy
Misoprostol associated symptoms headache
desogestrel gestodene progestagens containing used women higher incidence thromboembolism venous
desogestrel gestodene progestagens containing used women higher incidence thromboembolism
desogestrel gestodene progestagens containing used women higher incidence thromboembolism VTE
gestodene progestagens containing used women higher incidence thromboembolism venous
gestodene progestagens containing used women higher incidence thromboembolism
gestodene progestagens containing used women higher incidence thromboembolism VTE
progestagens gestodene progestagens containing used women higher incidence thromboembolism venous
progestagens gestodene progestagens containing used women higher incidence thromboembolism
progestagens gestodene progestagens containing used women higher incidence thromboembolism VTE
progestagens containing used women higher incidence thromboembolism venous
progestagens containing used women higher incidence thromboembolism
progestagens containing used women higher incidence thromboembolism VTE
progestagen users VTE
OCs use associated VTE cases recorded deep
OCs use associated VTE cases recorded deep thrombosis vein
OCs use associated VTE cases recorded deep thrombosis
OCs use associated VTE cases recorded deep thrombosis venous
OCs use associated VTE cases recorded deep thrombosis
OCs use associated VTE cases recorded deep thrombosis 35 thrombosis
desogestrel users higher risk VTE
desogestrel gestodene users higher risk VTE
gestodene users higher risk VTE
ethinyloestradiol higher risk VTE
ethinyloestradiol higher risk VTE
progestagens users higher risk VTE
desogestrel 1 49 odds 3 ratios VTE
ethinyloestradiol 1 49 odds 3 ratios VTE
progestagens 18 odds 3 ratios VTE
Cyclophosphamide cardiotoxicity
CYA doses occur cardiotoxicity
CYA doses occur described factors development cardiotoxicity
CYA dose calculated patients determine correlated cardiotoxicity
CYA incidence correlated cardiotoxicity
CYA dose calculated correlates toxicity
CYA incidence correlated determine patients calculated correlates toxicity
CYA mg receive were patients underwent total transplants anemia aplastic
CYA mg receive were patients underwent total transplants anemia
CYA mg receive were patients underwent total syndrome severe
CYA mg receive were patients underwent total syndrome combined
CYA mg receive were patients underwent total syndrome immunodeficiency
CYA mg receive were patients underwent total syndrome
CYA mg receive were patients underwent total Wiskott
CYA mg receive were patients underwent total Wiskott syndrome Aldrich
CYA mg receive were patients underwent total Wiskott syndrome
CYA consistent symptoms had days cardiotoxicity
CYA doses receiving days cardiotoxicity
CYA related thought Cardiotoxicity
CYA cardiotoxicity
CYA cardiotoxicity correlates calculated prepared grafting d days incidence cardiotoxicity
CYA dosage correlates cardiotoxicity
CYA dosage correlates calculated prepared grafting d days incidence cardiotoxicity
CYA dose grafting prepared calculated correlates cardiotoxicity
CYA dose grafting d days incidence cardiotoxicity
CYA dosage calculated patients cardiotoxicity incidence days d grafting prepared calculated correlates cardiotoxicity
CYA dosage calculated patients cardiotoxicity
CYA cardiotoxicity correlates calculated prepared patients anemia aplastic
CYA cardiotoxicity correlates calculated prepared patients anemia
CYA dosage correlates calculated prepared patients anemia aplastic
CYA dosage correlates calculated prepared patients anemia
CYA dose grafting prepared patients anemia aplastic
CYA dose grafting prepared patients anemia
CYA dosage calculated patients cardiotoxicity incidence days d grafting prepared patients anemia aplastic
CYA dosage calculated patients cardiotoxicity incidence days d grafting prepared patients anemia
CYA cardiotoxicity correlates calculated prepared patients anemia immunodeficiencies
CYA dosage correlates calculated prepared patients anemia immunodeficiencies
CYA dose grafting prepared patients anemia immunodeficiencies
CYA dosage calculated patients cardiotoxicity incidence days d grafting prepared patients anemia immunodeficiencies
Viracept irregular
Viracept warning heartbeat
Viracept cause beat irregular
Viracept cause beat heart
Viracept cause beat
bilirubin value plasma sex Factors associated development failure fulminant
bilirubin value plasma sex Factors associated development failure hepatic
bilirubin value plasma sex Factors associated development failure
Nifedipine induced neuropathy autonomic
Nifedipine induced neuropathy
nifedipine 40 slowed min rate have flutter atrial
nifedipine 40 slowed min rate have flutter
pethidine infusion induced dysfunction Cerebellar
pethidine infusion induced dysfunction Cerebellar and
pethidine infusion induced dysfunction Cerebellar oculomotor
pethidine infusion induced dysfunction
Pethidine opioid gains control pain
pethidine cause patients renal impaired
pethidine cause patients renal
pethidine cause patients renal and
pethidine cause patients renal function liver
pethidine cause patients renal function
pethidine cause metabolite neurotoxic
norpethidine cause patients those need control pain
norpethidine cause resulting attack irritability
pethidine cause resulting attack irritability seizure
pethidine cause resulting attack irritability
norpethidine cause patients renal impaired
norpethidine cause patients renal
norpethidine cause patients renal and
norpethidine cause patients renal function liver
norpethidine cause patients renal function
norpethidine cause metabolite neurotoxic
pethidine cause patients those need control pain
dexamethasone lenalidomide efficacy data Real myeloma multiple
dexamethasone lenalidomide efficacy data Real myeloma
dexamethasone lenalidomide efficacy data Real myeloma treated practice study Group Myeloma
lenalidomide efficacy data Real myeloma multiple
lenalidomide efficacy data Real myeloma
lenalidomide efficacy data Real myeloma treated practice study Group Myeloma
dexamethasone Lenalidomide standard care myeloma multiple
dexamethasone Lenalidomide standard care myeloma
dexamethasone Lenalidomide standard care myeloma RRMM
Lenalidomide standard care myeloma multiple
Lenalidomide standard care myeloma
Lenalidomide standard care myeloma RRMM
RD Lenalidomide standard care myeloma multiple
RD Lenalidomide standard care myeloma
RD Lenalidomide standard care myeloma RRMM
RD received patients RRMM
RD effective RRMM
sumatriptan use occurring published vasospasm infarction myocardial
sumatriptan use occurring published vasospasm infarction
sumatriptan use occurring published vasospasm coronary
sumatriptan use occurring published vasospasm
sumatriptan use occurring published vasospasm ischemia myocardial
sumatriptan use occurring published vasospasm ischemia
sumatriptan treated migraine
diazinon exposed Incidence tumours
organophosphate diazinon exposed Incidence tumours
Diazinon associated examined associated risk cancer
diazinon associated risk cancer
organophosphate insecticide Diazinon associated examined associated risk cancer
organophosphate insecticide Diazinon associated cancer lung
organophosphate insecticide Diazinon associated cancer
diazinon exposure information cancer
diazinon exposure used evaluate risk tumour
diazinon use reported Carolina METHODS assessed incidence cancer
Metformin protects seizures impairments learning
Metformin protects seizures impairments learning and
Metformin protects seizures impairments learning memory
Metformin protects seizures impairments
Metformin protects seizures
pentylenetetrazole induced damage seizures impairments learning
pentylenetetrazole induced damage seizures impairments learning and
pentylenetetrazole induced damage seizures impairments learning memory
pentylenetetrazole induced damage seizures impairments
metformin effects evaluate designed observed impairment cognitive
metformin effects evaluate designed observed impairment
metformin effects evaluate seizures
metformin suppressed ameliorated impairment cognitive
metformin suppressed ameliorated impairment
metformin agent treatment medicine impairment cognitive
metformin agent treatment medicine impairment
metformin agent treatment medicine impairment induced seizures
metformin agent treatment epilepsy
theophylline asthma
oxitropium effect Comparison theophylline asthma
bromide effect Comparison theophylline asthma
theophylline effects preparation asthma
oxitropium bromide drug effects preparation asthma
bromide drug effects preparation asthma
oxitropium effects reported as subjects reporting nausea tremors
oxitropium effects reported as subjects reporting nausea vomiting
oxitropium effects reported as subjects reporting nausea
theophylline asthma
Oxitropium proves alternative theophylline asthma
aminonucleoside nephrosis
aminonucleoside nephrosis function glomerular
aminonucleoside nephrosis function sclerosis
puromycin model studied relationship dysfunction mesangial
puromycin model studied relationship dysfunction
aminonucleoside model studied relationship dysfunction mesangial
aminonucleoside model studied relationship dysfunction
puromycin model studied relationship dysfunction sclerosis glomerular
puromycin model studied relationship dysfunction sclerosis
aminonucleoside model studied relationship dysfunction sclerosis glomerular
aminonucleoside model studied relationship dysfunction sclerosis
PAN model studied relationship dysfunction mesangial
PAN model studied relationship dysfunction
PAN model studied relationship dysfunction sclerosis glomerular
PAN model studied relationship dysfunction sclerosis
carbon given proteinuric
PAN rats glomeruli % / found sclerosis glomerular
PAN rats glomeruli % / found sclerosis
PAN treatment change conclude caused develop sclerosis
PAN model Similar nephrosis
PAN model Similar nephrosis related development sclerosis glomerular
PAN model Similar nephrosis related development sclerosis
succinylcholine administration blockade neuromuscular
succinylcholine administration blockade
simvastatin telaprevir treated Rhabdomyolysis patient hepatitis
simvastatin telaprevir treated Rhabdomyolysis patient C
simvastatin telaprevir treated Rhabdomyolysis patient virus
simvastatin telaprevir treated Rhabdomyolysis patient infected
telaprevir treated Rhabdomyolysis patient hepatitis
telaprevir treated Rhabdomyolysis patient C
telaprevir treated Rhabdomyolysis patient virus
telaprevir treated Rhabdomyolysis patient infected
ribavirin interferon received man infection hepatitis
ribavirin interferon received man infection C
ribavirin interferon received man infection virus
ribavirin interferon received man infection
telaprevir interferon received man infection hepatitis
telaprevir interferon received man infection C
telaprevir interferon received man infection virus
telaprevir interferon received man infection
pegylated interferon received man infection hepatitis
pegylated interferon received man infection C
pegylated interferon received man infection virus
pegylated interferon received man infection
interferon received man infection hepatitis
interferon received man infection C
interferon received man infection virus
interferon received man infection
simvastatin discontinued toxicity
alkylxanthines Effect failure acute
alkylxanthines Effect failure renal
alkylxanthines Effect failure
Adenosine antagonists shown benefit models ischaemic nephrotoxic
Adenosine antagonists shown benefit models ischaemic
Adenosine antagonists shown benefit models failure acute
Adenosine antagonists shown benefit models failure renal
Adenosine antagonists shown benefit models failure
Adenosine antagonists shown benefit models failure ARF
alkylxanthines effects examined rats developing failure acute
alkylxanthines effects examined rats developing failure renal
alkylxanthines effects examined rats developing failure
8 examined rats developing failure acute
8 examined rats developing failure renal
8 examined rats developing failure
phenyltheophylline 8 examined rats developing failure acute
phenyltheophylline 8 examined rats developing failure renal
phenyltheophylline 8 examined rats developing failure
adenosine antagonists examined rats developing failure acute
adenosine antagonists examined rats developing failure renal
adenosine antagonists examined rats developing failure
theophylline phenyltheophylline 8 examined rats developing failure acute
theophylline phenyltheophylline 8 examined rats developing failure renal
theophylline phenyltheophylline 8 examined rats developing failure
enprofylline phenyltheophylline 8 examined rats developing failure acute
enprofylline phenyltheophylline 8 examined rats developing failure renal
enprofylline phenyltheophylline 8 examined rats developing failure
creatinine urea biochemical degree necrosis
p analysis functional biochemical degree necrosis
aminohippuric clearances analysis functional biochemical degree necrosis
acid clearances analysis functional biochemical degree necrosis
urea biochemical degree necrosis
alkylxanthines noted effect lack indicates plays role ARF
adenosine plays role ARF
ecstasy users generation prognosis cause Given record memory impaired
ecstasy users generation prognosis cause Given record memory
fluocinolone Safety acetonide implant retinochoroidopathy birdshot
fluocinolone Safety acetonide implant retinochoroidopathy
acetonide implant retinochoroidopathy birdshot
acetonide implant retinochoroidopathy
fluocinolone acetonide implant outcomes report patients retinochoroidopathy birdshot
fluocinolone acetonide implant outcomes report patients retinochoroidopathy
acetonide implant outcomes report patients retinochoroidopathy birdshot
acetonide implant outcomes report patients retinochoroidopathy
fluocinolone implant helps control inflammation
acetonide implant helps control inflammation
fluocinolone implant helps control treatment cases retinochoroidopathy birdshot
fluocinolone implant helps control treatment cases retinochoroidopathy
acetonide implant helps control treatment cases retinochoroidopathy birdshot
acetonide implant helps control treatment cases retinochoroidopathy
meloxicam due developed arthritis rheumatoid
meloxicam due developed arthritis
propranolol daily year treatment angina
propranolol evidence accepted cause disorder conduction
propranolol evidence accepted cause disorder
olanzapine comparison episode schizophrenia
risperidone comparison episode schizophrenia
olanzapine outcomes OBJECTIVE schizophrenia
risperidone olanzapine outcomes OBJECTIVE schizophrenia
olanzapine assigned METHOD subjects schizophrenia
olanzapine assigned METHOD subjects schizophrenia disorder schizophreniform
olanzapine assigned METHOD subjects schizophrenia disorder
olanzapine assigned METHOD subjects schizophrenia disorder schizoaffective
olanzapine assigned METHOD subjects schizophrenia disorder
risperidone olanzapine assigned METHOD subjects schizophrenia disorder schizophreniform
risperidone olanzapine assigned METHOD subjects schizophrenia disorder
risperidone olanzapine assigned METHOD subjects schizophrenia disorder schizoaffective
risperidone olanzapine assigned METHOD subjects schizophrenia disorder
risperidone olanzapine assigned METHOD subjects schizophrenia
lithium treated depression manic
lithium treated depression
glucose negative polyuria
glucose negative polyuria polydipsia
glucose concentrations remained indicated induced insipidus nephrogenic
glucose concentrations remained indicated induced insipidus diabetes
glucose concentrations remained indicated induced insipidus
glucose concentrations remained polyuric
lithium likely insipidus induced indicated remained recovery hyperglycaemia
glucose concentrations remained recovery hyperglycaemia
K + Na ouabain administration suggested mimic symptoms mania bipolar
K + Na ouabain administration suggested mimic symptoms mania
Na ouabain administration suggested mimic symptoms mania bipolar
Na ouabain administration suggested mimic symptoms mania
ouabain hyperlocomotion
zolmitriptan took had migraines
zolmitriptan times days headache migraine
zolmitriptan times days headache
benzodiazepine flumazenil Administration unmask seizures
benzodiazepine intoxication seizures
sodium nitrite rats percent had thrombosis
nitrite rats percent had thrombosis
quinacrine hydrochloride nitrite rats percent had thrombosis
hydrochloride nitrite rats percent had thrombosis
sodium nitrite rats percent had have thrombosis atrial
sodium nitrite rats percent had have thrombosis
nitrite rats percent had have thrombosis atrial
nitrite rats percent had have thrombosis
tacrolimus induced crisis scleroderma
tacrolimus induced crisis renal
tacrolimus induced crisis
prednisolone tacrolimus induced crisis scleroderma
prednisolone tacrolimus induced crisis renal
prednisolone tacrolimus induced crisis
corticosteroid recognized factor SRC
cyclosporine patients SSc
tacrolimus induced SRC
corticosteroids tacrolimus induced SRC
chlorhexidine diphosphanilate study agent burns
diphosphanilate study agent burns
Chlorhexidine phosphanilate evaluated wound burn
phosphanilate evaluated wound burn
CHP phosphanilate evaluated wound burn
CHP concentrations each treated site burn
CHP concentrations each treated site agent used treatment wounds burn
silver 1 cent 2 cent cream 25 site burn
sulphadiazine cream 25 site burn
silver 1 cent 2 cent cream 25 site agent used treatment wounds burn
sulphadiazine cream 25 site agent used treatment wounds burn
AgSD cream 25 site burn
AgSD cream 25 site agent used treatment wounds burn
AgSD closest tolerance pain
AgSD statistically differed closest tolerance pain
Lindane insecticide effects neurotoxic
gamma Lindane insecticide effects neurotoxic
hexachlorocyclohexane gamma Lindane insecticide effects neurotoxic
dopamine GABA concentration measuring onset seizures
GABA concentration measuring onset seizures
D Effect damage renal
D Effect damage
Glucarates Effect damage renal
Glucarates Effect damage
aminoglycoside antibiotics injection failure develop rats Dehydrated
kanamycin induced failure renal
kanamycin induced failure
2 administration dilactone failure renal
2 administration dilactone failure
5 2 administration dilactone failure renal
5 2 administration dilactone failure
di 2 administration dilactone failure renal
di 2 administration dilactone failure
O 2 administration dilactone failure renal
O 2 administration dilactone failure
acetyl 2 administration dilactone failure renal
acetyl 2 administration dilactone failure
D 2 administration dilactone failure renal
D 2 administration dilactone failure
glucaro 2 administration dilactone failure renal
glucaro 2 administration dilactone failure
1 2 administration dilactone failure renal
1 2 administration dilactone failure
4 2 administration dilactone failure renal
4 2 administration dilactone failure
6 4 2 administration dilactone failure renal
6 4 2 administration dilactone failure
3 6 4 2 administration dilactone failure renal
3 6 4 2 administration dilactone failure
dilactone failure renal
dilactone failure
D effective damage renal
D effective damage
Glucarates effective damage renal
Glucarates effective damage
aminoglycoside antibitocis antibiotics induced damage renal
aminoglycoside antibitocis antibiotics induced damage
D obtained damages renal
D obtained damages
glucarate D obtained damages renal
glucarate D obtained damages
D had ability prevent damage renal
D had ability prevent damage
Glucarates had ability prevent damage renal
Glucarates had ability prevent damage
monosaccharides spared lesions renal
monosaccharides spared lesions
D glucarates nephrotoxicity
glucarates nephrotoxicity
tacrolimus discontinuation occurred Deterioration
tacrolimus discontinuation occurred Deterioration vision of
tacrolimus discontinuation occurred Deterioration vision
nitric oxide derived cell Loss hallmark dysfunction arterial
nitric oxide derived cell Loss hallmark dysfunction
oxide derived cell Loss hallmark dysfunction arterial
oxide derived cell Loss hallmark dysfunction
NO oxide derived cell Loss hallmark dysfunction arterial
NO oxide derived cell Loss hallmark dysfunction
Nomega role hypertension
nitro role hypertension
L role hypertension
arginine hypertension
LNNA hypertension
LNNA hypertension
LNNA weeks elevated hypertension
LNNA rats hypertensive
hexamethonium blockade caused fall rats hypertensive
histamine receptors Blockade reduce immunization induced encephalopathy
histamine receptors Blockade reduce immunization pertussis
gamma isoniazid microinjection produced seizures
vinyl Susceptibility seizures
GABA vinyl Susceptibility seizures
isoniazid microinjection produced seizures
Pilocarpine reproduces sequelae epilepsy temporal
Pilocarpine reproduces sequelae epilepsy lobe
Pilocarpine reproduces sequelae epilepsy
gamma activity manipulating effects inhibition nigra seizures
aminobutyric acid gamma activity manipulating effects inhibition nigra seizures
acid gamma activity manipulating effects inhibition nigra seizures
GABA gamma activity manipulating effects inhibition nigra seizures
GABA activity inhibitor micrograms resulted seizures epilepticus status
GABA activity inhibitor micrograms resulted seizures epilepticus
L enzyme activity inhibitor micrograms resulted seizures epilepticus status
L enzyme activity inhibitor micrograms resulted seizures epilepticus
glutamic decarboxylase activity inhibitor micrograms resulted seizures epilepticus status
glutamic decarboxylase activity inhibitor micrograms resulted seizures epilepticus
acid decarboxylase activity inhibitor micrograms resulted seizures epilepticus status
acid decarboxylase activity inhibitor micrograms resulted seizures epilepticus
pilocarpine doses kg activity inhibitor micrograms resulted seizures epilepticus status
pilocarpine doses kg activity inhibitor micrograms resulted seizures epilepticus
isoniazid microinjections pretreated animals resulted seizures epilepticus status
isoniazid microinjections pretreated animals resulted seizures epilepticus
L enzyme activity inhibitor micrograms resulted seizures
glutamic decarboxylase activity inhibitor micrograms resulted seizures
acid decarboxylase activity inhibitor micrograms resulted seizures
GABA activity inhibitor micrograms resulted seizures
isoniazid microinjections pretreated animals resulted seizures
isoniazid injections augment seizures
gamma transaminase inhibitor Application suppressed appearance seizures
vinyl transaminase inhibitor Application suppressed appearance seizures
GABA D vinyl transaminase inhibitor Application suppressed appearance seizures
D vinyl transaminase inhibitor Application suppressed appearance seizures
L D vinyl transaminase inhibitor Application suppressed appearance seizures
4 vinyl transaminase inhibitor Application suppressed appearance seizures
amino transaminase inhibitor Application suppressed appearance seizures
hex amino transaminase inhibitor Application suppressed appearance seizures
5 amino transaminase inhibitor Application suppressed appearance seizures
enoic acid 5 amino transaminase inhibitor Application suppressed appearance seizures
acid 5 amino transaminase inhibitor Application suppressed appearance seizures
GABA transaminase inhibitor Application suppressed appearance seizures
gamma Microinjections failed prevent development convulsions
vinyl gamma Microinjections failed prevent development convulsions
GABA gamma Microinjections failed prevent development convulsions
GABA regulation subjected seizures
doxorubicin immunocytoma
doxorubicin nephrotoxicity effect cardiotoxicity
doxorubicin nephrotoxicity
doxorubicin induced activity studied Antitumor inbred bearing immunocytoma
doxorubicin induced activity cardiotoxicity
doxorubicin induced activity nephrotoxicity
doxorubicin injections treated Animals tumor
doxorubicin kg observed regression Tumor
doxorubicin mg induced disappearance tumor
doxorubicin mg dose observed scored evidence cardiotoxicity
doxorubicin kg dose seen evidence damage renal
doxorubicin kg dose seen evidence damage
calcium antagonist Effects induced ischemia myocardial
calcium antagonist Effects induced ischemia
CD induced ischemia myocardial
CD induced ischemia
832 CD induced ischemia myocardial
832 CD induced ischemia
isoproterenol 832 CD induced stenosis coronary
isoproterenol 832 CD induced stenosis
calcium antagonist Effects induced stenosis coronary
calcium antagonist Effects induced stenosis
CD induced stenosis coronary
CD induced stenosis
832 CD induced stenosis coronary
832 CD induced stenosis
nifedipine those compared studied dogs stenosis coronary
nifedipine those compared studied dogs stenosis
CD Effects induced studied ischemia myocardial
CD Effects induced studied ischemia
832 Effects induced studied ischemia myocardial
832 Effects induced studied ischemia
nifedipine those compared studied ischemia myocardial
nifedipine those compared studied ischemia
isoproterenol 832 Effects induced studied dogs stenosis coronary
isoproterenol 832 Effects induced studied dogs stenosis
ISO isoproterenol 832 Effects induced studied dogs stenosis coronary
ISO isoproterenol 832 Effects induced studied dogs stenosis
diltiazem nifedipine those compared studied ischemia myocardial
diltiazem nifedipine those compared studied ischemia
diltiazem nifedipine those compared studied dogs stenosis coronary
diltiazem nifedipine those compared studied dogs stenosis
CD Effects induced studied dogs stenosis coronary
CD Effects induced studied dogs stenosis
832 Effects induced studied dogs stenosis coronary
832 Effects induced studied dogs stenosis
ISO infusion periods 3 increased presence stenosis coronary
ISO infusion periods 3 increased presence stenosis artery
ISO infusion periods 3 increased presence stenosis
ISO infusion stenosis
ISO infusion infused performed infusion stenosis
CD doses infused performed infusion stenosis
832 CD doses infused performed infusion stenosis
nifedipine CD doses infused performed infusion stenosis
diltiazem CD doses infused performed infusion stenosis
ISO infusion stenosis
CD nifedipine contrast + mV min infusion stenosis
832 CD nifedipine contrast + mV min infusion stenosis
nifedipine contrast + mV min infusion stenosis
ISO infusion stenosis
Diltiazem prevented decrease segmental shortening infusion stenosis
CD improves ischemia myocardial
CD improves ischemia
832 CD improves ischemia myocardial
832 CD improves ischemia
CD property plays suggest improves ischemia myocardial
CD property plays suggest improves ischemia
832 CD property plays suggest improves ischemia myocardial
832 CD property plays suggest improves ischemia
CD effects role plays suggest improves ischemia myocardial
CD effects role plays suggest improves ischemia
832 role plays suggest improves ischemia myocardial
832 role plays suggest improves ischemia
ISO infusion stenosis
CD improves infusion stenosis
832 CD improves infusion stenosis
CD property plays suggest improves infusion stenosis
832 CD property plays suggest improves infusion stenosis
CD effects role plays suggest improves infusion stenosis
832 role plays suggest improves infusion stenosis
cocaine users Prevalence disease heart
cocaine users Prevalence disease
cocaine users determine prevalence disease heart
cocaine users determine prevalence disease
cocaine users users determine prevalence disease heart
cocaine users users determine prevalence disease
cocaine users common artery coronary
cocaine users common artery
cocaine users common artery or
cocaine users common artery disease myocardial
cocaine users common artery disease
S BACKGROUND 23121 retardation rats studies toxicity
53482 BACKGROUND 23121 retardation rats studies toxicity
S 53482 BACKGROUND 23121 retardation rats studies toxicity
23121 retardation rats studies toxicity
S rats exposure RESULTS produced similar patterns toxicity
53482 exposure RESULTS produced similar patterns toxicity
phosphate binder switching hypercalcemic
calcium reabsorption parameters compared results patients matched age etiology disease renal
calcium reabsorption parameters compared results patients matched age etiology disease
calcium reabsorption parameters compared identify factors associated development hypercalcemia
calcium values experiencing episodes hypercalcemic
calcium concentration exhibited patients group hypercalcemic
capsaicin post
capsaicin neuralgia herpetic
capsaicin neuralgia
capsaicin evaluate capsaicin patients post
capsaicin evaluate capsaicin patients treated neuralgia herpetic
capsaicin evaluate capsaicin patients treated neuralgia
capsaicin evaluate capsaicin patients treated neuralgia PHN
capsaicin patients post
capsaicin patients treated neuralgia herpetic
capsaicin patients treated neuralgia
capsaicin patients treated neuralgia PHN
capsaicin PHN
nitroglycerin reversed ischemia
calcium nitroglycerin reversed ischemia
calcium nitroglycerin reversed ischemia induced spasm coronary
calcium nitroglycerin reversed ischemia induced spasm artery
calcium nitroglycerin reversed ischemia induced spasm
nitroglycerin reversed ischemia induced spasm coronary
nitroglycerin reversed ischemia induced spasm artery
nitroglycerin reversed ischemia induced spasm
amlodipine loss report case female hypertension
amlodipine loss
amlodipine loss sensation of
amlodipine loss sensation taste
amlodipine loss sensation
Penicillamine related abnormalities presentation anxiety
zinc acetate dermatitis related abnormalities presentation anxiety
acetate dermatitis related abnormalities presentation anxiety
zinc acetate dermatitis lichenoid
zinc acetate dermatitis
acetate dermatitis lichenoid
acetate dermatitis
zinc acetate dermatitis related patient Wilson
zinc acetate dermatitis related patient disease
acetate dermatitis related patient Wilson
acetate dermatitis related patient disease
Penicillamine related patient Wilson
Penicillamine related patient disease
copper metabolism toxicity tissues disorders neurologic hepatic
copper metabolism toxicity tissues disorders neurologic
copper metabolism toxicity tissues disorders neurologic and
copper metabolism toxicity tissues disorders neurologic psychiatric
copper metabolism toxicity tissues disorders
copper accumulation metabolism toxicity tissues disorders neurologic hepatic
copper accumulation metabolism toxicity tissues disorders neurologic
copper accumulation metabolism toxicity tissues disorders neurologic and
copper accumulation metabolism toxicity tissues disorders neurologic psychiatric
copper accumulation metabolism toxicity tissues disorders
copper metabolism disorder disease Wilson
copper metabolism disorder disease Wilson '
copper metabolism disorder disease s
copper metabolism disorder disease
copper accumulation metabolism disorder disease Wilson
copper accumulation metabolism disorder disease Wilson '
copper accumulation metabolism disorder disease s
copper accumulation metabolism disorder disease
copper metabolism toxicity
copper accumulation metabolism toxicity
zinc acetate permitted interrupted appearance dermatitis lichenoid
zinc acetate permitted interrupted appearance dermatitis
acetate permitted interrupted appearance dermatitis lichenoid
acetate permitted interrupted appearance dermatitis
zinc acetate therapy represented treatment patient Wilson
zinc acetate therapy represented treatment patient Wilson '
zinc acetate therapy represented treatment patient s
zinc acetate therapy represented treatment patient disease
acetate therapy represented treatment patient Wilson
acetate therapy represented treatment patient Wilson '
acetate therapy represented treatment patient s
acetate therapy represented treatment patient disease
penicillamine represented treatment patient Wilson
penicillamine represented treatment patient Wilson '
penicillamine represented treatment patient s
penicillamine represented treatment patient disease
zinc acetate safety allowed line evidence efficacy drug treatment disease Wilson
zinc acetate safety allowed line evidence efficacy drug treatment disease Wilson '
zinc acetate safety allowed line evidence efficacy drug treatment disease s
zinc acetate safety allowed line evidence efficacy drug treatment disease
acetate safety allowed line evidence efficacy drug treatment disease Wilson
acetate safety allowed line evidence efficacy drug treatment disease Wilson '
acetate safety allowed line evidence efficacy drug treatment disease s
acetate safety allowed line evidence efficacy drug treatment disease
penicillamine most conceivable seem develop lesion skin
penicillamine most conceivable seem develop lesion
penicillamine Wilson
penicillamine Wilson '
penicillamine s
penicillamine disease
I leading factor cardiotoxicity
131 HA factor cardiotoxicity
HA factor cardiotoxicity
warfarin users 0 MB
warfarin users 0 MB TIA RESULTS analysis ICH IS
warfarin users 0 MB frequent TIA IS
warfarin users 0 MB TIA
warfarin users 0 MB frequent TIA
warfarin MB
warfarin users none 0 nonusers users excess MB
warfarin MB excess users nonusers 0 none users TIA IS
warfarin users TIA IS
warfarin MB excess users nonusers 0 none users TIA
warfarin users TIA
warfarin users MB
warfarin users MB excess CONCLUSIONS suggests increase MB
warfarin risk increase suggests CONCLUSIONS excess MB
warfarin risk increase MB
NCQ treated cells observed necrosis
436 NCQ treated cells observed necrosis
NCQ treated cells observed had inducing concentrations necrosis
436 NCQ treated cells observed had inducing concentrations necrosis
NCQ 344 had observed necrosis
344 had observed necrosis
NCQ 344 had inducing concentrations necrosis
344 had inducing concentrations necrosis
NCQ ability contribute induce anemia aplastic
NCQ ability contribute induce anemia
436 NCQ ability contribute induce anemia aplastic
436 NCQ ability contribute induce anemia
NCQ ability contribute anemia aplastic
NCQ ability contribute anemia
436 NCQ ability contribute anemia aplastic
436 NCQ ability contribute anemia
NCQ NCQ ability contribute induce anemia aplastic
NCQ NCQ ability contribute induce anemia
344 NCQ NCQ ability contribute induce anemia aplastic
344 NCQ NCQ ability contribute induce anemia
NCQ NCQ ability contribute anemia aplastic
NCQ NCQ ability contribute anemia
344 NCQ NCQ ability contribute anemia aplastic
344 NCQ NCQ ability contribute anemia
Bepridil induced bradycardia anti effect tachycardial
Bepridil compound treatment attacks anginal
Bepridil compound treatment attacks
Curcumin prevents maleate induced nephrotoxicity
oxygen consumption alterations relation induced nephrotoxicity
curcumin effect injury renal
curcumin effect injury
sodium gelatinase excretion besides necrosis
glucose gelatinase excretion included included injury renal
glucose gelatinase excretion included included injury
glucose gelatinase excretion glucosaminidase upregulation molecule kidney
glucose gelatinase excretion glucosaminidase upregulation molecule injury
sodium gelatinase excretion included included injury renal
sodium gelatinase excretion included included injury
sodium gelatinase excretion glucosaminidase upregulation molecule kidney
sodium gelatinase excretion glucosaminidase upregulation molecule injury
glucose gelatinase excretion besides necrosis
curcumin able attenuate maleate induced and nephropathy
Levetiracetam phenobarbital cats epilepsy idiopathic
Levetiracetam phenobarbital cats epilepsy
phenobarbital cats epilepsy idiopathic
phenobarbital cats epilepsy
levetiracetam administered epilepsy idiopathic
levetiracetam administered epilepsy
phenobarbital treatment adjunct epilepsy idiopathic
phenobarbital treatment adjunct epilepsy
phenobarbital controlled have epilepsy idiopathic
phenobarbital controlled have epilepsy
phenobarbital treated suspected have epilepsy idiopathic
phenobarbital treated suspected have epilepsy
levetiracetam treatment initiation compared frequencies Seizure
levetiracetam frequency seizure
levetiracetam frequency mo / seizures
levetiracetam frequency higher frequency seizure
levetiracetam frequency higher mo seizures
levetiracetam frequency higher classified responded levetiracetam ie frequency seizure
levetiracetam treatment initiation higher frequency seizure
levetiracetam treatment initiation higher frequency mo / seizures
levetiracetam treatment initiation higher frequency seizure
levetiracetam treatment initiation higher mo seizures
levetiracetam treatment initiation higher classified responded levetiracetam ie frequency seizure
levetiracetam responded classified higher frequency seizure
levetiracetam responded classified higher frequency mo / seizures
levetiracetam responded classified higher frequency seizure
levetiracetam responded classified higher mo seizures
levetiracetam ie frequency seizure
levetiracetam tolerated suggested useful adjunct phenobarbital cats epilepsy idiopathic
levetiracetam tolerated suggested useful adjunct phenobarbital cats epilepsy
phenobarbital cats epilepsy idiopathic
phenobarbital cats epilepsy
metronidazole toxicity
naloxone training Reversal amnesia
naloxone role deficit retention
naloxone role deficit
scopolamine role deficit retention
scopolamine role deficit
methyl scopolamine Scopolamine induced as amnesia
scopolamine Scopolamine induced as amnesia
Naloxone injected prior training attenuated deficit retention
Naloxone injected prior training attenuated deficit
naloxone administration single attenuated amnesia
scopolamine responsible appear increase sensitivity pain
naloxone pre sensitivity increase appear responsible scopolamine induced deficit retention
naloxone pre sensitivity increase appear responsible scopolamine induced deficit
naloxone post state increase appear responsible scopolamine induced deficit retention
naloxone post state increase appear responsible scopolamine induced deficit
naloxone influence responsible scopolamine induced deficit retention
naloxone influence responsible scopolamine induced deficit
scopolamine induced deficit retention
scopolamine induced deficit
naloxone pre sensitivity pain
naloxone post state increase sensitivity pain
naloxone influence responsible appear increase sensitivity pain
Testosterone streptozotocin induced impairment memory
Testosterone streptozotocin induced impairment
testosterone effects study induced impairment memory
testosterone effects study induced impairment
testosterone replacement attenuated impaired
testosterone replacement attenuated impaired memory the
testosterone replacement attenuated impaired memory
testosterone replacement attenuated impaired impairment memory
testosterone replacement attenuated impaired impairment
Testosterone ameliorates CONCLUSION impairment memory
Testosterone ameliorates CONCLUSION impairment
Serotonin reuptake inhibitors paranoia
serotonin fluoxetine exacerbation paranoid
serotonin inhibitors associated exacerbations paranoid
serotonin inhibitors associated exacerbations present disorders depressive
serotonin inhibitors associated exacerbations present disorders
serotonin inhibitors associated exacerbations present disorders atypicality course psychosis
serotonin inhibitors associated exacerbations present disorders atypicality course onset course psychosis
dopamine release HT mechanisms apply remain pharmacology paranoia
serotonin blockers call exacerbations paranoid
serotonin blockers call raise considerations paranoia
monoHER administration interval influence cardiotoxicity
doxorubicin monoHER administration interval influence cardiotoxicity
doxorubicin protection administration interval influence cardiotoxicity
doxorubicin continues known cardiotoxicity
DOX doxorubicin continues known cardiotoxicity
DOX induced results cardiac
DOX induced results damage
DOX induced results cardiac
DOX induced results damage
iron properties scavenging induced cardiotoxicity
monohydroxyethylrutoside showed DOX induced cardiotoxicity
monoHER monohydroxyethylrutoside showed DOX induced cardiotoxicity
flavonoid monohydroxyethylrutoside showed DOX induced cardiotoxicity
DOX induced cardiotoxicity
DOX treatment induced damage cardiac
DOX treatment induced damage
azimilide sotalol dl induced prolongation initiate pointes torsade
azimilide sotalol dl induced prolongation initiate pointes de
azimilide sotalol dl induced prolongation initiate pointes
azimilide sotalol dl induced prolongation initiate pointes TdP
azimilide sotalol dl induced prolongation QT
azimilide sotalol dl induced prolongation
azimilide sotalol dl EADs produced rabbits seen prolongation QT
azimilide sotalol dl EADs produced rabbits seen prolongation
nicotine effects investigates anxiety
Nicotine pretreatment blocked caffeine induced anxiety
nicotine anxiety
alanine > jaundice
alanine > jaundice limits patients hepatitis
alanine > jaundice limits patients % observed anemia
NVP therapy associated rash therapy neuropathy peripheral
NVP therapy associated rash therapy neuropathy
d therapy rash
4 therapy rash
T therapy rash
diclofenac treatment dysmenorrhea
glyceryl comparison trinitrate diclofenac treatment dysmenorrhea
trinitrate diclofenac treatment dysmenorrhea
prostaglandins hypersecretion caused uterine characterized syndrome dysmenorrhea
diclofenac comparison dysmenorrhea
DCF efficacy resolution dysmenorrhea
glyceryl trinitrate efficacy resolution dysmenorrhea
trinitrate efficacy resolution dysmenorrhea
GTN efficacy resolution dysmenorrhea
NO donor efficacy resolution dysmenorrhea
DCF continued effective reducing pain pelvic
DCF continued effective reducing pain
GTN scores remained effective reducing pain pelvic
GTN scores remained effective reducing pain
GTN hour higher more remained effective reducing pain pelvic
GTN hour higher more remained effective reducing pain
GTN hours 6 23 7 20 5 DFC GTN hour higher more remained effective reducing pain pelvic
GTN hours 6 23 7 20 5 DFC GTN hour higher more remained effective reducing pain
DCF increased increased Headache
DCF comparison tolerability treatment dysmenorrhea
GTN has tolerability treatment dysmenorrhea
Glucose metabolism patients schizophrenia
glucose test metabolism patients schizophrenia
glucose metabolism affecting remains increasing incidence mellitus diabetes
glucose metabolism affecting remains increasing incidence mellitus
glucose metabolism affecting increasing factors diabetes
glucose metabolism affecting remains increasing patients schizophrenia
glucose test using evaluated schizophrenia
olanzapine either treated matched subjects disorder schizophrenia schizoaffective
olanzapine either treated matched subjects disorder
risperidone either treated matched subjects disorder schizophrenia
olanzapine either treated matched subjects disorder schizophrenia
clozapine either treated matched subjects disorder schizophrenia
clozapine either treated matched subjects disorder schizophrenia schizoaffective
clozapine either treated matched subjects disorder
risperidone either treated matched subjects disorder schizophrenia schizoaffective
risperidone either treated matched subjects disorder
glucose index insulin
glucose index sensitivity
glucose assessment resistance insulin
glucose assessment resistance
glucose effectiveness glucose index insulin
glucose effectiveness glucose index sensitivity
glucose effectiveness glucose assessment resistance insulin
glucose effectiveness glucose assessment resistance
risperidone difference index insulin
risperidone difference index sensitivity
risperidone difference was subjects received exhibiting resistance insulin
risperidone difference was subjects received exhibiting resistance
risperidone treated subjects resistance exhibiting received subjects was difference index insulin
risperidone treated subjects resistance exhibiting received subjects was difference index sensitivity
risperidone treated subjects resistance insulin
risperidone treated subjects resistance
risperidone risperidone treated subjects resistance exhibiting received subjects was difference index insulin
risperidone risperidone treated subjects resistance exhibiting received subjects was difference index sensitivity
risperidone risperidone treated subjects resistance insulin
risperidone risperidone treated subjects resistance
risperidone 001 exhibiting received subjects was difference index insulin
risperidone 001 exhibiting received subjects was difference index sensitivity
risperidone 001 exhibiting resistance insulin
risperidone 001 exhibiting resistance
risperidone 4 differed assessment resistance insulin
risperidone 4 differed assessment resistance
risperidone clozapine differed assessment resistance insulin
risperidone clozapine differed assessment resistance
risperidone risperidone clozapine differed assessment resistance insulin
risperidone risperidone clozapine differed assessment resistance
risperidone displayed resistance insulin
risperidone displayed resistance
glucose effectiveness resistance insulin
glucose effectiveness resistance
midazolam Fentanyl myoclonus
Fentanyl myoclonus
midazolam fentanyl effectiveness compare prevent etomidate myoclonus
midazolam fentanyl combination fentanyl effectiveness compare prevent etomidate myoclonus
fentanyl effectiveness compare prevent etomidate myoclonus
fentanyl combination fentanyl effectiveness compare prevent etomidate myoclonus
etomidate injection minutes severity observed evaluated movements Myoclonic
etomidate injection minutes severity observed evaluated movements
etomidate injection due pain
midazolam fentanyl fentanyl pretreatment effective preventing etomidate myoclonus
fentanyl pretreatment effective preventing etomidate myoclonus
fentanyl fentanyl pretreatment effective preventing etomidate myoclonus
All trans myositis patient leukemia acute
All trans myositis patient leukemia promyelocytic
All trans myositis patient leukemia
trans myositis patient leukemia acute
trans myositis patient leukemia promyelocytic
trans myositis patient leukemia
retinoic acid trans myositis patient leukemia acute
retinoic acid trans myositis patient leukemia promyelocytic
retinoic acid trans myositis patient leukemia
acid trans myositis patient leukemia acute
acid trans myositis patient leukemia promyelocytic
acid trans myositis patient leukemia
All associated acid component therapy leukemia promyelocytic acute
All associated acid component therapy leukemia promyelocytic
All associated acid component therapy leukemia
trans acid component therapy leukemia promyelocytic acute
trans acid component therapy leukemia promyelocytic
trans acid component therapy leukemia
retinoic acid component therapy leukemia promyelocytic acute
retinoic acid component therapy leukemia promyelocytic
retinoic acid component therapy leukemia
acid component therapy leukemia promyelocytic acute
acid component therapy leukemia promyelocytic
acid component therapy leukemia
All associated acid component therapy leukemia APL
trans acid component therapy leukemia APL
retinoic acid component therapy leukemia APL
acid component therapy leukemia APL
ATRA acid component therapy leukemia promyelocytic acute
ATRA acid component therapy leukemia promyelocytic
ATRA acid component therapy leukemia
ATRA acid component therapy leukemia APL
L bradykinesia rigidity
DOPA February bradykinesia rigidity
L bradykinesia
DOPA February bradykinesia
L bradykinesia February pallidotomy underwent patients disease Parkinson
L bradykinesia February pallidotomy underwent patients disease Parkinson '
L bradykinesia February pallidotomy underwent patients disease s
L bradykinesia February pallidotomy underwent patients disease
DOPA February pallidotomy underwent patients disease Parkinson
DOPA February pallidotomy underwent patients disease Parkinson '
DOPA February pallidotomy underwent patients disease s
DOPA February pallidotomy underwent patients disease
hydrochlorothiazide mg administered month patients hypertensive
timolol maleate mg mg administered month patients hypertensive
maleate mg mg administered month patients hypertensive
propranolol loading induced confirmed absence MR
phosphorus poisoning
phosphorus known cause hepatotoxicity
phosphorus Poisoning
phosphorus poisoning presented highlighting feature hepatotoxicity
phosphorus hepatotoxicity
phosphorus poisoning
phosphorus hepatotoxicity feature highlighting presented poisoning
angiotensin therapy use caused Syncope
angiotensin therapy use caused hyperkalemia
spironolactone inhibitor converting caused Syncope
aldosterone antagonist spiranolactone doses considered cause hyperkalemia
potassium using patients possibility hyperkalemia
potassium using patients have disturbance renal
potassium using patients have disturbance
aspirin discuss adults risk disease coronary
aspirin discuss adults risk disease heart
aspirin discuss adults risk disease
aspirin taking prevention infarctions myocardial
aspirin taking prevention infarctions
aspirin control prevention disease cardiovascular
aspirin control prevention disease
aspirin reviews SELECTION CVD
aspirin reviews SELECTION selected answer questions decrease CVD
aspirin decrease questions answer selected SELECTION reviews aspirin control prevention disease cardiovascular
aspirin decrease questions answer selected SELECTION reviews aspirin control prevention disease
aspirin decrease questions answer selected SELECTION CVD
aspirin decrease CVD
aspirin increase bleeding strokes hemorrhagic
aspirin increase bleeding strokes
aspirin use reduces number events CVD
aspirin use reduces CVD
Aspirin seem affect mortality CVD
aspirin use increases risk events bleeding
aspirin use strokes hemorrhagic
aspirin use strokes
aspirin prevention CVD
Aspirin reduces risk infarction myocardial
Aspirin reduces risk infarction
Aspirin use increases risk events bleeding
Hydroxytyrosol ameliorates induced stress dysfunction mitochondrial
Hydroxytyrosol ameliorates induced stress dysfunction
doxorubicin stress dysfunction mitochondrial
doxorubicin stress dysfunction
Hydroxytyrosol ameliorates induced cardiotoxicity
doxorubicin stress induced cardiotoxicity
Hydroxytyrosol ameliorates induced rats cancer breast
Hydroxytyrosol ameliorates induced rats cancer
doxorubicin stress induced rats cancer breast
doxorubicin stress induced rats cancer
doxorubicin drugs effect potentiate shown involved processes cancer
doxorubicin drugs effect potentiate shown involved processes cancer disease cardiovascular
doxorubicin drugs effect potentiate shown involved processes cancer disease
Doxorubicin causes cardiotoxicity characterized increases stress dysfunction mitochondrial
Doxorubicin causes cardiotoxicity characterized increases stress dysfunction
Doxorubicin causes cardiotoxicity
hydroxytyrosol ameliorated toxicity cardiac
hydroxytyrosol ameliorated toxicity
doxorubicin associated ameliorated toxicity cardiac
doxorubicin associated ameliorated toxicity
hydroxytyrosol rats cancer breast
hydroxytyrosol rats cancer
doxorubicin associated ameliorated hydroxytyrosol rats cancer breast
doxorubicin associated ameliorated hydroxytyrosol rats cancer
hydroxytyrosol mg groups divided Thirty rats bearing tumors breast
hydroxytyrosol mg groups divided Thirty rats bearing tumors
hydroxytyrosol doxorubicin groups divided Thirty rats bearing tumors breast
hydroxytyrosol doxorubicin groups divided Thirty rats bearing tumors
doxorubicin groups divided Thirty rats bearing tumors breast
doxorubicin groups divided Thirty rats bearing tumors
doxorubicin groups divided Thirty rats bearing tumors breast
doxorubicin groups divided Thirty rats bearing tumors
Hydroxytyrosol improved disturbances cardiac
Hydroxytyrosol improved disturbances
hydroxytyrosol protect damage heart
hydroxytyrosol protect damage
amitriptyline therapy syndrome neuroleptic
amitriptyline therapy syndrome malignant
amitriptyline therapy syndrome
amitriptyline therapy syndrome disorders serotonin
amitriptyline therapy syndrome disorders syndrome
amitriptyline therapy course developed remission depression unipolar
amitriptyline therapy course developed remission depression
glycopyrrolate hyperhidrosis gustatory
glycopyrrolate hyperhidrosis
glycopyrrolate applying excellent sweating
glycopyrrolate applying excellent reduced sweating
glycopyrrolate patients throat mouth dry
glycopyrrolate patients throat mouth
glycopyrrolate patient headache patients throat mouth dry
glycopyrrolate patient headache patients throat mouth
glycopyrrolate pad application appeared tolerated method treatment sympathectomy moderate symptoms hyperhidrosis gustatory
glycopyrrolate pad application appeared tolerated method treatment sympathectomy moderate symptoms hyperhidrosis
cocaine contributes impairment Mitochondrial
cocaine contributes impairment
MitoQ contributes impairment Mitochondrial
MitoQ contributes impairment
MitoQ contributes cocaine dysfunction cardiac
MitoQ contributes cocaine dysfunction
cocaine exposure short detectable suggesting late abnormalities mitochondrial
cocaine exposure short detectable suggesting late abnormalities
cocaine response late abnormalities mitochondrial
cocaine response late abnormalities
MitoQ shown prevent abnormalities dysfunction characterized dysfunction diastolic
MitoQ shown prevent abnormalities dysfunction characterized dysfunction
MitoQ shown prevent abnormalities mitochondrial
MitoQ shown prevent abnormalities
MitoQ shown prevent abnormalities dysfunction cardiac
MitoQ shown prevent abnormalities dysfunction
cocaine demonstrate extend due defect mitochondrial
cocaine demonstrate extend due defect
contrast Incidence nephropathy patients cancer
contrast related factors frequency determine induced cancer
irinotecan more more patients hypertension
bevacizumab / irinotecan more more patients hypertension
irinotecan combination Hypertension
bevacizumab irinotecan combination Hypertension
bevacizumab Hypertension
alcohol association use progression HIV
alcohol association use progression disease
alcohol consumption association effects progression HIV
alcohol consumption association effects progression disease
Topotecan combination radiotherapy glioblastoma
Topotecan option exhibits inhibition glioma
topotecan mg radiotherapy combination assessed adults GBM
amiodarone dronedarone effects animals infarction myocardial
amiodarone dronedarone effects animals infarction
dronedarone effects animals infarction myocardial
dronedarone effects animals infarction
amiodarone related compound effects compared compared stimulation dogs infarction myocardial
amiodarone related compound effects compared compared stimulation dogs infarction
amiodarone those compared compared stimulation dogs infarction myocardial
amiodarone those compared compared stimulation dogs infarction
dronedarone effects compared compared stimulation dogs infarction myocardial
dronedarone effects compared compared stimulation dogs infarction
amiodarone dronedarone reduced exercise induced tachycardia
amiodarone dronedarone reduced exercise induced tachycardia
dronedarone reduced exercise induced tachycardia
dronedarone reduced exercise induced tachycardia
dronedarone suitable treatment arrhythmias
rifampin use associated complication failure Renal
rifampin use associated complication failure
rifampin failure developed leprosy
trimethaphan induced accompanied bradycardia
carbamazepine woman epileptic
carbamazepine toxicity bone
carbamazepine toxicity marrow
carbamazepine toxicity
cyclosporin A tablets Long hypertension patients psoriasis
A tablets Long hypertension patients psoriasis
nifedipine efficacy Long hypertension
nifedipine efficacy Long hypertension patients psoriasis
calcium blocker months treated cyclosporin course hypertension
cyclosporin course hypertension patients psoriatic
A therapy treated cyclosporin course hypertension patients psoriatic
nifedipine release patients hypertension
nifedipine release patients psoriatic
calcium blocker months treated cyclosporin course hypertension patients psoriatic
blood levels included 9 development hyperplasia gingival
blood levels included 9 development hyperplasia
urea levels included 9 development hyperplasia gingival
urea levels included 9 development hyperplasia
nitrogen levels included 9 development hyperplasia gingival
nitrogen levels included 9 development hyperplasia
cyclosporin A treatment sustained useful patients psoriatic
A treatment sustained useful patients psoriatic
nifedipine useful patients hypertensive
nifedipine useful patients psoriatic
Piperacillin tazobactam seizure
/ tazobactam seizure
tazobactam seizure
piperacillin use goes neurotoxicity
piperacillin associated neurotoxicity
piperacillin tazobactam doses seizure given report 57 woman end
piperacillin tazobactam doses seizure given report 57 disease stage
piperacillin tazobactam doses seizure given report 57 disease renal
piperacillin tazobactam doses seizure given report 57 disease
/ tazobactam doses seizure given report 57 woman end
/ tazobactam doses seizure given report 57 disease stage
/ tazobactam doses seizure given report 57 disease renal
/ tazobactam doses seizure given report 57 disease
tazobactam doses seizure given report 57 woman end
tazobactam doses seizure given report 57 disease stage
tazobactam doses seizure given report 57 disease renal
tazobactam doses seizure given report 57 disease
piperacillin tazobactam doses seizure given bronchiectasis infection secondary
piperacillin tazobactam doses seizure given bronchiectasis infection
/ tazobactam doses seizure given bronchiectasis infection secondary
/ tazobactam doses seizure given bronchiectasis infection
tazobactam doses seizure given bronchiectasis infection secondary
tazobactam doses seizure given bronchiectasis infection
piperacillin tazobactam doses seizure given bronchiectasis
/ tazobactam doses seizure given bronchiectasis
tazobactam doses seizure given bronchiectasis
ammonia levels electrolyte revealed leukocytosis
Piperacillin considered patients uremic
Piperacillin considered encephalopathy
piperacillin removing inefficient terminate piperacillin induced encephalopathy
piperacillin induced encephalopathy
gentamicin treated Animals BACKGROUND show areas fibrosis
clentiazem effect injury cardiac
clentiazem effect injury
epinephrine clentiazem effect injury cardiac
epinephrine clentiazem effect injury
calcium antagonist clentiazem effects induced cardiomyopathy
1 clentiazem effects induced cardiomyopathy
5 clentiazem effects induced cardiomyopathy
benzothiazepine antagonist clentiazem effects induced cardiomyopathy
clentiazem effects induced cardiomyopathy
epinephrine infusion 2 died observed lesions fibrosis
epinephrine infusion 2 died observed lesions ischemic
epinephrine infusion 2 died observed lesions
clentiazem Treatment prevented attenuated lesions fibrosis
epinephrine prevented attenuated lesions fibrosis
clentiazem Treatment prevented attenuated lesions ischemic
clentiazem Treatment prevented attenuated lesions
epinephrine prevented attenuated lesions ischemic
epinephrine prevented attenuated lesions
clentiazem attenuated epinephrine induced injury cardiac
clentiazem attenuated epinephrine induced injury
epinephrine induced injury cardiac
epinephrine induced injury
digoxin hypokalemia
digoxin hypokalemia excess factors context occurred Consistent TdP
amiodarone therapy context tone resulted amiodarone induced proarrhythmia
amiodarone induced proarrhythmia
amiodarone therapy absence induce hypokalemia hypomagnesemia
amiodarone therapy absence induce hypokalemia
dexamethasone Bortezomib myeloma multiple
dexamethasone Bortezomib myeloma
Bortezomib myeloma multiple
Bortezomib myeloma
dexamethasone therapy myeloma multiple
dexamethasone therapy myeloma
dexamethasone MM
dex dexamethasone therapy myeloma multiple
dex dexamethasone therapy myeloma
dex dexamethasone MM
Bortezomib dexamethasone therapy myeloma multiple
Bortezomib dexamethasone therapy myeloma
Bortezomib dexamethasone MM
bort Bortezomib dexamethasone therapy myeloma multiple
bort Bortezomib dexamethasone therapy myeloma
bort Bortezomib dexamethasone MM
dex bort combination investigated study stem MM
bort combination investigated study stem MM
bort day mg bort combination investigated study stem MM
dex treatment patients MM
Bort treatment patients MM
pentazocine morphine induced analgesia effect effect effect cataleptic
NA receptors stimulating drugs failed found enhanced induced catalepsy
MA chronically used subjects Studies revealed systems abnormalities metabolic
MA chronically used subjects Studies revealed systems abnormalities
MA abuse associated related cognitive
MA abuse associated related cognitive impairment
MA abusers had hippocampal hypertrophy
ACC have activity seizures
9653 have activity seizures
phenytoin sodium 9653 have activity seizures
sodium 9653 have activity seizures
ACC have activity tachycardia ventricular
ACC have activity tachycardia
9653 have activity tachycardia ventricular
9653 have activity tachycardia
phenytoin sodium 9653 have activity tachycardia ventricular
phenytoin sodium 9653 have activity tachycardia
sodium 9653 have activity tachycardia ventricular
sodium 9653 have activity tachycardia
ACC doses necessary convert arrhythmia
9653 doses necessary convert arrhythmia
phenytoin sodium 9653 doses necessary convert arrhythmia
sodium 9653 doses necessary convert arrhythmia
phenytoin sodium arrhythmias
sodium arrhythmias
ACC studies toxicity
9653 studies toxicity
phenytoin sodium 9653 studies toxicity
sodium 9653 studies toxicity
valproate induced encephalopathy
valproate migraine hemiplegic
valproate migraine
valproate started had number admissions hemiparesis
N D titre encephalopathy
methyl D titre encephalopathy
D titre encephalopathy
aspartate antibodies present showed consistent D titre encephalopathy
NMDA antibodies present showed consistent D titre encephalopathy
valproate aetiologies induced receptor encephalopathy
NMDA encephalopathy
NMDA encephalopathy receptor induced aetiologies associated present encephalitis
valproate aetiologies associated present encephalitis
citalopram concentration associated somnolence
citalopram concentration associated somnolence difficulties movement
citalopram concentration associated somnolence difficulties
desmethylfluoxetine concentration hyperkinetic
desmethylfluoxetine concentration delirium
L induced produced cell - hernias
norepinephrine produced cell - hernias
Ecstasy drug associated dysfunction psychobiological
Ecstasy drug associated dysfunction
MDMA Ecstasy drug associated dysfunction psychobiological
MDMA Ecstasy drug associated dysfunction
ecstasy observations line increases anxiety
Mefenamic acid induced hypothyroidism
acid induced hypothyroidism
mefenamic acid use patients hypothyroid
acid use patients hypothyroid
mefenamic acid use prudent seem corrected hypothyroidism
acid use prudent seem corrected hypothyroidism
cocaine presenting admitted receive syndrome acute
cocaine presenting admitted receive syndrome coronary
cocaine presenting admitted receive syndrome
cocaine efficacious associated pain account vasospasm coronary
cocaine efficacious associated pain account vasospasm
cocaine efficacious associated pain account some ischemia
cocaine result discharged patients ECG ischemic
cocaine patients ECG ischemic
methotrexate consequence P protocols acute
methotrexate consequence P protocols lymphoblastic
methotrexate consequence P protocols leukemia
methotrexate led children leukemia acute
methotrexate led children leukemia lymphoblastic
methotrexate led children leukemia
MTX methotrexate led children leukemia acute
MTX methotrexate led children leukemia lymphoblastic
MTX methotrexate led children leukemia
MTX administration frequency therapy modifications led children leukemia acute
MTX administration frequency therapy modifications led children leukemia lymphoblastic
MTX administration frequency therapy modifications led children leukemia
methotrexate led neurotoxicity
MTX methotrexate led neurotoxicity
MTX administration frequency therapy modifications led neurotoxicity
ginsenosides Effects hyperalgesia
Re effects ginsenosides OIH
Rg effects ginsenosides OIH
1 Rg effects ginsenosides OIH
and effects ginsenosides OIH
Rb ginsenosides OIH
1 ginsenosides OIH
ginsenosides OIH
Re inhibited OIH
acetic acid test inhibited OIH
acid test inhibited OIH
Rg failed prevent OIH
1 Rg failed prevent OIH
and Rg failed prevent OIH
Rb ginsenosides Rg failed prevent OIH
1 ginsenosides Rg failed prevent OIH
ginsenosides Rg failed prevent OIH
acetic acid OIH
acid OIH
Rg showed tendency aggravate OIH
1 Rg showed tendency aggravate OIH
ginsenoside contribute reversal OIH
Re ginsenoside contribute reversal OIH
Rb Rg ginsenoside contribute reversal OIH
1 Rb Rg ginsenoside contribute reversal OIH
Rg ginsenoside contribute reversal OIH
1 Rg ginsenoside contribute reversal OIH
triglyceride accumulation dose observed liver depression
triglyceride output liver depression
tetracycline dose observed liver depression
oleic acid provision observed liver depression
acid provision observed liver depression
triglyceride output depression
tetracycline effects resistant depression
triglyceride secretion accounted liver fatty
triglyceride secretion accounted liver
triglyceride % accounted liver fatty
triglyceride % accounted liver
triglyceride production involved indicating triglyceride % accounted liver fatty
triglyceride production involved indicating triglyceride % accounted liver
mesna prevention bladder lesions
mesna prevention bladder of
mesna prevention bladder the
mesna prevention bladder urinary
mesna prevention bladder
cyclophosphamide developed characterized detachment urothelium edema
cyclophosphamide developed characterized detachment urothelium edema owing damage bed necroses
cyclophosphamide developed characterized cystitis
cocaine intoxication pallidus infarction haemorrhagic
cocaine intoxication pallidus infarction
cocaine intoxication pallidus infarction globus of
cocaine intoxication pallidus infarction globus the
cocaine intoxication pallidus infarction globus
cocaine intoxication pallidus
alcohol cocaine intoxication pallidus infarction haemorrhagic
alcohol cocaine intoxication pallidus infarction
alcohol cocaine intoxication pallidus infarction globus of
alcohol cocaine intoxication pallidus infarction globus the
alcohol cocaine intoxication pallidus infarction globus
alcohol cocaine intoxication pallidus
Cocaine factor stroke ischemic
Cocaine factor stroke ischemic and
Cocaine factor stroke ischemic haemorrhagic
Cocaine factor stroke
alcohol pallidus case 31 man ischemia
alcohol pallidus case 31 man ischemia globus of
alcohol pallidus case 31 man ischemia globus the
alcohol pallidus case 31 man ischemia globus
alcohol pallidus
cocaine use infarcts basal
cocaine use infarcts ganglia
cocaine use infarcts
ethanol use cocaine related dysfunction arrhythmia cardiac
ethanol use cocaine related dysfunction arrhythmia
ethanol use cocaine related dysfunction arrhythmia causes hypoperfusion cerebral
ethanol use cocaine related dysfunction arrhythmia causes hypoperfusion
cocaine related dysfunction arrhythmia causes hypoperfusion cerebral
cocaine related dysfunction arrhythmia causes hypoperfusion
cocaine related dysfunction arrhythmia cardiac
cocaine related dysfunction arrhythmia
cocaine related dysfunction respiratory
cocaine related dysfunction
ethanol use cocaine related dysfunction respiratory
ethanol use cocaine related dysfunction
etoposide therapy glioma malignant
etoposide therapy glioma
etoposide therapy dysfunction Acute
etoposide therapy dysfunction neurologic
etoposide therapy dysfunction
Etoposide used treatment tumors
VP Etoposide used treatment tumors
16 VP Etoposide used treatment tumors
213 16 VP Etoposide used treatment tumors
Etoposide used treatment tumors malignancies hematologic
Etoposide used treatment tumors malignancies
VP Etoposide used treatment tumors malignancies hematologic
VP Etoposide used treatment tumors malignancies
16 VP Etoposide used treatment tumors malignancies hematologic
16 VP Etoposide used treatment tumors malignancies
213 16 VP Etoposide used treatment tumors malignancies hematologic
213 16 VP Etoposide used treatment tumors malignancies
etoposide therapy toxicity
etoposide therapy glioma malignant
etoposide therapy glioma
alpha alanine induced cardiotoxicity
fluoro alanine induced cardiotoxicity
beta fluoro alanine induced cardiotoxicity
alanine induced cardiotoxicity
5 Fluorouracil induced cardiotoxicity
Fluorouracil induced cardiotoxicity
5 treatment malignancies
fluorouracil treatment malignancies
5 treatment malignancies
FU 5 treatment malignancies
5 occurring Cardiotoxicity
fluorouracil treatment 5 occurring Cardiotoxicity
5 treatment 5 occurring Cardiotoxicity
FU 5 treatment 5 occurring Cardiotoxicity
alpha alanine level observed induced cardiotoxicity
fluoro alanine level observed induced cardiotoxicity
beta fluoro alanine level observed induced cardiotoxicity
alanine level observed induced cardiotoxicity
FBAL alanine level observed induced cardiotoxicity
5 man year induced cardiotoxicity
FU 5 man year induced cardiotoxicity
FBAL concentration occurred pain precordial
FBAL concentration occurred pain
FBAL concentration occurred pain block right
FBAL concentration occurred pain block bundle
FBAL concentration occurred pain block branch
FBAL concentration occurred pain block
5 induced cardiotoxicity
FU 5 induced cardiotoxicity
5 administration induced cardiotoxicity
FU abandoned considered due 5 induced cardiotoxicity
FBAL related 5 induced cardiotoxicity
5 induced cardiotoxicity
FU 5 induced cardiotoxicity
5 induced cardiotoxicity
FU 5 induced cardiotoxicity
cyclophosphamide adriamycin platinum Treatment cancer ovarian
cyclophosphamide adriamycin platinum Treatment cancer
adriamycin platinum Treatment cancer ovarian
adriamycin platinum Treatment cancer
hexamethylmelamine adriamycin platinum Treatment cancer ovarian
hexamethylmelamine adriamycin platinum Treatment cancer
cis combination Treatment cancer ovarian
cis combination Treatment cancer
platinum Treatment cancer ovarian
platinum Treatment cancer
cyclophosphamide m m mg combination treated patients cancer ovarian
cyclophosphamide m m mg combination treated patients cancer
adriamycin m mg combination treated patients cancer ovarian
adriamycin m mg combination treated patients cancer
hexamethylmelamine mg m m mg combination treated patients cancer ovarian
hexamethylmelamine mg m m mg combination treated patients cancer
HMM hexamethylmelamine mg m m mg combination treated patients cancer ovarian
HMM hexamethylmelamine mg m m mg combination treated patients cancer
CPDD combination treated patients cancer ovarian
CPDD combination treated patients cancer
cisplatinum combination treated patients cancer ovarian
cisplatinum combination treated patients cancer
HMM toxicity gastrointestinal
HMM toxicity
levomepromazine risperidone administration developed patient failure chronic
levomepromazine risperidone administration developed patient failure renal
levomepromazine risperidone administration developed patient failure
levomepromazine risperidone administration developed patient CRF
risperidone administration developed patient failure chronic
risperidone administration developed patient failure renal
risperidone administration developed patient failure
risperidone administration developed patient CRF
cocaine exposure linked hemorrhage
cocaine exposure increases incidence cysts subependymal
cocaine exposure increases incidence cysts
cocaine group was history abuse cocaine
cocaine group was history abuse
cocaine exposed infants cysts subependymal
cocaine exposed infants cysts
cocaine prenatally exposed incidence formation subependymal
cocaine prenatally exposed incidence formation cyst
bilirubin gender end
bilirubin gender score stage
bilirubin gender score liver
bilirubin gender score disease
TAC level gender end
TAC level gender score stage
TAC level gender score liver
TAC level gender score disease
bilirubin gender included factors associated seizures
oestrogen therapy receiving Prevention disease endometrial
oestrogen therapy receiving Prevention disease
oestrogen therapy receiving women described patients disease endometrial
oestrogen therapy receiving women described patients disease
progestagen associated hyperplasia
norethisterone days courses caused cases hyperplasia
norethisterone days courses caused cases 6 cases hyperplasia
oestrogen therapy problems demonstrated cases carcinoma endometrial
oestrogen therapy problems demonstrated cases carcinoma
oestrogen therapy problems demonstrated malignancy
progestagen low seem increase risk hyperplasia carcinoma
oestrogen therapy low seem increase risk hyperplasia carcinoma
progestagen low seem increase risk hyperplasia endometrial
progestagen low seem increase risk hyperplasia
oestrogen therapy low seem increase risk hyperplasia endometrial
oestrogen therapy low seem increase risk hyperplasia
lidocaine safety Clinical associated infarction myocardial
lidocaine safety Clinical associated infarction
lidocaine safety evaluate induced infarction myocardial
lidocaine safety evaluate induced infarction
lidocaine safety evaluate induced infarction MI
lidocaine received MI
lidocaine associated MI
lidocaine administration experienced died patients received lidocaine associated MI
lidocaine received patients died exhibited bradydysrhythmias
lidocaine administration experienced died exhibited bradydysrhythmias
cocaine setting lidocaine received patients died exhibited bradydysrhythmias tachycardia ventricular
cocaine setting lidocaine received patients died exhibited bradydysrhythmias tachycardia
cocaine setting lidocaine received patients died exhibited bradydysrhythmias
lidocaine received patients died exhibited bradydysrhythmias tachycardia ventricular
lidocaine received patients died exhibited bradydysrhythmias tachycardia
lidocaine administration experienced died exhibited bradydysrhythmias tachycardia ventricular
lidocaine administration experienced died exhibited bradydysrhythmias tachycardia
lidocaine received patients died exhibited bradydysrhythmias fibrillation ventricular
lidocaine received patients died exhibited bradydysrhythmias fibrillation
lidocaine administration experienced died exhibited bradydysrhythmias fibrillation ventricular
lidocaine administration experienced died exhibited bradydysrhythmias fibrillation
lidocaine received patients died experienced seizures
lidocaine administration experienced seizures
cocaine setting lidocaine received patients died exhibited bradydysrhythmias fibrillation ventricular
cocaine setting lidocaine received patients died exhibited bradydysrhythmias fibrillation
cocaine setting lidocaine received patients died experienced seizures
lidocaine enhance associated cardiovascular
lidocaine enhance associated cardiovascular or
lidocaine enhance associated cardiovascular toxicity central
lidocaine enhance associated cardiovascular toxicity nervous
lidocaine enhance associated cardiovascular toxicity system
lidocaine enhance associated cardiovascular toxicity
lidocaine use toxicity enhance associated cardiovascular
lidocaine use toxicity enhance associated cardiovascular or
lidocaine use toxicity enhance associated cardiovascular toxicity central
lidocaine use toxicity enhance associated cardiovascular toxicity nervous
lidocaine use toxicity enhance associated cardiovascular toxicity system
lidocaine use toxicity enhance associated cardiovascular toxicity
lidocaine enhance associated MI
lidocaine use toxicity enhance associated MI
lidocaine enhance toxicity
lidocaine use toxicity
cocaine toxicity enhance associated cardiovascular
cocaine toxicity enhance associated cardiovascular or
cocaine toxicity enhance associated cardiovascular toxicity central
cocaine toxicity enhance associated cardiovascular toxicity nervous
cocaine toxicity enhance associated cardiovascular toxicity system
cocaine toxicity enhance associated cardiovascular toxicity
cocaine patients enhance associated cardiovascular
cocaine patients enhance associated cardiovascular or
cocaine patients enhance associated cardiovascular toxicity central
cocaine patients enhance associated cardiovascular toxicity nervous
cocaine patients enhance associated cardiovascular toxicity system
cocaine patients enhance associated cardiovascular toxicity
cocaine toxicity
cocaine patients enhance toxicity
ethambutol tuberculosis
ethambutol tuberculosis node of
ethambutol tuberculosis node the
ethambutol tuberculosis node lung
ethambutol tuberculosis node lung or
ethambutol tuberculosis node lung lymph
ethambutol tuberculosis node
dobutamine echocardiography safety assess study associated pain chest
dobutamine echocardiography safety assess study associated pain
Dobutamine echocardiography test evaluating ischemia
dobutamine administration concern conducted study associated pain chest
dobutamine administration concern conducted study associated pain
cocaine toxicity
dobutamine administered patients pain chest
dobutamine administered patients pain
dobutamine treatment pointes patient cardiomyopathy dilated
dobutamine treatment pointes patient cardiomyopathy
dobutamine treatment pointes patient cardiomyopathy failure congestive
dobutamine treatment pointes patient cardiomyopathy failure heart
dobutamine treatment pointes patient cardiomyopathy failure
dobutamine treatment pointes tachycardia ventricular
dobutamine treatment pointes tachycardia
dobutamine dose cycle tachycardia torsade dilated cardiomyopathy developed prolongation QT
dobutamine dose cycle tachycardia torsade dilated cardiomyopathy developed prolongation
dobutamine dose cycle tachycardia torsade dilated cardiomyopathy arrhythmias ventricular
dobutamine dose cycle tachycardia torsade dilated cardiomyopathy arrhythmias
dobutamine dose cycle tachycardia torsade dilated
dobutamine dose cycle tachycardia torsade dilated cardiomyopathy
dobutamine dose cycle tachycardia torsade dilated secondary case 56 woman failure heart
dobutamine dose cycle tachycardia torsade dilated secondary case 56 woman failure
dobutamine dose cycle tachycardia ventricular
dobutamine dose cycle tachycardia
dobutamine tachycardia torsade report supports occur arrhythmias
dobutamine tachycardia ventricular
dobutamine tachycardia
Amiodarone requiring fibrillation infarction myocardial
Amiodarone requiring fibrillation infarction
Amiodarone requiring fibrillation atrial
Amiodarone requiring fibrillation
amiodarone patients fibrillation atrial
amiodarone patients fibrillation
amiodarone patients fibrillation AF
amiodarone therapy bradyarrhythmia Reports infrequent studies assessing use management patients arrhythmias ventricular
amiodarone therapy bradyarrhythmia Reports infrequent studies assessing use management patients arrhythmias
amiodarone patients AF MI
amiodarone patients AF
propranolol Modification hypoglycaemia
Thalidomide neuropathy
Thalidomide neuropathy treated cancer prostate
Thalidomide neuropathy treated cancer
thalidomide evaluated using neuropathy
androgen men Sixty cancer prostate
androgen men Sixty cancer
thalidomide underwent trial Sixty cancer prostate
thalidomide underwent trial Sixty cancer
thalidomide complication Neuropathy
prostaglandin bupivacaine effects E release pain
E release pain
2 release pain
prostaglandin bupivacaine effects E model pain
E model pain
2 release E model pain
lidocaine bupivacaine effects E release pain
lidocaine bupivacaine effects E model pain
bupivacaine effects E release pain
bupivacaine effects E model pain
prostaglandin E bupivacaine production effects expression increases pain postoperative
prostaglandin E bupivacaine production effects expression increases pain
E bupivacaine production effects expression increases pain postoperative
E bupivacaine production effects expression increases pain
2 E bupivacaine production effects expression increases pain postoperative
2 E bupivacaine production effects expression increases pain
PGE E bupivacaine production effects expression increases pain postoperative
PGE E bupivacaine production effects expression increases pain
2 PGE E bupivacaine production effects expression increases pain postoperative
2 PGE E bupivacaine production effects expression increases pain
bupivacaine RESULTS reported pain
rofecoxib group reported pain
PGE levels h reported pain
2 levels h reported pain
bupivacaine reported pain
PGE pain
2 production PGE pain
PGE associated injury tissue
PGE associated injury
2 production PGE associated injury tissue
2 production PGE associated injury
bupivacaine stimulates COX expression injury associated PGE pain
bupivacaine stimulates COX expression injury tissue
bupivacaine stimulates COX expression injury
tyrosine kinase receptors expression examined inflammation urinary
tyrosine kinase receptors expression examined inflammation bladder
tyrosine kinase receptors expression examined inflammation
isoproterenol dosages effects associated mortality reduced indicated had little severity infarction
Flecainide started fibrillation atrial
Flecainide started fibrillation
sodium channels interact cause delirium
flecainide prescribed occur toxicity
flecainide concentrations monitored occur toxicity
paroxetine prescribed occur toxicity
trimethoprim sulfamethoxazole toxicity drug
trimethoprim sulfamethoxazole toxicity
sulfamethoxazole toxicity drug
sulfamethoxazole toxicity
trimethoprim sulfamethoxazole toxicity drug
trimethoprim sulfamethoxazole toxicity
cephalexin sulfamethoxazole toxicity drug
cephalexin sulfamethoxazole toxicity
trimethoprim prescribed estimate risk liver
trimethoprim prescribed estimate risk liver blood
trimethoprim prescribed estimate risk liver skin
trimethoprim prescribed estimate risk liver and
trimethoprim prescribed estimate risk liver disorders renal
trimethoprim prescribed estimate risk liver disorders
sulfamethoxazole prescribed estimate risk liver
sulfamethoxazole prescribed estimate risk liver blood
sulfamethoxazole prescribed estimate risk liver skin
sulfamethoxazole prescribed estimate risk liver and
sulfamethoxazole prescribed estimate risk liver disorders renal
sulfamethoxazole prescribed estimate risk liver disorders
TMP sulfamethoxazole prescribed estimate risk liver
TMP sulfamethoxazole prescribed estimate risk liver blood
TMP sulfamethoxazole prescribed estimate risk liver skin
TMP sulfamethoxazole prescribed estimate risk liver and
TMP sulfamethoxazole prescribed estimate risk liver disorders renal
TMP sulfamethoxazole prescribed estimate risk liver disorders
SMZ TMP sulfamethoxazole prescribed estimate risk liver
SMZ TMP sulfamethoxazole prescribed estimate risk liver blood
SMZ TMP sulfamethoxazole prescribed estimate risk liver skin
SMZ TMP sulfamethoxazole prescribed estimate risk liver and
SMZ TMP sulfamethoxazole prescribed estimate risk liver disorders renal
SMZ TMP sulfamethoxazole prescribed estimate risk liver disorders
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver blood
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver skin
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver and
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver disorders renal
trimethoprim alone 266 sulfamethoxazole prescribed estimate risk liver disorders
cephalexin sulfamethoxazole prescribed estimate risk liver
cephalexin sulfamethoxazole prescribed estimate risk liver blood
cephalexin sulfamethoxazole prescribed estimate risk liver skin
cephalexin sulfamethoxazole prescribed estimate risk liver and
cephalexin sulfamethoxazole prescribed estimate risk liver disorders renal
cephalexin sulfamethoxazole prescribed estimate risk liver disorders
TMP exposed disorders experienced SMZ SMZ seven multiforme erythema
TMP exposed disorders experienced SMZ SMZ seven multiforme
SMZ seven multiforme erythema
SMZ seven multiforme
TMP exposed Johnson Stevens seven multiforme erythema
TMP exposed Johnson Stevens seven multiforme
SMZ SMZ seven multiforme erythema
SMZ SMZ seven multiforme
melatonin effects cortex induced dysplasia cortical
melatonin effects cortex induced dysplasia
melatonin effects investigate BCNU induced dysplasia cortical
melatonin effects investigate BCNU induced dysplasia
linezolid therapy associated vision loss
linezolid therapy associated vision of
linezolid therapy associated vision
linezolid drugs tuberculous presented loss
linezolid drugs tuberculous presented loss vision of
linezolid drugs tuberculous presented loss vision
ethambutol linezolid drugs tuberculous presented loss
ethambutol linezolid drugs tuberculous presented loss vision of
ethambutol linezolid drugs tuberculous presented loss vision
linezolid drug extensively
linezolid drug
linezolid drugs tuberculous presented tuberculosis resistant
linezolid drugs tuberculous presented tuberculosis
linezolid drugs tuberculous presented tuberculosis XDR
linezolid drugs tuberculous presented tuberculosis XDR TB
ethambutol linezolid drug extensively
ethambutol linezolid drug
ethambutol linezolid drugs tuberculous presented tuberculosis resistant
ethambutol linezolid drugs tuberculous presented tuberculosis
ethambutol linezolid drugs tuberculous presented tuberculosis XDR
ethambutol linezolid drugs tuberculous presented tuberculosis XDR TB
Ethambutol induced suspected neuropathy toxic
Ethambutol induced suspected neuropathy optic
Ethambutol induced suspected neuropathy
ethambutol withdrawn suspected neuropathy toxic
ethambutol withdrawn suspected neuropathy optic
ethambutol withdrawn suspected neuropathy
ethambutol withdrawal occurred Deterioration
ethambutol withdrawal occurred Deterioration vision of
ethambutol withdrawal occurred Deterioration vision
levodopa characterize dynamics patients PD
levodopa suggest confirm predictor dysphagia
levodopa suggest confirm predictor alterations PD
dexamethasone bortezomib Combination stem transplantation myeloma multiple
dexamethasone bortezomib Combination stem transplantation myeloma
bortezomib Combination stem transplantation myeloma multiple
bortezomib Combination stem transplantation myeloma
thalidomide bortezomib Combination stem transplantation myeloma multiple
thalidomide bortezomib Combination stem transplantation myeloma
dexamethasone bortezomib regimen safety analyzed patients MM
bortezomib regimen safety analyzed patients MM
thalidomide bortezomib regimen safety analyzed patients MM
imipramine induced Hypertension neuroblastoma
Imipramine given occurrence hypertension 4 girl neuroblastoma
Imipramine given control disorder behavior
Imipramine given control disorder
salbutamol inhaled asthmatics
salbutamol doses produce response patients asthma
salbutamol dose treatment 14 given patients asthmatic
salbutamol 14 given patients asthmatic
K metabolic responses chronotropic tremor
Glu K metabolic responses chronotropic tremor
doxorubicin hearts treated hypertrophic
doxorubicin given toxicity using determined schedule exerted toxicity
doxorubicin given toxicity
ICRF protection determined schedule exerted toxicity
187 ICRF protection determined schedule exerted toxicity
ICRF protection determined using toxicity
187 ICRF protection determined using toxicity
ICRF provided protection demonstrated induced cardiotoxicity
187 result induced cardiotoxicity
HCl exposure effect determined determining concentration bupivacaine caused myocyte become arrhythmic
N form given cardiotoxicity
2 conjugates form given cardiotoxicity
hydroxypropyl 2 conjugates form given cardiotoxicity
methacrylamide conjugates form given cardiotoxicity
N doxorubicin cardiotoxicity
2 cardiotoxicity
hydroxypropyl 2 cardiotoxicity
methacrylamide cardiotoxicity
HPMA conjugates methacrylamide cardiotoxicity
N doxorubicin cardiotoxicity methacrylamide used evaluate toxicity
2 cardiotoxicity methacrylamide used evaluate toxicity
hydroxypropyl 2 cardiotoxicity methacrylamide used evaluate toxicity
methacrylamide used evaluate toxicity
HPMA conjugates methacrylamide used evaluate toxicity
doxorubicin cardiotoxicity methacrylamide used evaluate toxicity
DOX doxorubicin cardiotoxicity methacrylamide used evaluate toxicity
HPMA copolymer mixture DOX received animals observed deaths related cardiotoxicity
HPMA copolymer mixture DOX received animals observed revealed heart consistent cardiotoxicity
K induced Nephropathy
Na Expression Decreased K induced Nephropathy
K Na expression related nephropathy
Na expression related nephropathy
caproate related effect Hyperglycemic
caproate derivatives amounts feeding resulted hyperglycemia glucosuria
glucose curve hyperglycemia
amino derivatives amounts feeding resulted hyperglycemia glucosuria
caproate derivatives amounts feeding resulted hyperglycemia
glucose curve hyperglycemia glucosuria
Levodopa induced disease Parkinson
Levodopa induced disease Parkinson '
Levodopa induced disease s
Levodopa induced disease
tiapride tetrabenazine therapy induced patient disease Huntington
tiapride tetrabenazine therapy induced patient disease Huntington '
tiapride tetrabenazine therapy induced patient disease s
tiapride tetrabenazine therapy induced patient disease
tetrabenazine therapy induced patient disease Huntington
tetrabenazine therapy induced patient disease Huntington '
tetrabenazine therapy induced patient disease s
tetrabenazine therapy induced patient disease
tiapride tetrabenazine therapy induced stage cancer breast
tiapride tetrabenazine therapy induced stage cancer
tetrabenazine therapy induced stage cancer breast
tetrabenazine therapy induced stage cancer
tiapride therapy initiation occurred disease Huntington
tiapride therapy initiation occurred disease Huntington '
tiapride therapy initiation occurred disease s
tiapride therapy initiation occurred disease
tetrabenazine tiapride therapy initiation occurred disease Huntington
tetrabenazine tiapride therapy initiation occurred disease Huntington '
tetrabenazine tiapride therapy initiation occurred disease s
tetrabenazine tiapride therapy initiation occurred disease
erdosteine protection induced nephrotoxicity
oxygen species production promotes stress vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment renal
oxygen species production promotes stress vancomycin examine investigate role erdosteine antioxidant tissue VCM induced impairment
erdosteine antioxidant tissue VCM induced impairment renal
erdosteine antioxidant tissue VCM induced impairment
superoxide dismutase excretion NAG marker injury renal
superoxide dismutase excretion NAG marker injury tubular
superoxide dismutase excretion NAG marker injury
malondialdehyde excretion NAG marker injury renal
malondialdehyde excretion NAG marker injury tubular
malondialdehyde excretion NAG marker injury
MDA malondialdehyde excretion NAG marker injury renal
MDA malondialdehyde excretion NAG marker injury tubular
MDA malondialdehyde excretion NAG marker injury
Erdosteine showed induced nephrotoxicity
erdosteine groups control those were dilatation lumens atrophy
VCM necrosis lumens atrophy
erdosteine groups control those were dilatation lumens necrosis
erdosteine groups control those were dilatation lumens desquamation
VCM necrosis lumens desquamation
VCM necrosis
erdosteine modulation induced nephrotoxicity
erdosteine modulation induced reduces VCM induced damage kidney
erdosteine modulation induced reduces VCM induced damage
propranolol isomers properties arrhythmias cardiac
propranolol isomers properties arrhythmias
propranolol isomers capable preventing adrenaline induced arrhythmias cardiac
propranolol isomers capable preventing adrenaline induced arrhythmias
propranolol + - dose anaesthetized cats induced arrhythmias cardiac
propranolol + - dose anaesthetized cats induced arrhythmias
propranolol + that 4 kg + - dose anaesthetized cats induced arrhythmias cardiac
propranolol + that 4 kg + - dose anaesthetized cats induced arrhythmias
propranolol isomers capable reversing tachycardia ventricular
propranolol isomers capable reversing tachycardia
direct inhibitor using mandates treatment HIT
thrombin inhibitor using mandates treatment HIT
inhibitor using mandates treatment HIT
Direct inhibitors appropriate based heparin patients history HIT
thrombin inhibitors appropriate based heparin patients history HIT
inhibitors appropriate based heparin patients history HIT
busulfan Dose neurotoxicity
Busulfan known neurotoxic
Busulfan known remains neurotoxicity
busulfan receiving children study report transplantation tumors tumors brain
busulfan receiving children study report transplantation tumors tumors
busulfan receiving children study report transplantation tumors
busulfan dose taken was difference terms incidence neurotoxicity
busulfan m dose v mg 600 given had symptoms neurological
busulfan m dose v mg 600 given had symptoms
clonazepam infusion given had symptoms neurological
clonazepam infusion given had symptoms
Busulfan levels measured mg disease assay fluid children system central
Busulfan levels measured mg disease assay fluid children system nervous
Busulfan levels measured mg disease assay fluid children system
Busulfan levels measured mg disease
busulfan m mg disease assay fluid children system central
busulfan m mg disease assay fluid children system nervous
busulfan m mg disease assay fluid children system
busulfan m mg disease
busulfan fluid busulfan m mg disease assay fluid children system central
busulfan fluid busulfan m mg disease assay fluid children system nervous
busulfan fluid busulfan m mg disease assay fluid children system
busulfan fluid busulfan m mg disease
clonazepam busulfan m mg disease assay fluid children system central
clonazepam busulfan m mg disease assay fluid children system nervous
clonazepam busulfan m mg disease assay fluid children system
clonazepam busulfan m mg disease
clonazepam prevented children dependent dose neurotoxicity
busulfan neurotoxicity
busulfan dose followed neurotoxicity
busulfan dose followed neurotoxicity close incidence neurotoxicity
rapamycin inhibitors target treated patients complication Proteinuria
tacrolimus developed proteinuria
tacrolimus developed amyloidosis
propranolol effects 76 induced hypertrophy heart
propranolol effects 76 induced hypertrophy
ornithine activity blockers hearts hypertrophied
ornithine activity blockers hearts
propranolol stop pattern heart hypertrophied
propranolol beta have potency prevent producing hypertrophy heart
propranolol beta have potency prevent producing hypertrophy
lidocaine phase infarction myocardial
lidocaine phase infarction
lidocaine placebo trial double entered patients infarction myocardial
lidocaine placebo trial double entered patients infarction
Lidocaine prevent tachycardia ventricular
Lidocaine prevent tachycardia
lidocaine number reduction was prevent tachycardia ventricular
lidocaine number reduction was prevent tachycardia
Lidocaine prevent was reduction number arrhythmias
lidocaine number arrhythmias
lidocaine level administration patients infarction myocardial
lidocaine level administration patients infarction
lidocaine level higher infarction
lidocaine group hypotension patients died asystole
lidocaine received nine hypotension patients died asystole
lidocaine had asystole
lidocaine prophylactically administration advocate hours infarction myocardial
lidocaine prophylactically administration advocate hours infarction
estrogen phenotypes hemorrhagic
estrogen phenotypes separation growth tumor
estrogen phenotypes separation tumor
estrogen rat administration induces growth tumors pituitary
estrogen rat administration induces growth tumors
estrogen rat administration induces growth tumors hemorrhagic
diethylstilbestrol treatment weeks caused grow become hemorrhagic
DES treatment weeks caused grow become hemorrhagic
DES exhibited exhibited phenotype hemorrhagic
methylprednisolone therapy received patients arthritis rheumatoid
methylprednisolone therapy received patients arthritis
MP therapy received patients arthritis rheumatoid
MP therapy received patients arthritis
MP contraindicated patients disease heart
MP contraindicated patients disease
verapamil increased patients syndromes chest
verapamil increased patients syndromes pain
angiotensin system patients diabetes type
angiotensin system patients diabetes type 1
angiotensin system patients diabetes
angiotensin system renin blockade retard progression nephropathy
angiotensin system renin blockade retard suggesting involved pathogenesis nephropathy diabetic
angiotensin system renin blockade retard suggesting involved pathogenesis nephropathy
angiotensin system renin blockade retard suggesting involved pathogenesis nephropathy nephropathy diabetic
angiotensin system renin blockade retard suggesting involved pathogenesis nephropathy nephropathy
streptozotocin diabetes
STZ streptozotocin diabetes
streptozotocin contributes development fibrosis
STZ streptozotocin contributes development fibrosis
calcium pathogenesis disease cardiovascular
calcium pathogenesis disease
calcium importance recognition stimulated blocking treatment variety diseases cardiovascular
calcium importance recognition stimulated blocking treatment variety diseases
calcium channel use stimulated recognition importance calcium pathogenesis disease cardiovascular
calcium channel use stimulated recognition importance calcium pathogenesis disease
channel use stimulated recognition importance calcium pathogenesis disease cardiovascular
channel use stimulated recognition importance calcium pathogenesis disease
blocking stimulated recognition importance calcium pathogenesis disease cardiovascular
blocking stimulated recognition importance calcium pathogenesis disease
agents blocking stimulated recognition importance calcium pathogenesis disease cardiovascular
agents blocking stimulated recognition importance calcium pathogenesis disease
calcium channel use stimulated blocking treatment variety diseases cardiovascular
calcium channel use stimulated blocking treatment variety diseases
channel use stimulated blocking treatment variety diseases cardiovascular
channel use stimulated blocking treatment variety diseases
blocking treatment variety diseases cardiovascular
blocking treatment variety diseases
agents blocking treatment variety diseases cardiovascular
agents blocking treatment variety diseases
dihydropyridine controls angina
dihydropyridine controls angina hypertension
nifedipine controls angina hypertension
nifedipine controls angina
nitrendipine possible dosage offers therapy hypertension
nisoldipine nitrendipine possible dosage offers therapy hypertension
nisoldipine properties led angina
nimodipine treatment hemorrhage headache migraine
nimodipine treatment hemorrhage headache
nimodipine treatment hemorrhage stroke
nimodipine treatment hemorrhage subarachnoid
nimodipine treatment hemorrhage
nimodipine treatment hemorrhage dementia
dihydropyridine blockers tolerated effects headache edema anorexia
dihydropyridine blockers tolerated effects headache edema nausea
dihydropyridine blockers tolerated effects headache flushing
dihydropyridine blockers tolerated effects headache edema dizziness
dihydropyridine blockers tolerated effects headache
dihydropyridine blockers tolerated effects headache edema
dihydropyridine blockers tolerated effects headache palpitations
calcium blockers tolerated effects headache palpitations
channel blockers tolerated effects headache palpitations
blockers tolerated effects headache palpitations
diphenylhydantoin taking patient developed rash skin
diphenylhydantoin taking patient developed rash
diphenylhydantoin treatment complication known well rash Skin
diphenylhydantoin treatment complication known well rash
diphenylhydantoin ingestion relation occurrence rash skin
diphenylhydantoin ingestion relation occurrence rash
methamphetamine dose neurotoxic
dopamine levels reduction indicated depressive
HVA dopamine levels reduction indicated depressive
DOPAC dopamine levels reduction indicated depressive
serotonin hydroxylase administration tyrosine depressive
tyrosine depressive
morphine synergy Studies pain inflammatory neuropathic
morphine synergy Studies pain
sodium blocker synergy Studies pain inflammatory neuropathic
sodium blocker synergy Studies pain
CNSB blocker synergy Studies pain inflammatory neuropathic
CNSB blocker synergy Studies pain
002 CNSB blocker synergy Studies pain inflammatory neuropathic
002 CNSB blocker synergy Studies pain
morphine models pain inflammatory neuropathic
morphine models pain
sodium blocker properties given and combinations morphine models pain inflammatory neuropathic
sodium blocker properties given and combinations morphine models pain
CNSB effect blocker properties given and combinations morphine models pain inflammatory neuropathic
CNSB effect blocker properties given and combinations morphine models pain
002 CNSB effect blocker properties given and combinations morphine models pain inflammatory neuropathic
002 CNSB effect blocker properties given and combinations morphine models pain
streptozotocin inflammation paw carrageenan using heat models pain
STZ inflammation paw carrageenan using heat models pain
CNSB doses curves constructed effect using carrageenan paw inflammation
002 CNSB doses curves constructed effect using carrageenan paw inflammation
CNSB doses curves constructed effect using carrageenan induced neuropathy diabetic
CNSB doses curves constructed effect using carrageenan induced neuropathy
002 CNSB doses curves constructed effect using carrageenan induced neuropathy diabetic
002 CNSB doses curves constructed effect using carrageenan induced neuropathy
carrageenan induced neuropathy diabetic
carrageenan induced neuropathy
morphine doses curves constructed effect using carrageenan induced neuropathy diabetic
morphine doses curves constructed effect using carrageenan induced neuropathy
CNSB doses curves constructed effect using heat models pain
002 CNSB doses curves constructed effect using heat models pain
morphine doses curves constructed effect using carrageenan paw inflammation
morphine doses curves constructed effect using heat models pain
carrageenan using heat models pain
streptozotocin inflammation
STZ inflammation
CNSB model neuropathy
002 CNSB model neuropathy
CNSB model doses calculated cause 7 reversal hyperalgesia
002 CNSB model doses calculated cause 7 reversal hyperalgesia
STZ 1 14 doses model neuropathy
morphine CNSB model neuropathy
carrageenan model 1 83 doses model neuropathy
morphine CNSB model doses calculated cause 7 reversal hyperalgesia
CNSB combination given dose 37 1 model neuropathy
002 CNSB combination given dose 37 1 model neuropathy
morphine values dose 37 1 model neuropathy
carrageenan model dose 37 1 model neuropathy
CNSB administration reversal hyperalgesia models inflammatory neuropathic
002 CNSB administration reversal hyperalgesia models inflammatory neuropathic
CNSB administration reversal hyperalgesia
002 CNSB administration reversal hyperalgesia
morphine antinociception increased co reversal hyperalgesia models inflammatory neuropathic
morphine antinociception increased co reversal hyperalgesia
triglycerides changes MATERIALS les cancer prostate
triglycerides changes MATERIALS les cancer
TG triglycerides changes MATERIALS les cancer prostate
TG triglycerides changes MATERIALS les cancer
cyproterone acetate les cancer prostate
cyproterone acetate les cancer
acetate les cancer prostate
acetate les cancer
CPA acetate les cancer prostate
CPA acetate les cancer
cholesterols changes MATERIALS les cancer prostate
cholesterols changes MATERIALS les cancer
C changes MATERIALS les cancer prostate
C changes MATERIALS les cancer
CPA treatment years period found affected disease coronary
CPA treatment years period found affected disease heart
CPA treatment years period found affected disease
cholesterol changes mediated % coronary
cholesterol changes mediated % coronary arteriosclerosis
estrogen caused effect hyperglyceridemic
estrogen caused effect
cholesterol changes mediated % coronary A known effect hyperglyceridemic
cholesterol changes mediated % coronary A known effect
estrogen caused effect known A coronary
estrogen caused effect known A coronary arteriosclerosis
carbamazepine therapy induced Asterixis
carbamazepine adding triggered asterixis
CBZ carbamazepine adding triggered asterixis
CBZ used consider sign neurotoxicity
lithium drugs used consider sign neurotoxicity
CBZ used consider asterixis
clozapine lithium drugs used consider sign neurotoxicity
halothane anaesthesia became developed bradycardia
halothane anaesthesia became hypotensive
halothane anaesthesia enhanced bradycardia
halothane anaesthesia enhanced bradycardia hypotension
methotrexate treatment cause toxicity hepatic
methotrexate treatment cause toxicity hepatic and
methotrexate treatment cause toxicity hepatic renal
methotrexate treatment cause toxicity
MTX HD methotrexate treatment cause toxicity hepatic
MTX HD methotrexate treatment cause toxicity hepatic and
MTX HD methotrexate treatment cause toxicity hepatic renal
MTX HD methotrexate treatment cause toxicity
methotrexate treatment lymphoma Burkitt
methotrexate treatment lymphoma
MTX HD methotrexate treatment lymphoma Burkitt
MTX HD methotrexate treatment lymphoma
MTX therapy year transplantation atresia biliary
MTX therapy year transplantation atresia
olanzapine mania bipolar
olanzapine mania
olanzapine placebo efficacy compared treatment mania bipolar
olanzapine placebo efficacy compared treatment mania
olanzapine randomized total diagnosis disorder bipolar
olanzapine randomized total diagnosis disorder
olanzapine randomized total manic
Olanzapine demonstrated treatment mania bipolar
Olanzapine demonstrated treatment mania
ondansetron peri depression
ondansetron prophylaxis used anaesthetic presented woman history nausea postoperative
ondansetron prophylaxis used anaesthetic presented woman history nausea
ondansetron prophylaxis used anaesthetic presented woman history nausea and
ondansetron prophylaxis used anaesthetic presented woman history nausea vomiting
serotonin antagonist use related developed disorder major
serotonin antagonist use related developed disorder depression
serotonin antagonist use related developed disorder
serotonin antagonists infusion Anaesthesia provided nausea
propofol infusion Anaesthesia provided nausea
serotonin antagonists infusion Anaesthesia provided exacerbation disorder depression
serotonin antagonists infusion Anaesthesia provided exacerbation disorder
propofol infusion Anaesthesia provided exacerbation disorder depression
propofol infusion Anaesthesia provided exacerbation disorder
dopamine hyperprolactinemia
dopamine antagonist haloperidol induced Hyperprolactinemia
dopamine concentrations increased months hyperprolactinemia
DA dopamine concentrations increased months hyperprolactinemia
DA concentrations increase produced months hyperprolactinemia
DA response lost followed 9 month hyperprolactinemia
norepinephrine change metabolites months hyperprolactinemia
norepinephrine change metabolites months hyperprolactinemia
NE norepinephrine change metabolites months hyperprolactinemia
NE norepinephrine change metabolites months hyperprolactinemia
5 decrease metabolites months hyperprolactinemia
hydroxyindoleacetic acid metabolites months hyperprolactinemia
acid metabolites months hyperprolactinemia
5 decrease metabolites months hyperprolactinemia
hydroxyindoleacetic acid metabolites months hyperprolactinemia
acid metabolites months hyperprolactinemia
5 acid metabolites months hyperprolactinemia
HIAA 5 acid metabolites months hyperprolactinemia
5 acid metabolites months hyperprolactinemia
HIAA 5 acid metabolites months hyperprolactinemia
DA levels change metabolites months hyperprolactinemia
DA levels change metabolites months hyperprolactinemia
DA concentrations increase months hyperprolactinemia
DA concentrations increase months metabolites months hyperprolactinemia
serotonin norepinephrine change metabolites months hyperprolactinemia
serotonin norepinephrine change metabolites months hyperprolactinemia
5 serotonin norepinephrine change metabolites months hyperprolactinemia
HT 5 serotonin norepinephrine change metabolites months hyperprolactinemia
5 serotonin norepinephrine change metabolites months hyperprolactinemia
HT 5 serotonin norepinephrine change metabolites months hyperprolactinemia
guanethidine reduced potentiated inhibited enlargement
guanethidine reduced potentiated inhibited enlargement pulse of
guanethidine reduced potentiated inhibited enlargement pulse
guanethidine reduced potentiated inhibited pressure
propranolol i v i inhibited enlargement
propranolol i v i inhibited enlargement pulse of
propranolol i v i inhibited enlargement pulse
propranolol i v i inhibited pressure
phentolamine guanethidine reduced potentiated inhibited enlargement
phentolamine guanethidine reduced potentiated inhibited enlargement pulse of
phentolamine guanethidine reduced potentiated inhibited enlargement pulse
phentolamine guanethidine reduced potentiated inhibited pressure
phentolamine guanethidine reduced potentiated inhibited pressure tachycardia
guanethidine reduced potentiated inhibited pressure tachycardia
propranolol i v i inhibited pressure tachycardia
hexamethonium guanethidine reduced potentiated inhibited pressure tachycardia
hexamethonium guanethidine reduced potentiated inhibited enlargement
hexamethonium guanethidine reduced potentiated inhibited enlargement pulse of
hexamethonium guanethidine reduced potentiated inhibited enlargement pulse
hexamethonium guanethidine reduced potentiated inhibited pressure
desmethylimipramine mg i inhibited pressure tachycardia
sirolimus cyclosporine Conversion induced nephropathy
sirolimus A conversion Protocols used prevent CsA induced nephropathy
SRL sirolimus A conversion Protocols used prevent CsA induced nephropathy
hematoxylin analyzed lesions Renal
hematoxylin analyzed lesions
eosin hematoxylin analyzed lesions Renal
eosin hematoxylin analyzed lesions
SRL treated rats presented markers impairment renal
SRL treated rats presented markers impairment
SRL Conversion prevented CsA induced evolution renal
SRL Conversion prevented CsA induced evolution damage
SRL biomarker seems induced evolution renal
SRL biomarker seems induced evolution damage
triglycerides decrease hepatomegaly
glucose triglycerides decrease hepatomegaly
amiodarone mice resulted rate extent loss weight
amiodarone mice resulted rate extent loss
amiodarone cells hepatoma
amiodarone effects indirect indicates inability cells hepatoma
ecstasy explained manifested deficit
ecstasy explained manifested deficit accuracy in
ecstasy explained manifested deficit accuracy fear
ecstasy explained manifested deficit accuracy recognition
dexamphetamine trazodone effect METHODS induced stereotypies oral
dexamphetamine trazodone effect METHODS induced stereotypies
ergometrine haloperidol behavior induced catalepsy
apomorphine dexamphetamine trazodone effect METHODS induced stereotypies oral
apomorphine dexamphetamine trazodone effect METHODS induced stereotypies
apomorphine haloperidol behavior induced catalepsy induced stereotypies oral
apomorphine haloperidol behavior induced catalepsy induced stereotypies
trazodone effect METHODS induced catalepsy
haloperidol behavior induced catalepsy induced stereotypies oral
haloperidol behavior induced catalepsy induced stereotypies
fluoxetine METHODS induced catalepsy
ergometrine haloperidol behavior induced catalepsy induced stereotypies oral
ergometrine haloperidol behavior induced catalepsy induced stereotypies
fluoxetine METHODS induced stereotypies oral
fluoxetine METHODS induced stereotypies
dexamphetamine trazodone effect METHODS induced catalepsy
trazodone effect METHODS induced stereotypies oral
trazodone effect METHODS induced stereotypies
trazodone induces catalepsy
Trazodone induce catalepsy
Trazodone induce RESULTS induced catalepsy
ergometrine enhanced antagonized catalepsy
trazodone enhanced antagonized catalepsy
fluoxetine behavior ergometrine enhanced antagonized catalepsy
dexamphetamine enhanced antagonized catalepsy
Trazodone mg induced catalepsy
dexamphetamine apomorphine stereotypies antagonized induced catalepsy
5 blocking trazodone releases suggest dexamphetamine antagonizes catalepsy
HT receptors 5 blocking trazodone releases suggest dexamphetamine antagonizes catalepsy
5 caused inhibition releases suggest dexamphetamine antagonizes catalepsy
HT releases suggest dexamphetamine antagonizes catalepsy
trazodone releases suggest dexamphetamine antagonizes catalepsy
dexamphetamine antagonizes catalepsy
dexamethasone mice Treatment led elevation pressure loss cells retinal
dexamethasone mice Treatment led elevation pressure loss cells ganglion
sodium TM induced hypertension ocular
sodium TM induced hypertension
4 sodium TM induced hypertension ocular
4 sodium TM induced hypertension
phenylbutyrate TM induced hypertension ocular
phenylbutyrate TM induced hypertension
levodopa effects Parkinson
levodopa effects Parkinson '
levodopa effects gene variants Association patients s
levodopa effects gene variants Association patients disease
Levodopa therapy disease Parkinson
Levodopa therapy disease Parkinson '
Levodopa therapy disease s
Levodopa therapy disease
doxorubicin induced cardiotoxicity
doxorubicin model utilized provide underlying toxicity
DOX doxorubicin model utilized provide underlying toxicity
gadolinium correlated enhancement dysfunction diastolic
gadolinium correlated enhancement dysfunction
nicergoline lysine due occlusion retinal
nicergoline lysine due occlusion vein
nicergoline lysine due occlusion
bendazac nicergoline lysine due occlusion retinal
bendazac nicergoline lysine due occlusion vein
bendazac nicergoline lysine due occlusion
lysine due occlusion retinal
lysine due occlusion vein
lysine due occlusion
acetaminophen 2004 undergone patients outcomes severity LT disease chronic
acetaminophen 2004 undergone patients outcomes severity LT disease liver
acetaminophen 2004 undergone patients outcomes severity LT disease
acetaminophen 2004 undergone patients outcomes severity LT disease CLD
acetaminophen severity LT disease chronic
acetaminophen severity LT disease liver
acetaminophen severity LT disease
acetaminophen severity LT disease CLD
acetaminophen had had LT non 01 0 35 = CLD
acetaminophen 01 0 35 = CLD
acetaminophen ALF years CLD
acetaminophen non years CLD
acetaminophen transplanted comparable CLD
acetaminophen transplanted comparable CLD
epinephrine infusion required treat hypotension
d use Efficacy proarrhythmia
l d use Efficacy proarrhythmia
sotalol Efficacy proarrhythmia
d use Efficacy sotalol tachyarrhythmias ventricular
d use Efficacy sotalol tachyarrhythmias
l d use Efficacy sotalol tachyarrhythmias ventricular
l d use Efficacy sotalol tachyarrhythmias
sotalol tachyarrhythmias ventricular
sotalol tachyarrhythmias
d treated patients pointes efficacy evaluated study sotalol tachyarrhythmias ventricular
d treated patients pointes efficacy evaluated study sotalol tachyarrhythmias
l d treated patients pointes efficacy evaluated study sotalol tachyarrhythmias ventricular
l d treated patients pointes efficacy evaluated study sotalol tachyarrhythmias
sotalol tachyarrhythmias ventricular
sotalol tachyarrhythmias
d received sustained patients 54 disease coronary
d received sustained patients 54 disease artery
d received sustained patients 54 disease
l d received sustained patients 54 disease coronary
l d received sustained patients 54 disease artery
l d received sustained patients 54 disease
sotalol l d received sustained patients 54 disease coronary
sotalol l d received sustained patients 54 disease artery
sotalol l d received sustained patients 54 disease
d received sustained patients 54 20 cardiomyopathy dilated
d received sustained patients 54 20 cardiomyopathy
l d received sustained patients 54 20 cardiomyopathy dilated
l d received sustained patients 54 20 cardiomyopathy
sotalol l d received sustained patients 54 20 cardiomyopathy dilated
sotalol l d received sustained patients 54 20 cardiomyopathy
d received tachycardia fibrillation ventricular
d received tachycardia fibrillation
l d received tachycardia fibrillation ventricular
l d received tachycardia fibrillation
sotalol l d received tachycardia fibrillation ventricular
sotalol l d received tachycardia fibrillation
d received tachycardia ventricular
d received tachycardia
l d received tachycardia ventricular
l d received tachycardia
sotalol l d received tachycardia ventricular
sotalol l d received tachycardia
d l sotalol prevent induction tachyarrhythmia ventricular
d l sotalol prevent induction tachyarrhythmia
l sotalol prevent induction tachyarrhythmia ventricular
l sotalol prevent induction tachyarrhythmia
sotalol prevent induction tachyarrhythmia ventricular
sotalol prevent induction tachyarrhythmia
d prevented discharged induction tachycardia fibrillation ventricular
d prevented discharged induction tachycardia fibrillation
l d prevented discharged induction tachycardia fibrillation ventricular
l d prevented discharged induction tachycardia fibrillation
sotalol prevented discharged induction tachycardia fibrillation ventricular
sotalol prevented discharged induction tachycardia fibrillation
d prevented discharged induction tachycardia ventricular
d prevented discharged induction tachycardia
l d prevented discharged induction tachycardia ventricular
l d prevented discharged induction tachycardia
sotalol prevented discharged induction tachycardia ventricular
sotalol prevented discharged induction tachycardia
d l patients prevented Induction tachyarrhythmia ventricular
d l patients prevented Induction tachyarrhythmia
l patients prevented Induction tachyarrhythmia ventricular
l patients prevented Induction tachyarrhythmia
sotalol l patients prevented Induction tachyarrhythmia ventricular
sotalol l patients prevented Induction tachyarrhythmia
d l patients prevented remained tachyarrhythmia ventricular
d l patients prevented remained tachyarrhythmia
l patients prevented remained tachyarrhythmia ventricular
l patients prevented remained tachyarrhythmia
sotalol l patients prevented remained tachyarrhythmia ventricular
sotalol l patients prevented remained tachyarrhythmia
d mg tolerate prevented Induction tachyarrhythmia ventricular
d mg tolerate prevented Induction tachyarrhythmia
l d mg tolerate prevented Induction tachyarrhythmia ventricular
l d mg tolerate prevented Induction tachyarrhythmia
sotalol tolerate prevented Induction tachyarrhythmia ventricular
sotalol tolerate prevented Induction tachyarrhythmia
d mg tolerate prevented remained tachyarrhythmia ventricular
d mg tolerate prevented remained tachyarrhythmia
l d mg tolerate prevented remained tachyarrhythmia ventricular
l d mg tolerate prevented remained tachyarrhythmia
sotalol tolerate prevented remained tachyarrhythmia ventricular
sotalol tolerate prevented remained tachyarrhythmia
d treatment years had patient disease cardiac
d treatment years had patient disease
l d treatment years had patient disease cardiac
l d treatment years had patient disease
sotalol l d treatment years had patient disease cardiac
sotalol l d treatment years had patient disease
citrate anticoagulation carries risk toxicity
citrate toxicity
citrate dialysate anticoagulated transplantation underwent AKI induced failure fulminant
citrate dialysate anticoagulated transplantation underwent AKI induced failure liver
citrate dialysate anticoagulated transplantation underwent AKI induced failure
citrate dialysate anticoagulated transplantation underwent AKI
citrate toxicity
Citrate dialysate alternative support transplantation failure fulminant
Citrate dialysate alternative support transplantation failure liver
Citrate dialysate alternative support transplantation failure
steroid injection neuropathy
steroid injection occurred neuropathy
steroid injection occurred treat epicondylitis lateral
steroid injection occurred treat epicondylitis
steroid injection treatment epicondylitis lateral
steroid injection treatment epicondylitis
dopamine levodopa Administration enhances learning subjects patients stroke
levodopa Administration enhances learning subjects patients stroke
dopamine agonist word impaired
dopamine agonist word novel
dopamine agonist word
dopamine agonist learning
dopamine enhances associative learning subjects patients stroke
dithiothreitol affected sites mice seizure
quinine sulfate cramps leg
quinine sulfate cramps
sulfate cramps leg
sulfate cramps
quinine toxicity
beclomethasone placed patients asthmatic
beclomethasone prednisone use increase risk developing hoarseness candidiasis
prednisone use increase risk developing hoarseness candidiasis
prednisone use increase risk developing hoarseness
methadone therapy male Rhabdomyolysis stroke ischemic
methadone therapy male Rhabdomyolysis stroke
heroin stroke ischemic
heroin stroke
heroin presented rhabdomyolysis stroke ischemic
heroin presented rhabdomyolysis stroke
methadone using Those CONCLUSION increase risk rhabdomyolysis stroke ischemic
methadone using Those CONCLUSION increase risk rhabdomyolysis stroke
heroin methadone using Those CONCLUSION increase risk rhabdomyolysis stroke ischemic
heroin methadone using Those CONCLUSION increase risk rhabdomyolysis stroke
tacrolimus ointment dermatitis treatment dermatoses facial
tacrolimus ointment dermatitis treatment dermatoses inflammatory
tacrolimus ointment dermatitis treatment dermatoses
tacrolimus ointment dermatitis
steroid effective aggravated dermatitis rosacea
steroid effective aggravated dermatitis rosacea perioral
steroid effective aggravated dermatitis
Tacrolimus ointment used indicate effective aggravated dermatitis rosacea perioral
Tacrolimus ointment used indicate effective aggravated dermatitis
tacrolimus ointment report dermatitis
tacrolimus ointment treated patients dermatoses inflammatory
tacrolimus ointment treated patients dermatoses facial
tacrolimus ointment treated patients dermatoses
tacrolimus ointment treatment complication dermatitis
Ifosfamide encephalopathy
Ifosfamide agent useful treatment range cancers cancers sarcomas
Ifosfamide agent useful treatment range cancers cancers sarcomas lymphoma
Ifosfamide agent useful treatment range cancers
Ifosfamide agent useful treatment range cancers cancers sarcomas gynecologic
Ifosfamide agent useful treatment range cancers cancers sarcomas and
Ifosfamide agent useful treatment range cancers cancers sarcomas testicular
Ifosfamide agent useful treatment range cancers cancers
ifosfamide reported Encephalopathy
ifosfamide encephalopathy
ifosfamide encephalopathy developed patients admitted Center Cancer
ifosfamide encephalopathy
ifosfamide soon encephalopathy
ifosfamide correlates encephalopathy
ifosfamide develop features encephalopathy
cyclophosphamide toxicity
CY toxicity
CY toxicity
Procaterol terbutaline asthma bronchial
Procaterol terbutaline asthma
terbutaline asthma bronchial
terbutaline asthma
Procaterol cross patients asthma bronchial
Procaterol cross patients asthma
procaterol effects asthmatic
anthraquinones containing slimming intake associated failure Acute
anthraquinones containing slimming intake associated failure renal
anthraquinones containing slimming intake associated failure
Chinese herbs caused Nephropathy
herbs caused Nephropathy
aristolochic acids use caused Nephropathy
acids use caused Nephropathy
anthraquinone derivatives contained pill use failure acute
anthraquinone derivatives contained pill use failure renal
anthraquinone derivatives contained pill use failure
anthraquinone use containing agent remains renal
anthraquinone use containing agent remains injury
anthraquinone use relationship associated nephropathy
anthraquinone use relationship associated considered patients present failure renal
anthraquinone use relationship associated considered patients present failure
methoxamine Effect incontinence stress
methoxamine Effect incontinence
methoxamine doses administered group women incontinence stress
methoxamine doses administered group women incontinence
propranolol atenolol tachycardia
atenolol tachycardia
atropine mg determined effects tachycardia
Tranexamic overdosage seizure failure renal
Tranexamic overdosage seizure failure
acid overdosage seizure failure renal
acid overdosage seizure failure
Tranexamic overdosage seizure
acid overdosage seizure
Tranexamic acid administered control bleeding
acid administered control bleeding
TNA acid administered control bleeding
TNA overdose believed cause convulsions
TNA overdose
crack cocaine Smoking infection HIV
crack cocaine Smoking infection
cocaine Smoking infection HIV
cocaine Smoking infection
crack cocaine incidence infection HIV
crack cocaine incidence infection
cocaine incidence infection HIV
cocaine incidence infection
crack cocaine use sought examine become factor infection HIV
crack cocaine use sought examine become factor infection
cocaine use sought examine become factor infection HIV
cocaine use sought examine become factor infection
rocuronium fasciculation myalgia
rocuronium fasciculation
rocuronium dose identified induced fasciculation myalgia
rocuronium influence evaluated identified induced fasciculation myalgia
rocuronium dose identified induced fasciculation
rocuronium influence evaluated identified induced fasciculation
rocuronium dose amount increasing less incidence fasciculation muscle
rocuronium dose amount increasing less incidence fasciculation
rocuronium dose amount increasing decrease tend Those myalgia
rocuronium dose considering reduction incidence fasciculation myalgia
rocuronium dose considering reduction incidence fasciculation
ribavirin contributing induced anemia
Interferon produces therapy C chronic
Interferon produces therapy C hepatitis
Interferon produces therapy C
ribavirin Interferon produces therapy C chronic
ribavirin Interferon produces therapy C hepatitis
ribavirin Interferon produces therapy C
ribavirin contributing factors identify conducted anemia
interferon received C chronic
interferon received C hepatitis
interferon received C
alpha interferon received C chronic
alpha interferon received C hepatitis
alpha interferon received C
2 b C chronic
2 b C hepatitis
2 b C
b C chronic
b C hepatitis
b C
ribavirin administered MU dose b C chronic
ribavirin administered MU dose b C hepatitis
ribavirin administered MU dose b C
ribavirin defined g anemia
Ribavirin anemia
thiol groups nephropathy
sulfhydryl reagent Chloroacetaldehyde role groups nephropathy
Chloroacetaldehyde role groups nephropathy
ifosfamide anti therapy tumor
IFO ifosfamide anti therapy tumor
IFO therapy tumor
Chloroacetaldehyde metabolite ifosfamide anti therapy tumor
CAA Chloroacetaldehyde metabolite ifosfamide anti therapy tumor
Chloroacetaldehyde metabolite ifosfamide anti responsible damage renal
Chloroacetaldehyde metabolite ifosfamide anti responsible damage
CAA Chloroacetaldehyde metabolite ifosfamide anti responsible damage renal
CAA Chloroacetaldehyde metabolite ifosfamide anti responsible damage
trypan exclusion content determined Toxicity
blue exclusion content determined Toxicity
CAA Toxicity
thiols loss increase markers necrosis
CAA reduced number induced loss increase markers necrosis
thiol donors slowed Acidification attenuate markers necrosis
thiol depletion markers necrosis
CAA reaction slowed Acidification attenuate markers necrosis
CAA effects attenuate markers necrosis
cysteine inhibition depletion markers necrosis
thiols mediating toxicity
CAA reacts thiols mediating toxicity
lomustine Tolerability cyclophosphamide dogs lymphoma
cyclophosphamide dogs lymphoma
lomustine protocol associated dogs lymphoma
CCNU lomustine protocol associated dogs lymphoma
cyclophosphamide lomustine protocol associated toxicity
CTX lomustine protocol associated toxicity
lomustine protocol associated toxicity
CCNU lomustine protocol associated toxicity
cyclophosphamide lomustine protocol associated dogs lymphoma
CTX lomustine protocol associated dogs lymphoma
CTX m tolerable tumor
CCNU m combined mg bearing tolerable tumor
bile neutral synthesis inhibition associated cholestasis intrahepatic
bile neutral synthesis inhibition associated cholestasis
salt synthesis inhibition associated cholestasis intrahepatic
salt synthesis inhibition associated cholestasis
BS synthesis inhibition associated cholestasis intrahepatic
BS synthesis inhibition associated cholestasis
Gemfibrozil therapy hyperlipoproteinemias
lovastatin therapy hyperlipoproteinemias
lovastatin treatment patients hyperlipidemia
gemfibrozil label safety treatment patients hyperlipidemia
lovastatin treatment safety % had disease atherosclerotic
lovastatin treatment safety % had disease vascular
lovastatin treatment safety % had disease
gemfibrozil label safety % had disease atherosclerotic
gemfibrozil label safety % had disease vascular
gemfibrozil label safety % had disease
creatine phosphokinase occurred Myositis
creatine phosphokinase occurred had rhabdomyolysis
creatine phosphokinase occurred had rhabdomyolysis ABSTRACT myoglobinuria
CCK induced decreases amnesia
8 morphine CCK induced decreases amnesia
morphine effect attenuates 8 CCK induced impairment memory
morphine effect attenuates 8 CCK induced impairment
morphine 8 8 CCK induced impairment memory
morphine 8 8 CCK induced impairment
CCK induced impairment memory
CCK induced impairment
8 CCK induced impairment memory
8 CCK induced impairment
CCK function suggest attenuates 8 CCK induced impairment memory
CCK function suggest attenuates 8 CCK induced impairment
8 8 CCK induced impairment memory
8 8 CCK induced impairment
propylthiouracil carbimazole prescribed treatment hyperthyroidism
PTU carbimazole prescribed treatment hyperthyroidism
Anti drugs prescribed treatment hyperthyroidism
thyroid drugs prescribed treatment hyperthyroidism
drugs prescribed treatment hyperthyroidism
carbimazole prescribed treatment hyperthyroidism
carbimazole developed patient disease Graves
carbimazole developed patient disease Graves '
carbimazole developed patient disease
carbimazole induced vasculitis
carbimazole induced case vasculitis
misoprostol effect dose dysfunction cirrhosis
misoprostol effect dose dysfunction renal
misoprostol effect dose dysfunction
indomethacin misoprostol effect dose dysfunction cirrhosis
Misoprostol shown counteract indomethacin induced patients cirrhotic
Misoprostol shown counteract indomethacin induced dysfunction renal
Misoprostol shown counteract indomethacin induced dysfunction
indomethacin induced patients cirrhotic
misoprostol doses mg combination assessed techniques patients cirrhotic
indomethacin mg combination assessed techniques patients cirrhotic
sodium hemodynamics Parameters assessed techniques patients cirrhotic
misoprostol micrograms ability confirmed prudent avoid cirrhosis
indomethacin effects prevent micrograms ability confirmed prudent avoid cirrhosis
oxygen consumption pressure accompanied Hypotension
oxygen difference pressure observed hypotension
doxorubicin study squamous
doxorubicin study squamous carcinoma cell
doxorubicin study squamous carcinoma
doxorubicin study squamous carcinoma cervix of
doxorubicin study squamous carcinoma cervix the
doxorubicin study squamous carcinoma cervix
carboplatin doxorubicin study squamous
carboplatin doxorubicin study squamous carcinoma cell
carboplatin doxorubicin study squamous carcinoma
carboplatin doxorubicin study squamous carcinoma cervix of
carboplatin doxorubicin study squamous carcinoma cervix the
carboplatin doxorubicin study squamous carcinoma cervix
doxorubicin combination activity tested study patients carcinoma cervical
doxorubicin combination activity tested study patients carcinoma
carboplatin doxorubicin combination activity tested study patients carcinoma cervical
carboplatin doxorubicin combination activity tested study patients carcinoma
carboplatin combination METHODS administered determine activity profile toxicity
doxorubicin combination METHODS administered carcinoma squamous
doxorubicin combination METHODS administered carcinoma cell
doxorubicin combination METHODS administered carcinoma cervical
doxorubicin combination METHODS administered carcinoma
Doxil doxorubicin combination METHODS administered carcinoma squamous
Doxil doxorubicin combination METHODS administered carcinoma cell
Doxil doxorubicin combination METHODS administered carcinoma cervical
Doxil doxorubicin combination METHODS administered carcinoma
doxorubicin combination METHODS administered determine activity profile toxicity
Doxil doxorubicin combination METHODS administered determine activity profile toxicity
carboplatin combination METHODS administered carcinoma squamous
carboplatin combination METHODS administered carcinoma cell
carboplatin combination METHODS administered carcinoma cervical
carboplatin combination METHODS administered carcinoma
doxorubicin combination has activity patients carcinoma cervical
doxorubicin combination has activity patients carcinoma
carboplatin doxorubicin combination has activity patients carcinoma cervical
carboplatin doxorubicin combination has activity patients carcinoma
Sulfadiazine acute reviving use toxoplasmosis
sulfadiazine treatment developed failure renal
sulfadiazine treatment developed failure
sulfadiazine treatment developed failure abdominal
sulfadiazine treatment developed failure pain
sulfadiazine treatment developed failure oliguria
Glibenclamide hypotension
glibenclamide attenuated Hypotension
K channels activation attributable hypotension
K channels activation attributable hypotension
glibenclamide activation attributable hypotension
ATP K channels activation attributable hypotension
nitric oxide seem produced hypotension
oxide seem produced hypotension
Mesna reduces s genotoxicity
IFO s genotoxicity
everolimus Efficacy patients NSCLC
RAD Efficacy patients NSCLC
001 RAD Efficacy patients NSCLC
RAD shown phase NSCLC
001 RAD shown phase NSCLC
rapamycin target inhibitor RAD shown phase NSCLC
tyrosine inhibitors received day toxicity
platinum IIIb inhibitors received day toxicity
RAD received inhibitors IIIb patients NSCLC
001 RAD received inhibitors IIIb patients NSCLC
platinum IIIb patients NSCLC
RAD received day toxicity
001 RAD received day toxicity
tyrosine inhibitors IIIb patients NSCLC
RAD CONCLUSIONS tolerated showing NSCLC
001 10 mg RAD CONCLUSIONS tolerated showing NSCLC
RAD Evaluation therapy NSCLC
001 RAD Evaluation therapy NSCLC
Streptozotocin events neurotoxicity
Streptozotocin activation toxicity
STZ role activation toxicity
nitrite Ca level increased reduced preparation illustrating generation excitotoxicity
STZ increased reduced preparation illustrating generation excitotoxicity
Ca level increased reduced preparation illustrating generation excitotoxicity
STZ treatment showed remains indicating neurotoxicity
STZ induced glial death neurotoxicity
Memantine treatment attenuated glial death neurotoxicity
Ibuprofen Memantine treatment attenuated glial death neurotoxicity
STZ impairment factors activation neurotoxicity
propranolol Use treatment hypotension idiopathic
propranolol Use treatment hypotension orthostatic
propranolol Use treatment hypotension
norepinephrine effects marked hypersensitivity
catecholamines reduced marked hypersensitivity
propranolol drug patients hypotension idiopathic
propranolol drug patients hypotension orthostatic
propranolol drug patients hypotension
pilocarpine caused maneuver hyperventilation
sodium hypotension
MPTP model disease Parkinson
MPTP model disease Parkinson '
MPTP model disease s
MPTP model disease
levodopa lesioned used model symptoms neuropsychiatric
levodopa lesioned used model symptoms
levodopa lesioned used model symptoms patients PD
MPTP treated levodopa lesioned used model symptoms neuropsychiatric
MPTP treated levodopa lesioned used model symptoms
MPTP treated levodopa lesioned used model symptoms patients PD
levodopa course induced neuropsychiatric
levodopa course induced determine like
levodopa course induced determine behaviors
1 administered methyl tetrahydropyridine resulting parkinsonism
methyl tetrahydropyridine resulting parkinsonism
4 methyl tetrahydropyridine resulting parkinsonism
phenyl - 4 methyl tetrahydropyridine resulting parkinsonism
- 4 methyl tetrahydropyridine resulting parkinsonism
1 - 4 methyl tetrahydropyridine resulting parkinsonism
2 - 4 methyl tetrahydropyridine resulting parkinsonism
3 - 4 methyl tetrahydropyridine resulting parkinsonism
6 - 4 methyl tetrahydropyridine resulting parkinsonism
tetrahydropyridine resulting parkinsonism
levodopa prior neuropsychiatric
levodopa prior neuropsychiatric behaviors like
levodopa prior neuropsychiatric behaviors
levodopa prior neuropsychiatric evaluated time disability parkinsonian
levodopa prior neuropsychiatric evaluated time disability
levodopa induced neuropsychiatric
levodopa like
levodopa like present behaviors
levodopa treatment Day present like levodopa induced neuropsychiatric
levodopa treatment Day present like
levodopa treatment Day present behaviors
levodopa interaction disorders neuropsychiatric
levodopa interaction disorders
levodopa interaction disorders PD
tobramycin combined infections
tobramycin combined infections patients cancer
carbenicillin combined infections
carbenicillin combined infections patients cancer
tobramycin given overcome effects neutropenia
carbenicillin combined given overcome effects neutropenia
creatinine serum greater mg dl azotemia
doxorubicin cardiomyopathy repair cardiomyopathy disease congenital
doxorubicin cardiomyopathy repair cardiomyopathy disease heart
doxorubicin cardiomyopathy repair cardiomyopathy disease
doxorubicin cardiomyopathy repair cardiomyopathy hypertrophic
doxorubicin cardiomyopathy repair cardiomyopathy
doxorubicin cardiomyopathy repair disease valvular
doxorubicin cardiomyopathy repair disease heart
doxorubicin cardiomyopathy repair disease
doxorubicin cardiomyopathy repair cardiomyopathy idiopathic
doxorubicin cardiomyopathy repair cardiomyopathy
ganciclovir treated infections Cytomegalovirus
ganciclovir treated infections
6 vulnerability dyskinesias
hydroxydopamine lesion vulnerability dyskinesias
L Treatment benserazide resulted dyskinesias
DOPA benserazide resulted dyskinesias
+ benserazide resulted dyskinesias
benserazide resulted dyskinesias
DA lesion impairment severity increased reduced dyskinesias
CM toxicity
all complications leukemia acute
all complications leukemia promyelocytic
all complications leukemia
trans complications leukemia acute
trans complications leukemia promyelocytic
trans complications leukemia
retinoic therapy trans complications leukemia acute
retinoic therapy trans complications leukemia promyelocytic
retinoic therapy trans complications leukemia
acid therapy trans complications leukemia acute
acid therapy trans complications leukemia promyelocytic
acid therapy trans complications leukemia
all treated occlusion vessels leukemia patient acute
all treated occlusion vessels leukemia promyelocytic
all treated occlusion vessels leukemia
trans all treated occlusion vessels leukemia patient acute
trans all treated occlusion vessels leukemia promyelocytic
trans all treated occlusion vessels leukemia
retinoic acid all treated occlusion vessels leukemia patient acute
retinoic acid all treated occlusion vessels leukemia promyelocytic
retinoic acid all treated occlusion vessels leukemia
acid all treated occlusion vessels leukemia patient acute
acid all treated occlusion vessels leukemia promyelocytic
acid all treated occlusion vessels leukemia
all treated occlusion vessels leukemia APL
trans all treated occlusion vessels leukemia APL
retinoic acid all treated occlusion vessels leukemia APL
acid all treated occlusion vessels leukemia APL
ATRA acid all treated occlusion vessels leukemia patient acute
ATRA acid all treated occlusion vessels leukemia promyelocytic
ATRA acid all treated occlusion vessels leukemia
ATRA acid all treated occlusion vessels leukemia APL
all treated occlusion
all treated occlusion vessels of
all treated occlusion vessels renal
all treated occlusion vessels
trans all treated occlusion
trans all treated occlusion vessels of
trans all treated occlusion vessels renal
trans all treated occlusion vessels
retinoic acid all treated occlusion
retinoic acid all treated occlusion vessels of
retinoic acid all treated occlusion vessels renal
retinoic acid all treated occlusion vessels
acid all treated occlusion
acid all treated occlusion vessels of
acid all treated occlusion vessels renal
acid all treated occlusion vessels
ATRA acid all treated occlusion
ATRA acid all treated occlusion vessels of
ATRA acid all treated occlusion vessels renal
ATRA acid all treated occlusion vessels
tranexamic acid all treated occlusion due failure acute
tranexamic acid all treated occlusion due failure renal
tranexamic acid all treated occlusion due failure
acid all treated occlusion due failure acute
acid all treated occlusion due failure renal
acid all treated occlusion due failure
tranexamic acid all treated occlusion vessels leukemia patient acute
tranexamic acid all treated occlusion vessels leukemia promyelocytic
tranexamic acid all treated occlusion vessels leukemia
acid all treated occlusion vessels leukemia patient acute
acid all treated occlusion vessels leukemia promyelocytic
acid all treated occlusion vessels leukemia
tranexamic acid all treated occlusion vessels leukemia APL
acid all treated occlusion vessels leukemia APL
tranexamic acid all treated occlusion
tranexamic acid all treated occlusion vessels of
tranexamic acid all treated occlusion vessels renal
tranexamic acid all treated occlusion vessels
acid all treated occlusion
acid all treated occlusion vessels of
acid all treated occlusion vessels renal
acid all treated occlusion vessels
ATRA treated patient APL
ATRA therapy associated patients APL
ATRA therapy associated complications thromboembolic
ATRA included presented signs APL
ATRA choice patients APL
heparin low using avoided events Thrombotic
Theophylline neurotoxicity
theophylline neurotoxicity
theophylline response neurotoxic
lithium therapy term CONCLUSION hyperparathyroidism Primary
lithium therapy term CONCLUSION hyperparathyroidism
methamphetamine diagnosis Patients based interviewed using Interview disorders psychiatric
methamphetamine diagnosis Patients based interviewed using Interview disorders
methamphetamine disorders psychiatric
methamphetamine disorders
methamphetamine use co disorder affective
methamphetamine use co disorder
Ca causes apoptosis arrhythmia
Na channels have roles cardiotoxicity
Ca role available poisoning
Ca signaling importance explored poisoning
Ca lead found caused arrhythmia
aconitine effects investigate performed assay cytotoxicity
aconitine effects investigate injury myocardial
aconitine effects investigate injury
lactate level myocytes performed investigate injury myocardial
lactate level myocytes performed investigate injury
lactate level myocytes performed assay cytotoxicity
aconitine resulted injury myocardial
aconitine resulted injury
Ca overload aggravates causes arrhythmia
beta adrenergic affected abolished tachycardia
adrenergic affected abolished tachycardia
and adrenergic affected abolished tachycardia
muscarinic blockade adrenergic affected abolished tachycardia
receptors blockade adrenergic affected abolished tachycardia
blockade adrenergic affected abolished tachycardia
beta adrenergic affected Vasodilation vessels hypotension
adrenergic affected Vasodilation vessels hypotension
and adrenergic affected Vasodilation vessels hypotension
muscarinic blockade adrenergic affected Vasodilation vessels hypotension
receptors blockade adrenergic affected Vasodilation vessels hypotension
blockade adrenergic affected Vasodilation vessels hypotension
Caffeine challenge test disorder depression
caffeine test respond patients disorder patients depression attacks Manual Disorders Mental
caffeine test respond patients disorder patients depression attacks Manual Disorders
caffeine test respond patients disorder patients depression attacks MDP
caffeine test respond patients disorder patients depression major
caffeine test respond patients disorder patients depression
caffeine administered applied scales anxiety
caffeine caffeine administered applied scales anxiety
caffeine sensitive patients PD MDP
caffeine sensitive patients MD
caffeine test associated associated PD MDP
trimethoprim induced crisis had girl year sulfomethoxazole resulting anoxia cerebral
trimethoprim induced crisis had girl year sulfomethoxazole resulting anoxia
sulfomethoxazole resulting anoxia cerebral
sulfomethoxazole resulting anoxia
dobutamine occurs patients disease coronary
dobutamine occurs patients disease artery
dobutamine occurs patients disease
dobutamine induced ischaemia myocardial
dobutamine induced ischaemia
dobutamine exercise ischaemia
dobutamine results left patients disease coronary
dobutamine results left patients disease artery
dobutamine results left patients disease
dobutamine results ischaemia
Dobutamine ischaemia used study patients disease coronary
Dobutamine ischaemia used study patients disease artery
Dobutamine ischaemia used study patients disease
Dobutamine ischaemia
paracetamol due failure patients Fas overdose
paracetamol overdose
albuterol exacerbations asthma
albuterol reported received patients admitted unit exacerbations asthma
albuterol treatments albuterol reported received patients admitted unit exacerbations asthma
ibuprofen administration trial treatment ductus patent
ibuprofen administration trial treatment ductus
ibuprofen administration arteriosus
ibuprofen arteriosus administration trial treatment ductus patent
ibuprofen arteriosus administration trial treatment ductus
ibuprofen arteriosus
nitric therapy resolved Hypoxaemia
oxide therapy resolved Hypoxaemia
bromocriptine treated oligomenorrhea
bromocriptine treated outpatients hyperprolactinemia amenorrhea
bromocriptine treated outpatients hyperprolactinemia
neuroleptic galactorrhea
bromocriptine evaluated therapy galactorrhea hyperprolactinemia amenorrhea
bromocriptine evaluated therapy galactorrhea hyperprolactinemia
bromocriptine evaluated therapy galactorrhea
Rifampicin administered developed nausea fever
Rifampicin administered developed nausea vomiting
Rifampicin administered developed nausea
desferrioxamine therapy occurring failure Acute
desferrioxamine therapy occurring failure renal
desferrioxamine therapy occurring failure
desferrioxamine treatment undergoing thalassemia
DFX treatment undergoing thalassemia
desferrioxamine caused failure acute
desferrioxamine caused failure renal
desferrioxamine caused failure
metolachlor use incidence Cancer
metolachlor using reported % applicators evaluated incidence cancer
metolachlor use incidence cancer
metolachlor use association cancers
metolachlor use association cancers site cancers
metolachlor use levels risk lung
metolachlor use levels risk cancer
metolachlor use effects up follow warrant findings cancer lymphoma
bupivacaine precipitate dysrhythmias
bupivacaine circulating potentiate precipitate dysrhythmias
epinephrine bupivacaine precipitate dysrhythmias
epinephrine effects potentiate precipitate dysrhythmias
epinephrine administration dysrhythmogenicity alters alters dogs infarction myocardial
epinephrine administration dysrhythmogenicity alters alters dogs infarction
bupivacaine alters alters dogs infarction myocardial
bupivacaine alters alters dogs infarction
epinephrine min day kg infarction myocardial
epinephrine min day kg infarction
halothane kg infarction myocardial
halothane kg infarction
halothane kg day min epinephrine appeared VT
Bupivacaine antagonizes epinephrine dogs susceptible VT
Bupivacaine antagonizes epinephrine epinephrine dogs dysrhythmias
epinephrine epinephrine dogs dysrhythmias
Vigabatrin changes elected continue medication control seizure
Vigabatrin pathogenesis reaction dose toxicity
dipyridamole infusion surface detection disease coronary
dipyridamole infusion surface detection disease artery
dipyridamole infusion surface detection disease
dipyridamole infusion changes studied patients disease coronary
dipyridamole infusion changes studied patients disease artery
dipyridamole infusion changes studied patients disease
dipyridamole observed ST depression
dipyridamole observed % group MI
dipyridamole observed ST ischemic
dipyridamole observed % group % INF
dipyridamole observed % MI
dipyridamole observed % group % ANT
dipyridamole observed % group MI
dipyridamole test useful test assessment disease coronary
dipyridamole test useful test assessment disease artery
dipyridamole test useful test assessment disease
eslicarbazepine acetate seizures
acetate seizures
BIA acetate seizures
2 BIA acetate seizures
093 BIA acetate seizures
eslicarbazepine acetate elicited seizures
acetate elicited seizures
eslicarbazepine acetate elicited changes patterns threshold seizure
acetate elicited changes patterns threshold seizure
Rifampicin glomerulonephritis endocarditis staphylococcal
Rifampicin glomerulonephritis endocarditis
rifampicin therapy complication reported patients receiving treatment tuberculosis
rifampicin infections Staphylococcal
rifampicin infections
rifampicin use increase led epidemiology infections endocarditis infective
rifampicin use increase led epidemiology infections endocarditis
rifampicin use increase led epidemiology IE
rifampicin use increase led epidemiology infections
rifampicin treated developed IE Staphylococcal
rifampicin treated developed IE
rifampicin therapy complication literature review treated developed IE Staphylococcal
rifampicin therapy complication literature review treated developed IE
nitric synthase expression irritation bladder
nitric synthase expression irritation
oxide synthase expression irritation bladder
oxide synthase expression irritation
nitric synthase expression alterations examine pathways irritation
nitric synthase expression alterations examine pathways irritation tract of
nitric synthase expression alterations examine pathways irritation tract the
nitric synthase expression alterations examine pathways irritation tract urinary
nitric synthase expression alterations examine pathways irritation tract
oxide synthase expression alterations examine pathways irritation
oxide synthase expression alterations examine pathways irritation tract of
oxide synthase expression alterations examine pathways irritation tract the
oxide synthase expression alterations examine pathways irritation tract urinary
oxide synthase expression alterations examine pathways irritation tract
acrolein metabolized cyclophosphamide induced cystitis
aminonucleoside nephrosis
protamine sulfate aminonucleoside administration developed model sclerosis focal
protamine sulfate aminonucleoside administration developed model sclerosis segmental
protamine sulfate aminonucleoside administration developed model sclerosis glomerular
protamine sulfate aminonucleoside administration developed model sclerosis
sulfate aminonucleoside administration developed model sclerosis focal
sulfate aminonucleoside administration developed model sclerosis segmental
sulfate aminonucleoside administration developed model sclerosis glomerular
sulfate aminonucleoside administration developed model sclerosis
protamine sulfate aminonucleoside administration developed model sclerosis FSGS
sulfate aminonucleoside administration developed model sclerosis FSGS
PS sulfate aminonucleoside administration developed model sclerosis focal
PS sulfate aminonucleoside administration developed model sclerosis segmental
PS sulfate aminonucleoside administration developed model sclerosis glomerular
PS sulfate aminonucleoside administration developed model sclerosis
PS sulfate aminonucleoside administration developed model sclerosis FSGS
AMNS toxicity
PS administration enhances produces FSGS
PS administration enhances produces rats resulting end
PS administration enhances produces rats disease stage
PS administration enhances produces rats disease renal
PS administration enhances produces rats disease
PS administration enhances toxicity
ethambutol overtreatment due Optochiasmatic neuropathy peripheral
ethambutol overtreatment due Optochiasmatic neuropathy
ethambutol toxicity
thalidomide treated erythematosus amplitude patients lupus cutaneous
thalidomide treated erythematosus amplitude patients lupus
thalidomide treated erythematosus
thalidomide treated erythematosus CLE
thalidomide potential identify use measure variations erythematosus amplitude patients lupus cutaneous
thalidomide potential identify use measure variations erythematosus amplitude patients lupus
thalidomide potential identify use measure variations erythematosus
thalidomide potential identify use measure variations erythematosus CLE
thalidomide treated erythematosus variations measure use identify potential neurotoxic
thalidomide potential neurotoxic
thalidomide treatment data patients CLE
thalidomide potential neurotoxic
vincristine sulfate given monkeys 2 inoculation resulted infection
sulfate given monkeys 2 inoculation resulted infection
corticosteroid suspensions long studies injection artery retinal
corticosteroid suspensions long studies injection artery
corticosteroid suspensions long studies injection artery and
corticosteroid suspensions long studies injection artery occlusion choriocapillaris
corticosteroid suspensions long studies injection artery occlusion
epinephrine lidocaine combination acetate injection reported Two occlusions blindness
penicillin lidocaine combination acetate injection reported Two occlusions blindness
lidocaine combination acetate injection reported Two occlusions cases artery retinal
lidocaine combination acetate injection reported Two occlusions cases artery
lidocaine combination acetate injection reported Two occlusions cases artery and
lidocaine combination acetate injection reported Two occlusions cases artery choriocapillaris
lidocaine combination acetate injection reported Two occlusions
methylprednisolone acetate injection reported Two occlusions blindness
acetate injection reported Two occlusions blindness
epinephrine lidocaine combination acetate injection reported Two occlusions cases artery retinal
epinephrine lidocaine combination acetate injection reported Two occlusions cases artery
epinephrine lidocaine combination acetate injection reported Two occlusions cases artery and
epinephrine lidocaine combination acetate injection reported Two occlusions cases artery choriocapillaris
epinephrine lidocaine combination acetate injection reported Two occlusions
penicillin lidocaine combination acetate injection reported Two occlusions cases artery retinal
penicillin lidocaine combination acetate injection reported Two occlusions cases artery
penicillin lidocaine combination acetate injection reported Two occlusions cases artery and
penicillin lidocaine combination acetate injection reported Two occlusions cases artery choriocapillaris
penicillin lidocaine combination acetate injection reported Two occlusions
lidocaine combination acetate injection reported Two occlusions blindness
propylthiouracil treated antibody patients Graves
propylthiouracil treated antibody patients Graves '
propylthiouracil treated antibody patients disease
propylthiouracil treated patients reported vasculitis
PTU propylthiouracil treated patients reported vasculitis
propylthiouracil treated patients disease Graves
propylthiouracil treated patients disease Graves '
propylthiouracil treated patients disease
PTU propylthiouracil treated patients disease Graves
PTU propylthiouracil treated patients disease Graves '
PTU propylthiouracil treated patients disease
PTU therapy vasculitis
PTU therapy vasculitis ANCA appearance ANCA patients Graves
PTU therapy vasculitis ANCA appearance ANCA patients Graves '
PTU therapy vasculitis ANCA appearance ANCA patients disease
PTU therapy starting investigated vasculitis
PTU therapy starting investigated vasculitis hyperthyroidism
PTU therapy starting investigated vasculitis due disease Graves
PTU therapy starting investigated vasculitis due disease Graves '
PTU therapy starting investigated vasculitis due disease
PTU therapy ml developed disorders vasculitic
PTU therapy ml developed disorders
PTU therapy related appear related vasculitis
dehydroepiandrosterone Effects models schizophrenia
dehydroepiandrosterone effects examine models schizophrenia
DHEA dehydroepiandrosterone effects examine models schizophrenia
Amphetamine induced locomotion hyper
Amphetamine induced apomorphine haloperidol induced used tests catalepsy
haloperidol apomorphine induced locomotion hyper
apomorphine haloperidol induced used tests catalepsy
apomorphine induced locomotion hyper
DHEA reduced increased catalepsy
DHEA displays used treatment schizophrenia
lithium polydipsia
lithium treating induced developed secondary trauma brain
lithium treating induced developed secondary trauma
ibuprofen took fever
aspirin put took fever
beta kg 05 reduced binding convulsions
carboline reduced binding convulsions
-LSB- increase markedly reduced binding convulsions
35 -LSB- increase markedly reduced binding convulsions
S binding convulsions
-RSB- binding convulsions
TBPS binding convulsions
pancuronium pretreatment occur rigidity prolonged
pancuronium pretreatment occur rigidity jaw
pancuronium pretreatment occur rigidity
pancuronium pretreatment occur rigidity myalgia
cocaine year 30 man became manic
DEP different changes power oscillation pupillary
DEP different changes power oscillation
1 induced patient hypoparathyroidism
25 1 induced patient hypoparathyroidism
OH 1 induced patient hypoparathyroidism
2 D 1 induced patient hypoparathyroidism
D 1 induced patient hypoparathyroidism
calcium amounts described context treatment disease peptic
calcium amounts described context treatment disease ulcer
calcium amounts described context treatment disease
alkali calcium amounts described context treatment disease peptic
alkali calcium amounts described context treatment disease ulcer
alkali calcium amounts described context treatment disease
omeprazole blockers H therapy ulcer
sucralfate blockers H therapy decreased remains triad hypercalcemia alkalosis
omeprazole blockers H therapy decreased remains triad hypercalcemia impairment renal
omeprazole blockers H therapy decreased remains triad hypercalcemia impairment
sucralfate blockers H therapy ulcer
omeprazole blockers H therapy decreased frequency milk
omeprazole blockers H therapy decreased syndrome alkali
omeprazole blockers H therapy decreased syndrome
omeprazole blockers H therapy decreased remains triad hypercalcemia
sucralfate blockers H therapy decreased frequency milk
sucralfate blockers H therapy decreased syndrome alkali
sucralfate blockers H therapy decreased syndrome
sucralfate blockers H therapy decreased remains triad hypercalcemia
sucralfate blockers H therapy decreased remains triad hypercalcemia impairment renal
sucralfate blockers H therapy decreased remains triad hypercalcemia impairment
omeprazole blockers H therapy decreased remains triad hypercalcemia alkalosis
calcium carbonate treated hypoparathyroidism
carbonate treated hypoparathyroidism
calcitriol carbonate treated hypoparathyroidism
pamidronate illustrates tool presents milk
pamidronate illustrates tool presents milk syndrome alkali
pamidronate illustrates tool presents milk syndrome
pamidronate illustrates tool presents emergency hypercalcemic
pamidronate illustrates tool presents emergency
epirubicin exposure predict dysfunction cardiac
epirubicin exposure predict dysfunction
epirubicin exposure predict T alterations strain myocardial
epirubicin exposure predict T alterations strain
epirubicin treated lymphoma patients non
epirubicin treated lymphoma Hodgkin
epirubicin treated lymphoma
anthracycline receiving patients predict dysfunction cardiac
anthracycline receiving patients predict dysfunction
isoproterenol rats diabetic
streptozotocin rats isoproterenol effect cardiotoxic
isoproterenol effect cardiotoxic
isoproterenol doses effect diabetes
ISO isoproterenol doses effect diabetes
streptozotocin diabetes effect cardiotoxic
isoproterenol doses effect cardiotoxic
ISO isoproterenol doses effect cardiotoxic
glucose fall slope correlation appeared analyzed fibrosis
catecholamines content estimated rats diabetic
ISO resistance causes points effect sensitivity rats diabetic
catecholamine sensitivity rats diabetic
1 3 CML
3 CML
Butadiene CML
1 studies UNASSIGNED suggest associated leukemia chronic
1 studies UNASSIGNED suggest associated leukemia myeloid
1 studies UNASSIGNED suggest associated leukemia
3 1 studies UNASSIGNED suggest associated leukemia chronic
3 1 studies UNASSIGNED suggest associated leukemia myeloid
3 1 studies UNASSIGNED suggest associated leukemia
butadiene suggest associated leukemia chronic
butadiene suggest associated leukemia myeloid
butadiene suggest associated leukemia
1 studies UNASSIGNED suggest associated leukemia CML
3 1 studies UNASSIGNED suggest associated leukemia CML
butadiene suggest associated leukemia CML
PAN nephropathy rats failure growth
PAN nephropathy rats failure
malondialdehyde content glomerulosclerosis injury tubulointerstitial
malondialdehyde content glomerulosclerosis injury
malondialdehyde content glomerulosclerosis
malondialdehyde content glomerulosclerosis increased associated hypertrophy glomerular
malondialdehyde content glomerulosclerosis increased associated hypertrophy
malondialdehyde content gain damage glomerular tubulointerstitial
malondialdehyde content gain damage
malondialdehyde content gain proteinuria
fluorescein angiography Convulsion
Quinine induced malaria severe
Quinine induced malaria
Quinine induced arrhythmia
quinine infusion getting reported presented case patient jaundice
quinine infusion getting reported presented case patient severe
quinine infusion getting reported presented case patient malaria
quinine infusion getting reported presented arrhythmia
dextrose got diagnosed jaundice
bilirubin falciparum diagnosed jaundice
bilirubin mg mg falciparum diagnosed jaundice
bilirubin mg mg mg falciparum diagnosed jaundice
quinine infusion got diagnosed jaundice
potassium 3 mg mg mg falciparum diagnosed jaundice
dextrose got diagnosed malaria severe
dextrose got diagnosed malaria
quinine infusion got diagnosed malaria severe
quinine infusion got diagnosed malaria
potassium 3 mg mg mg falciparum diagnosed malaria severe
potassium 3 mg mg mg falciparum diagnosed malaria
bilirubin falciparum diagnosed malaria severe
bilirubin falciparum diagnosed malaria
bilirubin mg mg falciparum diagnosed malaria severe
bilirubin mg mg falciparum diagnosed malaria
bilirubin mg mg mg falciparum diagnosed malaria severe
bilirubin mg mg mg falciparum diagnosed malaria
quinine infusion hours felt showed palpitation
quinine infusion hours felt showed > 5 minute wave sinoatrial
quinine infusion hours felt showed > 5 minute wave block
potassium level meq felt reduced frequency PVC
quinidine alkaloid property arrhythmic
quinidine alkaloid arrhythmic
quinidine alkaloid arrhythmias
quinidine alkaloid arrhythmia
Quinine alkaloid property arrhythmic
Quinine alkaloid arrhythmic
Quinine alkaloid arrhythmias
Quinine alkaloid arrhythmia
quinidine alkaloid arrhythmia PVC
quinine Administration done patients have diseases heart
quinine Administration done patients have diseases
quinine Administration done patients have diseases occurs due and cases malaria
quinine Administration done patients have diseases occurs due and vomiting
quinine Administration done patients have diseases hypokalemia
quinine Administration done patients have diseases disorder electrolyte
quinine Administration done patients have diseases disorder
quinine Administration done and observation effect arrhythmic
quinine Administration done patients have diseases occurs due and diarrhea
Fazadinium dose mg abolition fasciculations
Fazadinium dose mg abolition influence occurrence pain
bromide chloride used affected incidence pain
chloride used affected incidence pain
Althesin agent type used affected incidence pain
Thiopentone Althesin agent type used affected incidence pain
Propranolol antagonism hypertension
Phenylpropanolamine cause hypertension hemorrhage intracerebral
Phenylpropanolamine cause hypertension hemorrhage
PPA Phenylpropanolamine cause hypertension hemorrhage intracerebral
PPA Phenylpropanolamine cause hypertension hemorrhage
Phenylpropanolamine cause overdose
PPA Phenylpropanolamine cause overdose
propranolol efficacy studied treatment hypertension
PPA increased volume stroke
Lamivudine effective suppressing DNA hepatitis
Lamivudine effective suppressing DNA B
Lamivudine novel 3 analogue has effects replication hepatitis
Lamivudine novel 3 analogue has effects replication B
2 novel 3 analogue has effects replication hepatitis
2 novel 3 analogue has effects replication B
3 analogue has effects replication hepatitis
3 analogue has effects replication B
dideoxy cytosine analogue has effects replication hepatitis
dideoxy cytosine analogue has effects replication B
cytosine analogue has effects replication hepatitis
cytosine analogue has effects replication B
lamivudine receiving had decrease virus hepatitis
lamivudine receiving had decrease virus B
methimazole case hepatitis
methimazole case hepatitis cases associated lupus
methimazole case hepatitis cases described syndrome like
methimazole case hepatitis cases described syndrome
propylthiouracil cases necrosis hepatocellular
propylthiouracil cases necrosis
propylthiouracil case necrosis hepatocellular
propylthiouracil case necrosis
fluconazole initiation suppression bone
fluconazole initiation suppression marrow
fluconazole initiation suppression
Indomethacin induced arthritis gouty
Indomethacin induced arthritis
indomethacin developed treatment arthritis gouty
indomethacin developed treatment arthritis
prostaglandin synthesis hypoaidosteronism hyporeninemic
prostaglandin synthesis hypoaidosteronism
potassium balance function attention particularly preexisting disease renal
potassium balance function attention particularly preexisting disease
indomethacin receiving patients function attention particularly patients mellitus diabetes
indomethacin receiving patients function attention particularly patients mellitus
potassium balance function attention particularly patients mellitus diabetes
potassium balance function attention particularly patients mellitus
indomethacin receiving patients function attention particularly preexisting disease renal
indomethacin receiving patients function attention particularly preexisting disease
cephalothin therapy receiving anemia Coombs developed patient disease renal
cephalothin therapy receiving anemia Coombs developed patient disease
levodopa patients disease Parkinson
levodopa patients disease Parkinson '
levodopa patients disease s
levodopa patients disease
levodopa patients disease PD
celecoxib patients reactions skin
celecoxib patients reactions
CE tolerability evaluated group patients history reactions cutaneous
CE tolerability evaluated group patients history reactions
P studied patients hypersensitivity
N P studied patients hypersensitivity
P documented reaction hypersensitivity
CE reaction hypersensitivity
N P documented reaction hypersensitivity
CO pulses means applied pain
2 CO pulses means applied pain
CO pulses means applied induced pain
2 CO pulses means applied induced pain
CO stimuli obtained CSSEPs correlates pain
2 stimuli obtained CSSEPs correlates pain
lamivudine combined globulin hepatitis
lamivudine combined globulin B
lamivudine prevention recurrence hepatitis
lamivudine prevention recurrence B
lamivudine patients globulin hepatitis
lamivudine patients globulin B
lamivudine prophylaxis recurrence B hepatitis
lamivudine prophylaxis recurrence B
HBsAg survival improved B recurrence prophylaxis lamivudine patients globulin hepatitis
HBsAg survival improved B recurrence prophylaxis lamivudine patients globulin B
HBsAg survival improved B hepatitis
HBsAg survival improved B
Verapamil test hyperprolactinemia
Verapamil test investigated tool diagnosis hyperprolactinemia
verapamil value investigate population screened macroprolactinemia
verapamil hyperprolactinemia
Verapamil increased controls N macroprolactinoma
risperidone pseudoprolactinoma
Verapamil responsiveness finding diagnosis hyperprolactinemia
verapamil unresponsiveness discriminates causes hyperprolactinemia
oxygen nitrative reported present adriamycin cardiotoxicity
adriamycin cardiotoxicity
ADR adriamycin cardiotoxicity
nitrogen species reported present adriamycin cardiotoxicity
4 HNE showed point appeared injury mitochondrial
4 HNE showed point appeared injury
HNE showed point appeared injury mitochondrial
HNE showed point appeared injury
sodium mmol mosmol SIADH
sodium osmolality mosmol SIADH
zinc induced hearing
zinc induced hearing loss
superoxide protects zinc induced hearing
superoxide protects zinc induced hearing loss
copper Overexpression zinc induced hearing
copper Overexpression zinc induced hearing loss
superoxide radicals formation catalyze aminoglycoside observations deduced participation species aminoglycoside induced ototoxicity
superoxide radicals formation catalyze attenuate ototoxicity
aminoglycoside induced ototoxicity
aminoglycoside species participation deduced observations aminoglycoside catalyze attenuate ototoxicity
aminoglycoside observations deduced participation species aminoglycoside induced ototoxicity
aminoglycoside catalyze attenuate ototoxicity
oxygen species aminoglycoside induced ototoxicity
oxygen species participation deduced observations aminoglycoside catalyze attenuate ototoxicity
iron complexes catalyze aminoglycoside observations deduced participation species aminoglycoside induced ototoxicity
iron complexes catalyze attenuate ototoxicity
Zn overexpression hypothesized protect ototoxicity
superoxide dismutase protect ototoxicity
Cu Zn overexpression hypothesized protect ototoxicity
superoxide dismutase overexpression protection supports plays role aminoglycoside induced ototoxicity
aminoglycoside induced ototoxicity
Clonazepam epilepsy
clonazepam treated patients types epilepsy spasms infantile
clonazepam treated patients types epilepsy spasms
clonazepam treated patients types epilepsy
carboplatin combined directed patients non
carboplatin combined directed patients small
carboplatin combined directed patients cancer cell
carboplatin combined directed patients cancer lung
carboplatin combined directed patients cancer
Paclitaxel directed patients non
Paclitaxel directed patients small
Paclitaxel directed patients cancer cell
Paclitaxel directed patients cancer lung
Paclitaxel directed patients cancer
Taxol Bristol Paclitaxel directed patients non
Taxol Bristol Paclitaxel directed patients small
Taxol Bristol Paclitaxel directed patients cancer cell
Taxol Bristol Paclitaxel directed patients cancer lung
Taxol Bristol Paclitaxel directed patients cancer
paclitaxel trial patients cohort compared Toxicities
Carboplatin appear add toxicities hematologic
Carboplatin appear add toxicities
carboplatin combination dosed appear add toxicities hematologic
carboplatin combination dosed appear add toxicities
platinum ovarian m trial carcinoma
platinum ovarian m trial carcinoma peritoneum of
platinum ovarian m trial carcinoma peritoneum the
platinum ovarian m trial carcinoma peritoneum
platinum ovarian
platinum ovarian and
platinum ovarian cancers fallopian
platinum ovarian cancers tube
platinum ovarian cancers
doxorubicin trial carcinoma
doxorubicin trial carcinoma peritoneum of
doxorubicin trial carcinoma peritoneum the
doxorubicin trial carcinoma peritoneum
paclitaxel ovarian
paclitaxel ovarian and
paclitaxel ovarian cancers fallopian
paclitaxel ovarian cancers tube
paclitaxel ovarian cancers
paclitaxel ovarian m trial carcinoma
paclitaxel ovarian m trial carcinoma peritoneum of
paclitaxel ovarian m trial carcinoma peritoneum the
paclitaxel ovarian m trial carcinoma peritoneum
doxorubicin trial m ovarian
doxorubicin trial m ovarian and
doxorubicin trial m ovarian cancers fallopian
doxorubicin trial m ovarian cancers tube
doxorubicin trial m ovarian cancers
doxorubicin demonstrated agent platinum cancer ovarian
doxorubicin demonstrated agent platinum cancer
Doxil doxorubicin demonstrated agent platinum cancer ovarian
Doxil doxorubicin demonstrated agent platinum cancer
platinum agent limiting erythrodysesthesia
platinum agent demonstrated hand
platinum agent demonstrated hand foot -
platinum agent demonstrated hand foot
platinum agent demonstrated hand syndrome
platinum agent limiting toxicity
platinum cancer ovarian
platinum cancer
doxorubicin demonstrated agent limiting toxicity
Doxil doxorubicin demonstrated agent limiting toxicity
platinum agent demonstrated stomatitis
platinum carcinoma peritoneal
platinum carcinoma
platinum carcinoma Patients cancers ovarian
platinum carcinoma Patients cancers ovarian or
platinum carcinoma Patients cancers ovarian fallopian
platinum carcinoma Patients cancers tube
platinum carcinoma Patients cancers
doxorubicin treated METHODS Patients carcinoma peritoneal
doxorubicin treated METHODS Patients carcinoma
paclitaxel treated METHODS Patients cancers ovarian
paclitaxel treated METHODS Patients cancers ovarian or
paclitaxel treated METHODS Patients cancers ovarian fallopian
paclitaxel treated METHODS Patients cancers tube
paclitaxel treated METHODS Patients cancers
paclitaxel treated METHODS Patients carcinoma peritoneal
paclitaxel treated METHODS Patients carcinoma
doxorubicin treated METHODS Patients cancers ovarian
doxorubicin treated METHODS Patients cancers ovarian or
doxorubicin treated METHODS Patients cancers ovarian fallopian
doxorubicin treated METHODS Patients cancers tube
doxorubicin treated METHODS Patients cancers
doxorubicin results toxicity
platinum well cancer ovarian
platinum well cancer
paclitaxel well cancer ovarian
paclitaxel well cancer
zidovudine patient induced AIDS
caffeine exposure induced offspring glomerulosclerosis
creatinine levels accompanied exhibited glomerulosclerosis
creatinine levels accompanied exhibited glomerulosclerosis fibrosis interstitial
creatinine levels accompanied exhibited glomerulosclerosis fibrosis
isotretinoin drug treatment acne
Isotretinoin contraindicated use microphthalmos hypoplasia optic
Isotretinoin contraindicated use microphthalmos hypoplasia nerve
Isotretinoin contraindicated use microphthalmos hypoplasia
Isotretinoin contraindicated pregnancy abnormalities congenital
Isotretinoin contraindicated pregnancy abnormalities
Isotretinoin contraindicated use microphthalmos hypertelorism
Isotretinoin contraindicated use microphthalmos
Sotalol induced patient cardiomyopathy dilated
Sotalol induced patient cardiomyopathy
Sotalol induced patient cardiomyopathy associated tachycardia ventricular
Sotalol induced patient cardiomyopathy associated tachycardia
nifekalant hydrochloride administration terminated VT
hydrochloride administration terminated VT
sotalol agent effective prevention VT
atropine sulphate rectified experienced drop
atropine sulphate rectified experienced pressure in
atropine sulphate rectified experienced pressure blood
atropine sulphate rectified experienced pressure
sulphate rectified experienced drop
sulphate rectified experienced pressure in
sulphate rectified experienced pressure blood
sulphate rectified experienced pressure
Isradipine treatment hypertension
isradipine reported frequent headache palpitation
propofol formulations using depression cardiovascular
propofol formulations using depression
bupivacaine treatment Pre induced depression cardiovascular
bupivacaine treatment Pre induced depression
propofol content alleviate shown Pre induced cardiotoxicity
propofol effects investigate bupivacaine induced cardiotoxicity
bupivacaine consumption amount asystole time mean recorded occurrence dysrhythmia
propofol treatment pre induced effects cardiotoxic
propofol treatment pre induced effects cardiotoxic
phenylephrine effect ischemia cerebral
phenylephrine effect ischemia
phenylephrine effect induced injury ischemic
phenylephrine effect induced injury brain
phenylephrine effect induced injury
phenylephrine effect determined min occlusion middle
phenylephrine effect determined min occlusion cerebral
phenylephrine effect determined min occlusion artery
phenylephrine effect determined min occlusion
2 using staining evaluated evaluated 3 5 chloride edema
3 5 chloride edema
5 chloride edema
triphenyltetrazolium chloride edema
chloride edema
2 using staining evaluated rats injury brain
2 using staining evaluated rats injury
3 evaluated evaluated rats injury brain
3 evaluated evaluated rats injury
5 3 evaluated evaluated rats injury brain
5 3 evaluated evaluated rats injury
triphenyltetrazolium chloride 5 3 evaluated evaluated rats injury brain
triphenyltetrazolium chloride 5 3 evaluated evaluated rats injury
chloride 5 3 evaluated evaluated rats injury brain
chloride 5 3 evaluated evaluated rats injury
Evans Blue greater group HTN
Blue greater group HTN
Evans Blue greater group greater group HTN
Blue greater group greater group HTN
androgen thalidomide study prostate
androgen thalidomide study prostate cancer
thalidomide study prostate
thalidomide study prostate cancer
thalidomide effects assessed trials patients malignancies solid haematological
thalidomide effects assessed trials patients malignancies
androgen men cancer prostate
androgen men cancer
thalidomide mg using men cancer prostate
thalidomide mg using men cancer
dexamethasone bortezomib fasciitis containing patient macroglobulinaemia Waldenstrom
dexamethasone bortezomib fasciitis containing patient macroglobulinaemia
bortezomib fasciitis containing patient macroglobulinaemia Waldenstrom
bortezomib fasciitis containing patient macroglobulinaemia
Bortezomib dose dexamethasone containing considered tolerable infections bacterial
Bortezomib dose dexamethasone containing considered tolerable infections
dexamethasone containing considered tolerable infections bacterial
dexamethasone containing considered tolerable infections
Bortezomib dose dexamethasone malignancies
dexamethasone malignancies
dexamethasone dose treatment suffered neutropenia
bortezomib dose treatment suffered neutropenia
dexamethasone dose treatment suffered case 76 man macroglobulinaemia Waldenstrom
dexamethasone dose treatment suffered case 76 man macroglobulinaemia
bortezomib dose treatment suffered case 76 man macroglobulinaemia Waldenstrom
bortezomib dose treatment suffered case 76 man macroglobulinaemia
bortezomib related infections bacterial
bortezomib related infections
dexamethasone high bortezomib related infections bacterial
dexamethasone high bortezomib related infections
angiotensin doses Toleration inhibitors patients failure heart
angiotensin doses Toleration inhibitors patients failure
converting inhibitors patients failure heart
converting inhibitors patients failure
enzyme inhibitors patients failure heart
enzyme inhibitors patients failure
inhibitors patients failure heart
inhibitors patients failure
angiotensin Treatment BACKGROUND reduces patients failure heart
angiotensin Treatment BACKGROUND reduces patients failure
converting reduces patients failure heart
converting reduces patients failure
enzyme inhibitors converting reduces patients failure heart
enzyme inhibitors converting reduces patients failure
ACE inhibitors converting reduces patients failure heart
ACE inhibitors converting reduces patients failure
inhibitors converting reduces patients failure heart
inhibitors converting reduces patients failure
angiotensin Treatment BACKGROUND reduces patients failure CHF
converting reduces patients failure CHF
enzyme inhibitors converting reduces patients failure CHF
ACE inhibitors converting reduces patients failure CHF
inhibitors converting reduces patients failure CHF
lisinopril CHF
ACE inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction renal
ACE inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction
inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction renal
inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction
ACE inhibitor receiving titrated doses required symptoms related hypotension
inhibitor receiving titrated doses required symptoms related hypotension
ACE inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction hyperkalemia
inhibitor receiving titrated doses required symptoms related hypotension 2 because dysfunction hyperkalemia
creatinine > Hg pressure > -RSB- patients diabetes
ACE intolerance risk tolerated > -RSB- patients diabetes
inhibitor intolerance risk tolerated > -RSB- patients diabetes
ACE therapy patients CHF
inhibitor therapy patients CHF
argatroban therapy considerations harm Reducing induced thrombocytopenia
heparin therapy considerations harm Reducing induced thrombocytopenia
Argatroban hepatically inhibitor used prophylaxis thrombosis
Argatroban hepatically thrombocytopenia
Argatroban hepatically thrombocytopenia HIT
Argatroban hepatically patients HIT
heparin thrombosis
heparin thrombosis prophylaxis used inhibitor hepatically thrombocytopenia
heparin thrombosis prophylaxis used inhibitor hepatically thrombocytopenia HIT
heparin thrombosis prophylaxis used inhibitor hepatically patients HIT
argatroban therapy considerations summarize HIT
argatroban dose HIT
argatroban dose HIT microg reduced patients impairment hepatic
argatroban dose HIT microg reduced patients impairment
argatroban investigated unnecessary age obesity
argatroban therapy HIT
argatroban therapy professionals familiarity facilitate reduction harm associated HIT
argatroban errors g e HIT associated harm reduction facilitate familiarity professionals therapy HIT
argatroban errors g e HIT
cisplatin receiving patients Hypotension cardiotoxicity
5 cisplatin receiving patients Hypotension cardiotoxicity
fluorouracil Hypotension cardiotoxicity
5 cisplatin treated developed patients carcinoma colorectal
5 cisplatin treated developed patients carcinoma
fluorouracil 5 cisplatin treated developed patients carcinoma colorectal
fluorouracil 5 cisplatin treated developed patients carcinoma
5 fluorouracil 5 cisplatin treated developed patients carcinoma colorectal
5 fluorouracil 5 cisplatin treated developed patients carcinoma
FU 5 fluorouracil 5 cisplatin treated developed patients carcinoma colorectal
FU 5 fluorouracil 5 cisplatin treated developed patients carcinoma
cisplatin treated developed patients carcinoma colorectal
cisplatin treated developed patients carcinoma
CDDP cisplatin treated developed patients carcinoma colorectal
CDDP cisplatin treated developed patients carcinoma
CDDP influenced cardiotoxicity
5 manifestations cardiotoxicity
FU cardiotoxicity
dexamethasone days 4 treated woman myeloma multiple
dexamethasone days 4 treated woman myeloma
vincristine infusion 4 treated woman myeloma multiple
vincristine infusion 4 treated woman myeloma
doxorubicin vincristine infusion 4 treated woman myeloma multiple
doxorubicin vincristine infusion 4 treated woman myeloma
Minocycline induced vasculitis
minocycline taking pustulosis developed fever pain testicular
minocycline taking pustulosis developed fever pain
minocycline taking pustulosis palmoplantar
minocycline taking pustulosis
minocycline taking pustulosis developed fever polyneuropathy
minocycline taking pustulosis developed fever myalgias
minocycline taking pustulosis developed fever
minocycline case vasculitis
Fluoxetine gaining acceptance treatment depression
serotonin inhibitor Fluoxetine gaining acceptance treatment depression
fluoxetine developed cases adolescents depressed
fluoxetine pharmacotherapy mania development factors combination attention
fluoxetine pharmacotherapy mania development factors combination disorder deficit
fluoxetine pharmacotherapy mania development factors combination disorder hyperactivity
fluoxetine pharmacotherapy mania development factors combination disorder
fluoxetine pharmacotherapy mania development factors combination depression
fluoxetine pharmacotherapy mania development factors combination depression features psychotic
fluoxetine pharmacotherapy mania development factors combination history disorder affective
fluoxetine pharmacotherapy mania development factors combination history disorder
amphetamine influenced hyperactivity
amphetamine influenced induced Cocaine induced hyperactivity
Cocaine induced influenced hyperactivity
Cocaine induced hyperactivity
adenosine agonists influenced hyperactivity
adenosine agonists influenced induced Cocaine induced hyperactivity
amphetamine induced cocaine agonists influence examined hyperactivity
cocaine agonists influence examined hyperactivity
adenosine agonists influence examined hyperactivity
adenosine agonists decreased
adenosine agonists decreased activity the
adenosine agonists decreased activity locomotor
adenosine agonists decreased activity
amphetamine induced hyperactivity
amphetamine induced hyperactivity
cocaine active those doses induced hyperactivity
cocaine active those doses induced amphetamine induced hyperactivity
adenosine receptor agonists amphetamine induced hyperactivity
adenosine receptor agonists amphetamine induced hyperactivity
amphetamine shown induced influenced hyperactivity
amphetamine shown induced hyperactivity
amphetamine influenced hyperactivity
amphetamine influenced induced shown induced hyperactivity
cocaine reduce adenosine shown induced influenced hyperactivity
cocaine reduce adenosine shown induced hyperactivity
cocaine indicate induced shown induced influenced hyperactivity
cocaine indicate induced shown induced hyperactivity
adenosine shown induced influenced hyperactivity
adenosine shown induced hyperactivity
adenosine agonists influenced hyperactivity
adenosine agonists influenced induced shown induced hyperactivity
sumatriptan subcutaneously headache cluster
sumatriptan subcutaneously headache
warfarin induced epiphyses nasal
warfarin induced epiphyses hypoplasia
warfarin induced embryopathy
warfarin treated mothers born infants reported hypoplasia Nasal
warfarin treated mothers born infants reported hypoplasia
Histamine antagonists induced hypotension
MT induction effect explore aimed study dysfunction cognitive
MT induction effect explore aimed study dysfunction
BCNU administration resulted deterioration
BCNU administration resulted deterioration memory of
BCNU administration resulted deterioration memory learning
BCNU administration resulted deterioration memory learning and
BCNU administration resulted deterioration memory learning short
BCNU administration resulted deterioration memory term
BCNU administration resulted deterioration memory
glutathione resulted deterioration
glutathione resulted deterioration memory of
glutathione resulted deterioration memory learning
glutathione resulted deterioration memory learning and
glutathione resulted deterioration memory learning short
glutathione resulted deterioration memory term
glutathione resulted deterioration memory
glutathione activity content glutathione resulted deterioration
glutathione activity content glutathione resulted deterioration memory of
glutathione activity content glutathione resulted deterioration memory learning
glutathione activity content glutathione resulted deterioration memory learning and
glutathione activity content glutathione resulted deterioration memory learning short
glutathione activity content glutathione resulted deterioration memory term
glutathione activity content glutathione resulted deterioration memory
GSH glutathione activity content glutathione resulted deterioration
GSH glutathione activity content glutathione resulted deterioration memory of
GSH glutathione activity content glutathione resulted deterioration memory learning
GSH glutathione activity content glutathione resulted deterioration memory learning and
GSH glutathione activity content glutathione resulted deterioration memory learning short
GSH glutathione activity content glutathione resulted deterioration memory term
GSH glutathione activity content glutathione resulted deterioration memory
MT alpha factor tumor
BCNU administration increased factor necrosis
malondialdehyde contents MT alpha factor necrosis
MDA contents MT alpha factor necrosis
MT alpha factor necrosis
BCNU administration increased factor tumor
malondialdehyde contents MT alpha factor tumor
MDA contents MT alpha factor tumor
MDA TNFalpha levels counteracted induced toxicity
GSH depletion inhibition prevented induced toxicity
MT halts BCNU induced toxicity
BCNU induced toxicity
biperiden lactate application led long reaction characterized bradycardia dysphagia
lactate application led long reaction characterized bradycardia dysphagia
biperiden lactate application led long reaction characterized bradycardia
lactate application led long reaction characterized bradycardia
biperiden lactate application led long reaction characterized bradycardia dysarthria
lactate application led long reaction characterized bradycardia dysarthria
biperiden lactate application led 38 suffering neuralgia postzosteric
lactate application led 38 suffering neuralgia postzosteric
biperiden lactate application led 38 suffering neuralgia trigeminal
biperiden lactate application led 38 suffering neuralgia
lactate application led 38 suffering neuralgia trigeminal
lactate application led 38 suffering neuralgia
atropine effect dose attributed attributed Bradycardia
muscarine receptors drugs effect dose attributed attributed Bradycardia
spironolactone d d treated woman hyperaldosteronism
verapamil d treated woman hyperaldosteronism
melphalan patients amyloidosis primary
melphalan patients amyloidosis systemic
melphalan patients amyloidosis
creatinine level dL mg 5 insufficiency Acute
creatinine level dL mg 5 insufficiency renal
creatinine level dL mg 5 insufficiency
creatinine level dL mg 5 insufficiency ARI
melphalan injury prerequisite Ongoing injury tubular
melphalan injury prerequisite Ongoing injury
bis phosphate effect role induced nephrotoxicity
p phosphate effect role induced nephrotoxicity
nitrophenyl p phosphate effect role induced nephrotoxicity
phosphate effect role induced nephrotoxicity
bis phosphate effect role nephrotoxicity
p phosphate effect role nephrotoxicity
nitrophenyl p phosphate effect role nephrotoxicity
phosphate effect role nephrotoxicity
acetaminophen aminophenol role induced nephrotoxicity
acetaminophen aminophenol role nephrotoxicity
acetaminophen phosphate effect role induced nephrotoxicity
acetaminophen phosphate effect role nephrotoxicity
p role induced nephrotoxicity
aminophenol role induced nephrotoxicity
p role nephrotoxicity
aminophenol role nephrotoxicity
p acetaminophen phosphate effect role induced nephrotoxicity
aminophenol nephrotoxicity role induced nephrotoxicity
p acetaminophen phosphate effect role nephrotoxicity
aminophenol nephrotoxicity
APAP induced nephrotoxicity
PAP formation step APAP induced nephrotoxicity
bis phosphate effect nephrotoxicity
p phosphate effect nephrotoxicity
nitrophenyl p phosphate effect nephrotoxicity
phosphate effect nephrotoxicity
BNPP effect nephrotoxicity
APAP effect nephrotoxicity
PAP nephrotoxicity
BNPP animals Pretreatment resulted reduction nephrotoxicity
BNPP animals Pretreatment resulted nephrotoxicity
APAP prior animals Pretreatment resulted reduction nephrotoxicity
APAP prior animals Pretreatment resulted nephrotoxicity
APAP nephrotoxicity
APAP nephrotoxicity reduction resulted nephrotoxicity
PAP APAP prior animals Pretreatment resulted reduction nephrotoxicity
PAP APAP prior animals Pretreatment resulted nephrotoxicity
PAP reduction nephrotoxicity
PAP reduction resulted nephrotoxicity
BNPP appears nephrotoxicity
APAP reduction BNPP appears nephrotoxicity
APAP deacetylation inhibition due appears nephrotoxicity
aminocaproic therapy thrombosis acute
aminocaproic therapy thrombosis renal
aminocaproic therapy thrombosis artery
aminocaproic therapy thrombosis
acid therapy thrombosis acute
acid therapy thrombosis renal
acid therapy thrombosis artery
acid therapy thrombosis
aminocaproic therapy associated hemorrhage subarachnoid
aminocaproic therapy associated hemorrhage
acid therapy associated hemorrhage subarachnoid
acid therapy associated hemorrhage
EACA phenomena thromboembolic
EACA phenomena
EACA implicated patients coagulation disseminated
EACA implicated patients coagulation intravascular
EACA implicated patients coagulation
EACA implicated patients coagulation coagulopathies consumption
EACA implicated patients coagulation coagulopathies
acetaminophen found unresponsive toxicity
acetaminophen overdose edema patients used hypothermia
acetaminophen overdose
ketoconazole induced syndrome Baboon
ketoconazole induced syndrome
ketoconazole included history based syndrome baboon
ketoconazole included history based syndrome
ketoconazole case syndrome baboon
ketoconazole case syndrome
Nelarabine neurotoxicity
nelarabine neurotoxicity
nelarabine caused neurotoxicity
cyclosporine patients had bacteremias
Aza patients had occurred infections fungal
Aza patients had occurred infections
Aza patients had infections staphylococcal
Aza patients had infections
cyclosporine patients had symptoms related infection CMV
cyclosporine patients had symptoms related infection
cyclosporine patients % found evidence infection Epstein
cyclosporine patients % found evidence infection Barr
cyclosporine patients % found evidence infection Virus
cyclosporine patients % found evidence infection
monosodium glutamate injection treated mice thresholds seizure
glutamate injection treated mice thresholds seizure
monosodium glutamate injection treated mice thresholds evaluation parameters testing seizure
glutamate injection treated mice thresholds evaluation parameters testing seizure
MSG glutamate injection treated mice thresholds seizure
MSG glutamate injection treated mice thresholds evaluation parameters testing seizure
Flurothyl thresholds seizure
Flurothyl thresholds evaluation parameters testing seizure
flurothyl testing parameters evaluation thresholds seizure
flurothyl testing seizure
Monosodium produces convulsions
glutamate administration produces convulsions
MSG administration produces convulsions
MSG administration produced susceptibility seizure
ether technique seizure
ether technique used evaluate susceptibility seizure
MSG injections received susceptibility evaluate used technique seizure
MSG injections received susceptibility seizure
flurothyl technique seizure
flurothyl technique used evaluate susceptibility seizure
MSG treatment resulted alter threshold seizure
MSG control thresholds seizure
naloxone challenge ineffective altering thresholds seizure
ether produced unclear relationship hypothermia induction seizure
Flurothyl ether produced unclear relationship hypothermia induction seizure
flurothyl exposure duration correlated hypothermia produced unclear relationship hypothermia induction seizure
ether produced hypothermia
ether produced unclear relationship hypothermia
Flurothyl testing seizure
Flurothyl testing proved technique evaluate seizure
aspirin associated ESRD risk related high subset patients nephropathy
5 injection produced nerves destruction reduced magnitude vasodepressor responses bradycardiac
7 destruction reduced magnitude vasodepressor responses bradycardiac
dihydroxytryptamine 7 destruction reduced magnitude vasodepressor responses bradycardiac
5 destruction reduced magnitude vasodepressor responses bradycardiac
HT nerves destruction reduced magnitude vasodepressor responses bradycardiac
danazol women angioedema hereditary
danazol women angioedema
danazol safety investigated performing angioedema hereditary
danazol safety investigated performing angioedema
danazol treated angioedema hereditary
danazol treated angioedema
heparin aspects thrombocytopenia thrombosis
heparin therapy thrombocytopenia thrombosis
Heparin used treat thrombosis
heparin remains treat episodes thrombotic
heparin effect Bleeding
heparin therapy receiving patients concern bleeding
heparin use common HITT
cocaine hydrochloride infusion fraction volumes min measured patients referred catheterization evaluation pain chest
cocaine hydrochloride infusion fraction volumes min measured patients referred catheterization evaluation pain
hydrochloride infusion fraction volumes min measured patients referred catheterization evaluation pain chest
hydrochloride infusion fraction volumes min measured patients referred catheterization evaluation pain
digoxin beneficial patients fibrillation atrial
digoxin beneficial patients fibrillation
digoxin increase infarction myocardial
digoxin increase infarction
digoxin increase infarction MI
fludrocortisone reversed induced Hyperkalemia
mefenamic nephropathy history caused hypoaldosteronism hyperkalemia
acid nephropathy history caused hypoaldosteronism hyperkalemia
naproxen indomethacin caused history arthritis rheumatoid
naproxen indomethacin caused history arthritis
indomethacin caused history arthritis rheumatoid
indomethacin caused history arthritis
naproxen indomethacin caused history nephropathy
mefenamic nephropathy history arthritis rheumatoid
mefenamic nephropathy history arthritis
acid nephropathy history arthritis rheumatoid
acid nephropathy history arthritis
indomethacin caused history nephropathy
mefenamic nephropathy history caused hypoaldosteronism
acid nephropathy history caused hypoaldosteronism
prostaglandin inhibitors predisposed acidosis IV type
prostaglandin inhibitors predisposed acidosis IV
prostaglandin inhibitors predisposed acidosis renal
prostaglandin inhibitors predisposed acidosis tubular
prostaglandin inhibitors predisposed acidosis
prostaglandin inhibitors predisposed disease renal
prostaglandin inhibitors predisposed disease
fludrocortisone added correcting hyperkalemia
amisulpride overdose
amisulpride g cases poisoning
calcium gluconate administration respond appeared prolongation QT
calcium gluconate administration respond appeared prolongation
gluconate administration respond appeared prolongation QT
gluconate administration respond appeared prolongation
caffeine disorders panic
caffeine disorders
caffeine administration effects determined meeting attacks panic
caffeine administration effects determined meeting attacks
caffeine administration effects determined meeting attacks disorder panic
caffeine administration effects determined meeting attacks disorder
3 pressure ratings caffeine administration effects determined meeting attacks panic
3 pressure ratings caffeine administration effects determined meeting attacks
methoxy ratings caffeine administration effects determined meeting attacks panic
methoxy ratings caffeine administration effects determined meeting attacks
4 ratings caffeine administration effects determined meeting attacks panic
4 ratings caffeine administration effects determined meeting attacks
hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks panic
hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks
3 pressure ratings caffeine administration effects determined meeting attacks disorder panic
3 pressure ratings caffeine administration effects determined meeting attacks disorder
methoxy ratings caffeine administration effects determined meeting attacks disorder panic
methoxy ratings caffeine administration effects determined meeting attacks disorder
4 ratings caffeine administration effects determined meeting attacks disorder panic
4 ratings caffeine administration effects determined meeting attacks disorder
hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks disorder panic
hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks disorder
MHPG hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks panic
MHPG hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks
MHPG hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks disorder panic
MHPG hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting attacks disorder
caffeine administration effects determined meeting DSM criteria agoraphobia
cortisol ratings caffeine administration effects determined meeting DSM criteria agoraphobia
cortisol ratings caffeine administration effects determined meeting attacks panic
cortisol ratings caffeine administration effects determined meeting attacks
cortisol ratings caffeine administration effects determined meeting attacks disorder panic
cortisol ratings caffeine administration effects determined meeting attacks disorder
3 pressure ratings caffeine administration effects determined meeting DSM criteria agoraphobia
methoxy ratings caffeine administration effects determined meeting DSM criteria agoraphobia
4 ratings caffeine administration effects determined meeting DSM criteria agoraphobia
hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting DSM criteria agoraphobia
MHPG hydroxyphenethyleneglycol ratings caffeine administration effects determined meeting DSM criteria agoraphobia
Caffeine produced subject anxiety palpitations
Caffeine produced subject anxiety restlessness
caffeine effects similar those experienced attacks panic
caffeine effects similar those experienced attacks
caffeine antagonist suggest have patients panic
caffeine antagonist suggest have patients disorder
caffeine antagonist suggest have abnormalities
caffeine antagonist suggest have abnormalities systems in
caffeine antagonist suggest have abnormalities systems neuronal
caffeine antagonist suggest have abnormalities systems
adenosine antagonist suggest have abnormalities
adenosine antagonist suggest have abnormalities systems in
adenosine antagonist suggest have abnormalities systems neuronal
adenosine antagonist suggest have abnormalities systems
adenosine involving systems abnormalities
adenosine involving systems in
adenosine involving systems neuronal
adenosine involving systems
adenosine antagonist suggest have patients panic
adenosine antagonist suggest have patients disorder
adenosine involving systems abnormalities have patients panic
adenosine involving systems abnormalities have patients disorder
levodopa factors dyskinesia Malaysians disease Parkinson
levodopa factors dyskinesia Malaysians disease Parkinson '
levodopa factors dyskinesia Malaysians disease s
levodopa factors dyskinesia Malaysians disease
levodopa therapy disease Parkinson
levodopa therapy disease Parkinson '
levodopa therapy disease s
levodopa therapy disease
levodopa therapy disease PD
levodopa predictors prevalence studied PD
levodopa therapy involving patients PD
tranexamic acid aorta arrest hypothermic
acid aorta arrest hypothermic
tranexamic acid aorta failure congestive
tranexamic acid aorta failure heart
tranexamic acid aorta failure
acid aorta failure congestive
acid aorta failure heart
acid aorta failure
anthracycline cardiotoxicity
Doxorubicin anti therapeutic cancer
DOX Doxorubicin anti therapeutic cancer
Doxorubicin anti associated cardiotoxicity
DOX Doxorubicin anti associated cardiotoxicity
DOX examined cardiotoxicity
Methyldopa induced old presenting near syncope
Methyldopa causes anemia autoimmune
Methyldopa causes anemia hemolytic
Methyldopa causes anemia
methyldopa case report syncope anemia boy presented department emergency
methyldopa case report syncope anemia boy presented department
methyldopa case report syncope
methyldopa treated admission trauma
thiabendazole administration duct bile
thiabendazole administration duct
thiabendazole administration duct injury
thiabendazole developed wk jaundice
lamivudine mutants Rate patients infection chronic
lamivudine mutants Rate patients infection hepatitis
lamivudine mutants Rate patients infection B
lamivudine mutants Rate patients infection virus
lamivudine mutants Rate patients infection
Lamivudine used treatment patients chronic
Lamivudine used treatment patients hepatitis
Lamivudine used treatment patients B
lamivudine occur mutants virus hepatitis
lamivudine occur mutants virus B
lamivudine occur patients chronic
lamivudine occur patients hepatitis
lamivudine occur patients B
lamivudine mutants rate patients chronic
lamivudine mutants rate patients hepatitis
lamivudine mutants rate patients B
lamivudine treated patients chronic
lamivudine treated patients hepatitis
lamivudine treated patients B
lamivudine mutants patients B chronic
lamivudine mutants patients B hepatitis
lamivudine mutants patients B
lamivudine mutants occurrence reported detected patients chronic
lamivudine mutants occurrence reported detected patients hepatitis
lamivudine mutants occurrence reported detected patients B
lamivudine detected reported occurrence mutants patients B chronic
lamivudine detected reported occurrence mutants patients B hepatitis
lamivudine detected reported occurrence mutants patients B
lamivudine detected patients chronic
lamivudine detected patients hepatitis
lamivudine detected patients B
Vasopressin hypertension
vasopressin agent process hypertensive
DOCA pathogenesis plays hypertension treated insipidus diabetes
DOCA pathogenesis plays hypertension treated insipidus
DOCA treated insipidus diabetes
DOCA treated insipidus
Vasopressin plays hypertension treated insipidus diabetes
Vasopressin plays hypertension treated insipidus
lithium rats substantial hypertension
Vasopressin plays hypertension
vasopressin action appears important development model hypertension
vasopressin action appears important observed stage hypertension
vasopressin secretion promotes function hormone factor hypertension
vasopressin role remains determined hypertension
warfarin due hematoma
warfarin induced coagulopathy
warfarin causing coagulopathy
piroxicam interaction exacerbated coagulopathy
levobupivacaine block administration toxicity nervous Central
levobupivacaine block administration toxicity nervous
levobupivacaine block administration toxicity system
levobupivacaine block administration toxicity
epinephrine 2 % microgram mL administration developed seizures grand
epinephrine 2 % microgram mL administration developed seizures mal
epinephrine 2 % microgram mL administration developed seizures
epinephrine administration signs blood developed seizures grand
epinephrine administration signs blood developed seizures mal
epinephrine administration signs blood developed seizures
succinylcholine treated seizures
sodium thiopental treated seizures
thiopental treated seizures
bupivacaine have profile cardiac
bupivacaine have profile toxicity
levobupivacaine have result convulsions
levobupivacaine amounts reach have result convulsions
levobupivacaine have profile cardiac
levobupivacaine have profile toxicity
levobupivacaine amounts reach have profile cardiac
levobupivacaine amounts reach have profile toxicity
bupivacaine have result convulsions
K neither blockers morphine induced hypoactivity
K induced hypoactivity
morphine induced hypoactivity
morphine prevented blockers K induced hypoactivity
K neither blockers morphine induced hyperactivity
K induced morphine induced hyperactivity
quinine K connected seems morphine hypoactivity
K blockade sufficient suggested induced morphine hypoactivity
K connected seems morphine hypoactivity
4 - aminopyridine quinine K connected seems hyperactivity
- aminopyridine quinine K connected seems hyperactivity
aminopyridine quinine K connected seems hyperactivity
4 - aminopyridine quinine K connected seems morphine hypoactivity
- aminopyridine quinine K connected seems morphine hypoactivity
aminopyridine quinine K connected seems morphine hypoactivity
quinine K connected seems hyperactivity
morphine prevent sufficient suggested induced morphine hypoactivity
morphine hypoactivity
K blockade sufficient suggested induced morphine seems hyperactivity
K connected seems hyperactivity
temsirolimus lymphoma mantle
temsirolimus lymphoma cell
temsirolimus lymphoma
temsirolimus treated reported MCL
temsirolimus treated had opportunity study case MCL
temsirolimus treatment had case study opportunity had treated reported MCL
temsirolimus treatment had case MCL
temsirolimus treated had opportunity study case had regression tumor
temsirolimus treatment had regression tumor
temsirolimus inhibited proliferation tumor
temsirolimus inhibited induce number cells tumor
temsirolimus had effect decrease density tumor
temsirolimus reduced contribute efficiency MCL
temsirolimus effect contribute efficiency MCL
temsirolimus reduced burden tumor
temsirolimus reduced contribute effect temsirolimus tissue tumor
temsirolimus effect contribute reduced burden tumor
temsirolimus tissue tumor
triphenyltetrazolium staining using evaluated BBB destroy used hypertension
TTC staining using evaluated BBB destroy used hypertension
TTC exhibited s giving using evaluated BBB destroy used hypertension
glutathione ischemia injury reperfusion
glutathione ischemia injury
glutathione ischemia
epinephrine lipid Resuscitation toxicity cardiac
epinephrine lipid Resuscitation toxicity
levobupivacaine both lipid Resuscitation toxicity cardiac
levobupivacaine both lipid Resuscitation toxicity
epinephrine emulsion regimens determined neonates cases toxicity
Nefiracetam reverses effects apomorphine amnesia
DM Nefiracetam reverses effects apomorphine amnesia
9384 DM Nefiracetam reverses effects apomorphine amnesia
pyrrolidone derivative induced learning
pyrrolidone derivative induced and
pyrrolidone derivative induced post
pyrrolidone derivative induced training
pyrrolidone derivative induced training deficits consolidation
pyrrolidone derivative induced training deficits
Nefiracetam derivative induced learning
Nefiracetam derivative induced and
Nefiracetam derivative induced post
Nefiracetam derivative induced training
Nefiracetam derivative induced training deficits consolidation
Nefiracetam derivative induced training deficits
nefiracetam ability evaluated amnesia
nefiracetam administration reversed amnesia
chloride function cause depolarisation sustained
chloride function cause depolarisation membrane
chloride function cause depolarisation
chloride function defect caused congenita Myotonia
chloride function defect caused congenita
chloride function defect caused congenita MC
Vasurix Hexabrix polyvidone considered preferred toxicity
polyvidone considered preferred toxicity
Hexabrix polyvidone considered preferred toxicity
Hexabrix preferred toxicity
contrast media considered preferred toxicity
media considered preferred toxicity
Quetiapine induced carcinoma hepatocellular
Quetiapine induced carcinoma
Quetiapine induced neutropenia patient bipolar
clozapine derivative has risk causing dyscrasias neutropenia
Quetiapine derivative has risk causing dyscrasias blood
Quetiapine derivative has risk causing dyscrasias
clozapine derivative has risk causing dyscrasias blood
clozapine derivative has risk causing dyscrasias
quetiapine developed patient carcinoma hepatocellular
quetiapine developed patient carcinoma
quetiapine marker one dysfunction Hepatic
quetiapine marker one dysfunction
glutamate variability hyperalgesia
glutamate variability hyperalgesia allodynia
capsaicin glutamate injections attractive use mimic aspects disorders pain
capsaicin glutamate injections attractive use mimic aspects disorders
glutamate injections attractive use mimic aspects disorders pain
glutamate injections attractive use mimic aspects disorders
glutamate injections attractive use mimic hyperalgesia
glutamate injections attractive use mimic hyperalgesia allodynia
glutamate injections attractive use models pain
capsaicin glutamate injections attractive use models pain
glutamate injection gauges scale increase observed hyperalgesia
glutamate conclusion yield hyperalgesic
glutamate conclusion yield hyperalgesic responses allodynic
bepridil administration evaluation fibrillation atrial
bepridil administration evaluation fibrillation
bepridil administration evaluation fibrillation and
bepridil administration evaluation fibrillation flutter
Bepridil hydrochloride attracted drug fibrillation atrial
Bepridil hydrochloride attracted drug fibrillation
hydrochloride attracted drug fibrillation atrial
hydrochloride attracted drug fibrillation
Bepridil hydrochloride attracted drug fibrillation AF
hydrochloride attracted drug fibrillation AF
Bpd hydrochloride attracted drug fibrillation atrial
Bpd hydrochloride attracted drug fibrillation
Bpd hydrochloride attracted drug fibrillation AF
Bepridil hydrochloride attracted drug fibrillation flutter atrial
Bepridil hydrochloride attracted drug fibrillation flutter
hydrochloride attracted drug fibrillation flutter atrial
hydrochloride attracted drug fibrillation flutter
Bepridil hydrochloride attracted drug fibrillation AFL
hydrochloride attracted drug fibrillation AFL
Bpd hydrochloride attracted drug fibrillation flutter atrial
Bpd hydrochloride attracted drug fibrillation flutter
Bpd hydrochloride attracted drug fibrillation AFL
Bpd administered patients comprising AF
Bpd administered patients comprising AF cases AFL
GEM active treatment lymphoma Hodgkin
GEM active treatment lymphoma
Gemcitabine have activity HL non toxicity
Gemcitabine have activity HL
cisplatin Gemcitabine have activity HL
cisplatin Gemcitabine have activity HL non toxicity
methylprednisolone m analysis patients treated HL
gemcitabine 1 treated HL
GEM days included m analysis patients treated HL
cisplatin D m analysis patients treated HL
GEM chemotherapy rates treatment HL
androgen treated Fanconi
androgen treated Fanconi '
androgen treated s
androgen treated anemia
corticosteroid treated Fanconi
corticosteroid treated Fanconi '
corticosteroid treated s
corticosteroid treated anemia
androgens treated reported known have anemia Fanconi
androgens treated reported known have anemia Fanconi '
androgens treated reported known have anemia s
androgens treated reported known have anemia
corticosteroids androgens treated reported known have anemia Fanconi
corticosteroids androgens treated reported known have anemia Fanconi '
corticosteroids androgens treated reported known have anemia s
corticosteroids androgens treated reported known have anemia
androgen patients develop metastasizing non corticosteroid treated anemia Fanconi
androgen patients develop metastasizing non corticosteroid treated anemia Fanconi '
androgen patients develop metastasizing non corticosteroid treated anemia s
androgen patients develop metastasizing non corticosteroid treated anemia
androgen patients develop neoplasms hepatic
androgen patients develop neoplasms
corticosteroid non metastasizing develop neoplasms hepatic
corticosteroid non metastasizing develop neoplasms
corticosteroid treated anemia Fanconi
corticosteroid treated anemia Fanconi '
corticosteroid treated anemia s
corticosteroid treated anemia
VGB exposure current therapy basis grouped people epilepsy
garcinielliptone FC pretreated pilocarpine seizures
FC pretreated pilocarpine seizures
aspartate glutamine acid r levels activity determine mg parameters seizure
aspartate glutamine acid r levels activity determine seizures
amino levels activity determine mg parameters seizure
acid levels activity determine mg parameters seizure
amino levels activity determine seizures
acid levels activity determine seizures
glutathione glutamine acid r levels activity determine mg parameters seizure
glutathione glutamine acid r levels activity determine seizures
GFC effects evaluate aimed study mg parameters seizure
GFC effects evaluate aimed study mg determine seizures
glutamine acid r levels activity determine mg parameters seizure
glutamine acid r levels activity determine seizures
r levels activity determine mg parameters seizure
aminobutyric acid r levels activity determine mg parameters seizure
acid r levels activity determine mg parameters seizure
r levels activity determine seizures
aminobutyric acid r levels activity determine seizures
acid r levels activity determine seizures
GABA acid r levels activity determine mg parameters seizure
GABA acid r levels activity determine seizures
GFC produced kg latency seizure
GFC exert reduce frequency epilepticus status
GFC exert reduce frequency epilepticus
GFC exert reduce frequency epilepticus demonstrated seizure
acetaminophen NSAIDs using bleeding risks hospitalization AMI
COX NSAIDs using bleeding risks hospitalization AMI GI
COX NSAIDs using bleeding
2 inhibitors NSAIDs using bleeding risks hospitalization AMI GI
2 inhibitors NSAIDs using bleeding
inhibitors NSAIDs using bleeding risks hospitalization AMI GI
inhibitors NSAIDs using bleeding
acetaminophen NSAIDs using bleeding risks hospitalization AMI GI
acetaminophen NSAIDs using bleeding
diclofenac 1 1 59 group acetaminophen GI non users aspirin ratios hospitalization AMI
acetaminophen GI non users aspirin ratios hospitalization AMI
aspirin ratios hospitalization AMI
aspirin acetaminophen GI non users aspirin ratios hospitalization AMI
ibuprofen 0 17 group acetaminophen GI non users aspirin ratios hospitalization AMI
celecoxib 1 27 group acetaminophen GI non users aspirin ratios hospitalization AMI
aspirin users naproxen seemed carry risk GI AMI
aspirin users naproxen seemed carry risk GI
aspirin users naproxen seemed carry risk GI bleeding
acetaminophen that similar AMI
rofecoxib those better seemed similar toxicity
celecoxib toxicity
acetaminophen that similar toxicity
celecoxib toxicity similar AMI
methothexate concentration leakage development predispose inappropriately calculations presence preservatives neurotoxic
methotrexate doses inappropriately calculations presence preservatives neurotoxic
methotrexate preparations preservatives neurotoxic
methotrexate diluents use calculations presence preservatives neurotoxic
methothexate concentration leakage development dynamics related presence leukemia central
methothexate concentration leakage development dynamics related presence leukemia nervous
methothexate concentration leakage development dynamics related presence leukemia system
methothexate concentration leakage development dynamics related presence leukemia
methotrexate doses inappropriately predispose development dynamics related presence leukemia central
methotrexate doses inappropriately predispose development dynamics related presence leukemia nervous
methotrexate doses inappropriately predispose development dynamics related presence leukemia system
methotrexate doses inappropriately predispose development dynamics related presence leukemia
methotrexate preparations preservatives presence calculations inappropriately predispose development dynamics related presence leukemia central
methotrexate preparations preservatives presence calculations inappropriately predispose development dynamics related presence leukemia nervous
methotrexate preparations preservatives presence calculations inappropriately predispose development dynamics related presence leukemia system
methotrexate preparations preservatives presence calculations inappropriately predispose development dynamics related presence leukemia
methotrexate diluents use calculations inappropriately predispose development dynamics related presence leukemia central
methotrexate diluents use calculations inappropriately predispose development dynamics related presence leukemia nervous
methotrexate diluents use calculations inappropriately predispose development dynamics related presence leukemia system
methotrexate diluents use calculations inappropriately predispose development dynamics related presence leukemia
methotrexate contaminants irradiation pathogenesis toxicity
methotrexate toxicity
methotrexate contaminants deficiency folate
methotrexate contaminants deficiency
methotrexate toxicity pathogenesis irradiation contaminants deficiency folate
methotrexate toxicity pathogenesis irradiation contaminants deficiency
methotrexate doses employing reduced incidence neurotoxicity
methotrexate doses employing presence leukemia central
methotrexate doses employing presence leukemia nervous
methotrexate doses employing presence leukemia system
methotrexate doses employing presence leukemia
methotrexate levels monitoring predictive development neurotoxicity
5 infusion received Risk encephalopathy patients cancer
fluorouracil Risk encephalopathy patients cancer
5 infusion received Risk fluorouracil complication dehydration infection
fluorouracil complication dehydration infection
5 infusion received Risk encephalopathy hyperammonemic
5 infusion received Risk encephalopathy
fluorouracil Risk encephalopathy hyperammonemic
fluorouracil Risk encephalopathy
5 infusion received Risk fluorouracil complication dehydration
fluorouracil complication dehydration
5 infusion related patients cancer
fluorouracil identified related patients cancer
5 fluorouracil identified related patients cancer
FU 5 fluorouracil identified related patients cancer
5 infusion related patients had episodes encephalopathy hyperammonemic
5 infusion related patients had episodes encephalopathy
fluorouracil identified related patients had episodes encephalopathy hyperammonemic
fluorouracil identified related patients had episodes encephalopathy
5 fluorouracil identified related patients had episodes encephalopathy hyperammonemic
5 fluorouracil identified related patients had episodes encephalopathy
FU 5 fluorouracil identified related patients had episodes encephalopathy hyperammonemic
FU 5 fluorouracil identified related patients had episodes encephalopathy
ammonium levels seen patients infections bacterial
ammonium levels seen patients infections
ammonium levels onset hyperammonemia
5 doses receiving patients patients patients infections bacterial
5 doses receiving patients patients patients infections
FU doses receiving patients patients patients infections bacterial
FU doses receiving patients patients patients infections
5 infusion receiving patients occur encephalopathy hyperammonemic
5 infusion receiving patients occur encephalopathy
FU infusion receiving patients occur encephalopathy hyperammonemic
FU infusion receiving patients occur encephalopathy
levodopa rigidity
levodopa rigidity bradykinesia
levodopa rigidity Twenty patients suffering disease Parkinson
levodopa rigidity Twenty patients suffering disease Parkinson '
levodopa rigidity Twenty patients suffering disease s
levodopa rigidity Twenty patients suffering disease
cyclophosphamide therapy pelvis carcinoma
cyclophosphamide therapy pelvis of
cyclophosphamide therapy pelvis the
cyclophosphamide therapy pelvis renal
cyclophosphamide therapy pelvis
cyclophosphamide treated had obstruction due woman hydroureteronephrosis
cyclophosphamide treated had vasculitis cerebral
cyclophosphamide treated had vasculitis
cyclophosphamide abnormalities ability known appreciated associated carcinoma
cyclophosphamide abnormalities ability known appreciated associated carcinoma tract of
cyclophosphamide abnormalities ability known appreciated associated carcinoma tract the
cyclophosphamide abnormalities ability known appreciated associated carcinoma tract urinary
cyclophosphamide abnormalities ability known appreciated associated carcinoma tract
cyclophosphamide cause cystitis hemorrhagic
cyclophosphamide cause cystitis
cyclophosphamide treatment reported pelvis carcinoma
cyclophosphamide treatment reported pelvis of
cyclophosphamide treatment reported pelvis the
cyclophosphamide treatment reported pelvis renal
cyclophosphamide treatment reported pelvis
cyclophosphamide treatment reported cancer urinary
cyclophosphamide treatment reported cancer tract
cyclophosphamide treatment reported cancer
cyclophosphamide intensified prolonged suggests association tumor
cyclophosphamide intensified prolonged suggests association tumor hydroureteronephrosis
cyclophosphamide treatment evaluated uropathy obstructive
cyclophosphamide treatment evaluated uropathy
VNR comparing analysis treatment malignancies
VNR drugs treatment cancer
gemcitabine -RSB- drugs cardiotoxic
GEM -RSB- drugs cardiotoxic
anthracyclines fluorouracil -RSB- drugs cardiotoxic
fluorouracil -RSB- drugs cardiotoxic
vindesine VDS drugs cardiotoxic
VDS drugs cardiotoxic
serotonin complication reuptake important aware cause hypertension
daptomycin meningitis
daptomycin high concentrations treated bacteremia
daptomycin high concentrations treated bacteremia meningitis
methicillin case report sensitive treated bacteremia
methicillin case report sensitive treated bacteremia meningitis
creatinine mg developed failure acute
creatinine mg developed failure renal
creatinine mg developed failure
daptomycin discontinued Nafcillin initiated meningitis
Nafcillin initiated meningitis
nafcillin nephritis bacteremia
Daptomycin initiated nafcillin nephritis bacteremia
Daptomycin initiated nafcillin nephritis interstitial
Daptomycin initiated nafcillin nephritis
daptomycin option bacteremia
quetiapine schizo
quetiapine doses high add disorder affective
quetiapine doses high add disorder
lithium case year suffering schizo
lithium case disorder affective
lithium case disorder
lithium 0 lithium case year suffering schizo
lithium 0 lithium case disorder affective
lithium 0 lithium case disorder
zuclopenthixol antipsychotics case year suffering schizo
zuclopenthixol antipsychotics case disorder affective
zuclopenthixol antipsychotics case disorder
quetiapine introduction h presented contrasting absence history disorder aggressiveness
quetiapine introduction h presented contrasting absence history disorder aggressiveness personality
quetiapine introduction h presented contrasting absence history disorder
sulphonylurea treatment patients type
sulphonylurea treatment patients type 2
sulphonylurea treatment associated disease Risk diabetes
sulphonylurea treatment associated disease coronary
sulphonylurea treatment associated disease artery
sulphonylurea treatment associated disease
sulphonylureas associated treatment diabetes type
sulphonylureas associated treatment diabetes 2
sulphonylureas associated treatment diabetes
sulphonylureas associated disease coronary
sulphonylureas associated disease artery
sulphonylureas associated disease
sulphonylureas associated disease CAD
glipizide 0 fold fold 4 treatment associated hazard developing CAD
metformin unchanged associated hazard developing CAD
gliclazide risk CAD
glimepiride gliclazide risk CAD
glimepiride gliclazide risk associated CONCLUSIONS treatment diabetes type
glimepiride gliclazide risk associated CONCLUSIONS treatment diabetes 2
glimepiride gliclazide risk associated CONCLUSIONS treatment diabetes
glipizide glibenclamide treatment CONCLUSIONS associated risk CAD
gliclazide risk associated CONCLUSIONS treatment diabetes type
gliclazide risk associated CONCLUSIONS treatment diabetes 2
gliclazide risk associated CONCLUSIONS treatment diabetes
glipizide glibenclamide treatment diabetes type
glipizide glibenclamide treatment diabetes 2
glipizide glibenclamide treatment diabetes
glibenclamide treatment diabetes type
glibenclamide treatment diabetes 2
glibenclamide treatment diabetes
carboplatin chemotherapy retinoblastoma
carboplatin injections used Focal BACKGROUND adjunct chemotherapy retinoblastoma
carboplatin injections used toxicity
carboplatin received retinoblastoma
carboplatin injections treated retinoblastoma
carboplatin free toxicity
heparin patient alteplase thrombolysis
heparin patient alteplase thrombolysis Use thrombocytopenia thrombosis
argatroban Use thrombocytopenia thrombosis
argatroban Use thrombocytopenia
argatroban Use thrombolysis
heparin directed presented thrombolysis
heparin induced thrombosis
argatroban treated induced thrombosis
argatroban treated induced thrombocytopenia
argatroban treated induced heparin directed presented thrombolysis
argatroban treated induced thrombosis HITT
heparin induced thrombosis HITT
heparin embolism venous upper undergoing amyloidosis
heparin embolism venous upper
heparin embolism venous extremity
heparin embolism venous deep
heparin embolism venous
heparin embolism venous thrombosis
argatroban restarted resolved epistaxis
argatroban treated year man amyloidosis
argatroban treated year syndrome secondary HITT
argatroban treated year syndrome SVC
argatroban treated year syndrome
nocistatin FQ impairment learning
nocistatin FQ impairment learning and
nocistatin FQ impairment learning memory
nocistatin FQ impairment
scopolamine induced impairment learning
scopolamine induced impairment learning and
scopolamine induced impairment learning memory
scopolamine induced impairment
Nociceptin FQ impairment learning
Nociceptin FQ impairment learning and
Nociceptin FQ impairment learning memory
Nociceptin FQ impairment
orphanin FQ impairment learning
orphanin FQ impairment learning and
orphanin FQ impairment learning memory
orphanin FQ impairment
FQ impairment learning
FQ impairment learning and
FQ impairment learning memory
FQ impairment
nocistatin isolated nociceptin induced allodynia
nocistatin isolated nociceptin induced allodynia hyperalgesia
nociceptin nociceptin induced allodynia
nociceptin nociceptin induced allodynia hyperalgesia
nociceptin induced allodynia
nociceptin induced allodynia hyperalgesia
nocistatin FQ modulate impairment
nocistatin FQ modulate impairment learning of
nocistatin FQ modulate impairment learning
nocistatin FQ modulate impairment learning and
nocistatin FQ modulate impairment learning memory
scopolamine using induced impairment
scopolamine using induced impairment learning of
scopolamine using induced impairment learning
scopolamine using induced impairment learning and
scopolamine using induced impairment learning memory
nociceptin FQ modulate impairment
nociceptin FQ modulate impairment learning of
nociceptin FQ modulate impairment learning
nociceptin FQ modulate impairment learning and
nociceptin FQ modulate impairment learning memory
orphanin FQ modulate impairment
orphanin FQ modulate impairment learning of
orphanin FQ modulate impairment learning
orphanin FQ modulate impairment learning and
orphanin FQ modulate impairment learning memory
FQ modulate impairment
FQ modulate impairment learning of
FQ modulate impairment learning
FQ modulate impairment learning and
FQ modulate impairment learning memory
valproic year Reversible man epilepsy
acid year Reversible man epilepsy
Haloperidol failed prevent amphetamine seizures
Haloperidol decreased incidence seizures
haloperidol role suggest amphetamine reducing incidence seizures
dopamine haloperidol role suggest amphetamine reducing incidence seizures
haloperidol demonstrated ability reduce cocaine induced seizures
cocaethylene Cocaine cardiotoxity
Cocaine cardiotoxity
cocaethylene Cocaine model abuse cocaine
cocaethylene Cocaine model abuse cocaine and
cocaethylene Cocaine model abuse cocaine ethanol
cocaethylene Cocaine model abuse
Cocaine model abuse cocaine
Cocaine model abuse cocaine and
Cocaine model abuse cocaine ethanol
Cocaine model abuse
ethanol Cocaine cardiotoxity
ethanol Cocaine model abuse cocaine
ethanol Cocaine model abuse cocaine and
ethanol Cocaine model abuse cocaine ethanol
ethanol Cocaine model abuse
cocaethylene due formed due toxicity cardiac
cocaethylene due formed due toxicity
CE cocaethylene due formed due toxicity cardiac
CE cocaethylene due formed due toxicity
cocaine metabolite formed due toxicity cardiac
cocaine metabolite formed due toxicity
ethanol presence formed due toxicity cardiac
ethanol presence formed due toxicity
CE role delineate cardiotoxicity
cocaine cardiotoxicity
ethanol cocaine cardiotoxicity
cocaethylene concentrations associated depression myocardial
cocaethylene concentrations associated depression
alkylxanthines testing toxicity
cycloheximide treated rats epileptic
cycloheximide subject epilepticus status
cycloheximide subject epilepticus
CHX layer subject epilepticus status
CHX layer subject epilepticus
carbamazepine had had had hemosiderosis resulting shock cardiogenic
carbamazepine had had had hemosiderosis resulting shock
carbamazepine induced myocarditis eosinophilic
carbamazepine induced myocarditis
propranolol therapy correlated invariable conclude reported apnea hypoglycemia
propranolol therapy correlated invariable bradycardia
propranolol therapy correlated invariable conclude reported apnea neonatal
propranolol therapy correlated invariable conclude reported apnea
propranolol therapy correlated invariable conclude reported apnea hyperbilirubinemia
propranolol therapy correlated invariable conclude reported apnea polycythemia
Crocin reduced inhibition activation hyperlipemia
Crocin considered agent diazinon induced hyperlipemia
losartan treated progression nephropathy
losartan treated progression nephropathy rats hypertensive
adriamycin nephropathy rats hypertensive
adriamycin nephropathy
losartan blocker effects investigate slowing progression renal
losartan blocker effects investigate slowing progression disease
losartan blocker effects investigate slowing nephropathy
losartan blocker effects investigate slowing progression rats hypertensive
adriamycin progression rats hypertensive
ADR adriamycin progression rats hypertensive
angiotensin type effects investigate slowing progression rats hypertensive
II type effects investigate slowing progression rats hypertensive
adriamycin progression renal
adriamycin progression disease
adriamycin progression slowing nephropathy
ADR adriamycin progression renal
ADR adriamycin progression disease
ADR adriamycin progression slowing nephropathy
angiotensin type effects investigate slowing progression renal
angiotensin type effects investigate slowing progression disease
II type effects investigate slowing progression renal
II type effects investigate slowing progression disease
angiotensin type effects investigate slowing nephropathy
II type effects investigate slowing nephropathy
losartan treatment Short glomerulosclerosis
losartan treatment Short glomerulosclerosis resulting proteinuria
losartan treatment showed reduction glomerulosclerosis associated preventing proteinuria failure chronic
losartan treatment showed reduction glomerulosclerosis associated preventing proteinuria failure renal
losartan treatment showed reduction glomerulosclerosis associated preventing proteinuria failure
losartan treatment showed reduction glomerulosclerosis associated progression atrophy fibrosis interstitial
losartan treatment showed reduction glomerulosclerosis associated progression atrophy fibrosis
losartan treatment showed reduction glomerulosclerosis
losartan treatment showed reduction glomerulosclerosis associated preventing proteinuria
losartan treatment showed reduction glomerulosclerosis associated progression atrophy
Losartan reduced clearance nephropathy
ADR nephropathy
urea clearance uraemia
urea clearance nephropathy
Losartan reduced clearance uraemia
ADR infiltration atrophy
losartan prevent nephropathy
ADR infiltration prevent nephropathy
losartan prevent infiltration fibrosis
losartan prevent infiltration atrophy
ADR infiltration fibrosis
Losartan reduces rate induced end
Losartan reduces rate disease stage
Losartan reduces rate disease renal
Losartan reduces rate disease
ADR progression rate induced end
ADR progression rate disease stage
ADR progression rate disease renal
ADR progression rate disease
Losartan reduces rate induced glomerulosclerosis focal
Losartan reduces rate induced glomerulosclerosis segmental
Losartan reduces rate induced glomerulosclerosis
phenylephrine determined hypotension
Phe phenylephrine determined hypotension
sodium hypertension
nitroprusside hypertension
SN nitroprusside hypertension
AVP administration reduced hypotension
neuroleptic expression intact need promotes catalepsy
neuroleptic induced catalepsy
atropine blocker disrupted haloperidol induced catalepsy
acetylcholine inhibitor injection prevented catalepsy
hemicholinium injection prevented catalepsy
neuroleptics produced catalepsy
lithium therapy developed bradyarrhythmia
lithium conduct prompted findings patient receiving therapy developed bradyarrhythmia
lithium therapy receiving patient bipolar
lithium therapy receiving patient findings prompted conduct study patients bipolar
lithium conduct prompted findings patient bipolar
lithium conduct study patients bipolar
lithium non treated hypercalcemias related malignancies
lithium patients conditions malignancies
lithium sex age treated patients bipolar
lithium sex age included group included patients bipolar
lithium resulting diseases patients bipolar
botox injection Abductor paralysis
Botox injections paralysis
Botox injections dysphonia spasmodic
Botox injections dysphonia
Botox dose noted patients paralysis
Botox dose paralysis
Botox dose dose noted patients paralysis
Botox dose dose paralysis
Botox injection paralysis
Botox injections complication paralysis
Botox diffusion mechanism paralysis
statins are reported tolerated drugs cases drug
statins are reported injury induced
statins are reported injury liver
statins are reported injury
S d 312 312 S showed convulsions audiogenic
S d 312 312 S showed convulsions tonic
S d 312 312 S showed convulsions
312 312 312 S showed convulsions audiogenic
312 312 312 S showed convulsions tonic
312 312 312 S showed convulsions
l 312 S showed convulsions audiogenic
l 312 S showed convulsions tonic
l 312 S showed convulsions
S showed convulsions audiogenic
S showed convulsions tonic
S showed convulsions
312 S showed convulsions audiogenic
312 S showed convulsions tonic
312 S showed convulsions
S 312 S showed convulsions audiogenic
S 312 S showed convulsions tonic
S 312 S showed convulsions
312 312 S showed convulsions audiogenic
312 312 S showed convulsions tonic
312 312 S showed convulsions
d 312 312 S showed convulsions audiogenic
d 312 312 S showed convulsions tonic
d 312 312 S showed convulsions
calcium antagonists S showed convulsions audiogenic
calcium antagonists S showed convulsions tonic
calcium antagonists S showed convulsions
flunarizine that 34 o convulsions audiogenic
flunarizine that 34 o convulsions tonic
flunarizine that 34 o convulsions
S effects observed convulsions
312 S effects observed convulsions
d S effects observed convulsions
S effects observed observed convulsions
312 S effects observed observed convulsions
d S effects observed observed convulsions
N induced convulsions observed observed convulsions
methyl N induced convulsions observed observed convulsions
D N induced convulsions observed observed convulsions
aspartate N induced convulsions observed observed convulsions
N induced convulsions
methyl N induced convulsions
D N induced convulsions
aspartate N induced convulsions
S useful therapy types epilepsy
312 S useful therapy types epilepsy
d useful therapy types epilepsy
aracytine dose edema C lymphoma
C lymphoma
Ara developed C lymphomas
C lymphomas
Ara C associated hypothesize thought involved development shock syndrome adult
Ara C associated hypothesize thought involved development shock syndrome respiratory
Ara C associated hypothesize thought involved development shock syndrome distress
Ara C associated hypothesize thought involved development shock syndrome
C associated hypothesize thought involved development shock syndrome adult
C associated hypothesize thought involved development shock syndrome respiratory
C associated hypothesize thought involved development shock syndrome distress
C associated hypothesize thought involved development shock syndrome
phosphatidylserine exposure characterized eryptosis death result anemia
PS phosphatidylserine exposure characterized eryptosis death result anemia
estrogen sites evidence induced carcinomas renal
estrogen sites evidence induced carcinomas
Estrogen sites demonstrated autoradiography diethylstilbesterol induced carcinomas renal
Estrogen sites demonstrated autoradiography diethylstilbesterol induced carcinomas
estradiol H injection Radiolabelling increased nuclei cells tumor
silver grains nuclei cells tumor
estrogen nuclei cells carcinomas renal
estrogen nuclei cells carcinomas
estrogen carcinomas renal
estrogen carcinomas
tenofovir exposed persons investigation pattern injury kidney
tenofovir exposed persons investigation pattern injury
disoproxil fumarate tenofovir exposed persons investigation pattern injury kidney
disoproxil fumarate tenofovir exposed persons investigation pattern injury
fumarate tenofovir exposed persons investigation pattern injury kidney
fumarate tenofovir exposed persons investigation pattern injury
TDF criteria records disease kidney
TDF criteria records disease
TDF criteria records disease had features dysfunction kidney
TDF criteria records disease had features dysfunction tubular
TDF criteria records disease had features dysfunction
TDF criteria records found have features dysfunction glomerular
TDF criteria records found have features dysfunction
carbamazepine associated cases nystagmus downbeat
carbamazepine associated cases nystagmus
carbamazepine related nystagmus downbeat
carbamazepine related nystagmus
carbamazepine levels reduction resolved nystagmus
lead regulation learning exposed produces impairment cognitive
lead regulation learning exposed produces impairment
lead exposure absence produces impairment cognitive
lead exposure absence produces impairment
Pb exposure model using succimer agent treatment poisoning Pb
Pb exposure model using succimer agent treatment poisoning
succimer agent treatment poisoning Pb
succimer agent treatment poisoning
Pb exposure produced impairments
Pb exposure produced impairments learning in
Pb exposure produced impairments learning
Pb exposure produced impairments learning attention
Pb exposure produced impairments learning control inhibitory
Pb exposure produced impairments learning control
Pb exposure produced impairments learning and
Pb exposure produced impairments learning regulation arousal
Pb exposure produced impairments learning regulation
Pb seen dysfunction areas paralleling produced impairments
Pb seen dysfunction areas paralleling produced impairments learning in
Pb seen dysfunction areas paralleling produced impairments learning
Pb seen dysfunction areas paralleling produced impairments learning attention
Pb seen dysfunction areas paralleling produced impairments learning control inhibitory
Pb seen dysfunction areas paralleling produced impairments learning control
Pb seen dysfunction areas paralleling produced impairments learning and
Pb seen dysfunction areas paralleling produced impairments learning regulation arousal
Pb seen dysfunction areas paralleling produced impairments learning regulation
succimer treatment produced dysfunction cognitive
succimer treatment produced dysfunction cognitive and
succimer treatment produced dysfunction cognitive affective
succimer treatment produced dysfunction
Pb exposed rats treatment produced dysfunction cognitive
Pb exposed rats treatment produced dysfunction cognitive and
Pb exposed rats treatment produced dysfunction cognitive affective
Pb exposed rats treatment produced dysfunction
Pb regimen produced that produced dysfunction cognitive
Pb regimen produced that produced dysfunction cognitive and
Pb regimen produced that produced dysfunction cognitive affective
Pb regimen produced that produced dysfunction
Pb exposure due deficits cognitive
Pb exposure due deficits
rifampicin antibodies failure renal
rifampicin antibodies failure
rifampicin reintroduction induced failure acute
rifampicin reintroduction induced failure renal
rifampicin reintroduction induced failure
ethanol extract effect isoproterenol induced infarction myocardial
ethanol extract effect isoproterenol induced infarction
Terminalia chebula injury myocardial
Terminalia chebula injury
chebula injury myocardial
chebula injury
ethanolic extract effect examined isoproterenol induced damage myocardial
ethanolic extract effect examined isoproterenol induced damage
extract effect examined isoproterenol induced damage myocardial
extract effect examined isoproterenol induced damage
of fruits extract effect examined isoproterenol induced damage myocardial
of fruits extract effect examined isoproterenol induced damage
Terminalia fruits extract effect examined isoproterenol induced damage myocardial
Terminalia fruits extract effect examined isoproterenol induced damage
chebula fruits extract effect examined isoproterenol induced damage myocardial
chebula fruits extract effect examined isoproterenol induced damage
fruits extract effect examined isoproterenol induced damage myocardial
fruits extract effect examined isoproterenol induced damage
L effect treatment patients parkinsonian
dopa treatment patients parkinsonian
L treated patients parkinsonian
dopa L treated patients parkinsonian
potassium excretion dopa L influence studied patients hypokalemia
potassium concentration flow determination studied patients hypokalemia
potassium excretion flow determination studied patients hypokalemia
sodium flow determination studied patients hypokalemia
sodium potassium excretion flow determination studied patients hypokalemia
aldosterone potassium excretion flow determination studied patients hypokalemia
corticotropin releasing releasing modulate response hypercapnic
thyrotropin hormone releasing releasing modulate response hypercapnic
diethylcarbamazine loiasis
diethylcarbamazine treatment cases observed filariasis
DEC diethylcarbamazine treatment cases observed filariasis
Vincristine given child leukaemia
domperidone potentiate mirtazapine associated syndrome restless
domperidone potentiate mirtazapine associated syndrome legs
domperidone potentiate mirtazapine associated syndrome
levodopa agonists improved symptoms RLS
levodopa agonists improved induce symptoms RLS
dopamine levodopa agonists improved symptoms RLS
dopamine levodopa agonists improved induce symptoms RLS
dopamine antagonists induce improved symptoms RLS
dopamine antagonists induce symptoms RLS
domperidone induce symptoms RLS
dopamine antagonist domperidone induce symptoms RLS
domperidone therapy added developed dyspepsia postprandial
domperidone therapy added developed dyspepsia
mirtazapine RLS added developed dyspepsia postprandial
mirtazapine RLS added developed dyspepsia
domperidone therapy added RLS
domperione effect support relationship use symptoms RLS
domperione RLS
dopamine antagonists individuals associated RLS
vitamin E lack due Myopathy
E lack due Myopathy
vitamin E lack due induced myopathy
E lack due induced myopathy
steroids using obtained departments patients myopathic
steroids using obtained results encouraged investigate doses rats rendered myopathic
CIBA Dianabol agent effects investigate encouraged results obtained departments patients myopathic
CIBA Dianabol agent effects investigate doses rats rendered myopathic
vitamin E rendered rats doses investigate encouraged results obtained departments patients myopathic
E rendered rats doses investigate encouraged results obtained departments patients myopathic
vitamin E rendered myopathic
E rendered myopathic
Dianabol agent effects investigate encouraged results obtained departments patients myopathic
Dianabol agent effects investigate doses rats rendered myopathic
steroids disease myopathic
steroids disease
vitamin E certainly unknown carried have conclude affirming efficacy steroids disease myopathic
vitamin E certainly unknown carried have conclude affirming efficacy steroids disease
E certainly unknown carried have conclude affirming efficacy steroids disease myopathic
E certainly unknown carried have conclude affirming efficacy steroids disease
oral contraceptives hypertension association artery aneurysm case reported patient locked
oral contraceptives hypertension association artery aneurysm case reported syndrome in
oral contraceptives hypertension association artery aneurysm case reported syndrome
contraceptives hypertension association artery aneurysm case reported patient locked
contraceptives hypertension association artery aneurysm case reported syndrome in
contraceptives hypertension association artery aneurysm case reported syndrome
oral contraceptives hypertension
contraceptives hypertension
adriamycin ribose d effect evaluation evoked cardiotoxicity
d effect evaluation evoked cardiotoxicity
ribose d effect evaluation evoked cardiotoxicity
d induced myocardiopathy
ribose d induced myocardiopathy
Adriamycin evoked toxicity cardiac
Adriamycin evoked toxicity
ADR influence cardiotoxicity
D influence cardiotoxicity
ribose D influence cardiotoxicity
Famotidine H used prevention ulcers
propofol delirium
nitric oxide convulsions
oxide convulsions
GABA receptors blockage trough convulsions
L arginine NAME effects due role observed models epilepsy
NAME effects due role observed models epilepsy
Nitric oxide has role observed models epilepsy
oxide has role observed models epilepsy
NO oxide has role observed models epilepsy
NO syntheses precursor arginine NAME effects due role observed models epilepsy
L NAME effects due role observed models epilepsy
arginine NAME effects due role observed models epilepsy
NO effects determine characteristics epilepsy
lindane characteristics epilepsy
L administration arginine increased incidence convulsion
arginine increased incidence convulsion
L administration arginine increased shortened convulsion
arginine increased shortened convulsion
L pretreatment decreased incidence convulsion
NAME L pretreatment decreased incidence convulsion
L pretreatment decreased convulsion
NAME L pretreatment decreased convulsion
L pretreatment decreased convulsion dose convulsive
NAME L pretreatment decreased convulsion dose convulsive
NO plays model seizures
glucose transport followed system dysfunction associated dementia
glucose GLUT transport followed system dysfunction associated dementia
glucose metabolism dysfunction associated dementia
galactose injections induce deterioration memory
galactose injections induce deterioration
galactose treatment effects tested induce deterioration memory
galactose treatment effects tested induce deterioration
galactose exposure have worth investigating improvement deficits associated hypometabolism AD
galactose exposure have worth investigating improvement deficits associated hypometabolism glucose
galactose exposure have worth investigating improvement deficits associated hypometabolism
betaine isoproterenol pathways transducer Regulation injury myocardial
betaine isoproterenol pathways transducer Regulation injury
isoproterenol pathways transducer Regulation injury myocardial
isoproterenol pathways transducer Regulation injury
betaine effects investigate ischemia myocardial
betaine effects investigate ischemia
betaine administration reduced prevented remodeling ventricular
betaine administration reduced prevented remodeling
betaine damage myocardial
betaine damage
betaine pretreatment attenuated isoproterenol induced ischemia myocardial
betaine pretreatment attenuated isoproterenol induced ischemia
Temocapril modulates injury nephrosis
puromycin nephrosis injury glomerular
puromycin nephrosis injury
aminonucleoside nephrosis injury glomerular
aminonucleoside nephrosis injury
angiotensin SH Temocapril modulates injury nephrosis
Temocapril modulates injury glomerular
Temocapril modulates injury
angiotensin SH Temocapril modulates injury glomerular
angiotensin SH Temocapril modulates injury
temocapril administration acting inhibited hypertrophy
temocapril administration acting inhibited angiotensin converting inhibitor proteinuria
angiotensin converting inhibitor proteinuria
angiotensin inhibited acting induced rats nephrotic
temocapril administration acting induced rats nephrotic
puromycin aminonucleoside prevented glomerulosclerosis
aminonucleoside prevented glomerulosclerosis
PAN aminonucleoside prevented glomerulosclerosis
angiotensin inhibited hypertrophy
temocapril administration acting inhibited prevented glomerulosclerosis
puromycin aminonucleoside prevented inhibited acting induced rats nephrotic
aminonucleoside prevented inhibited acting induced rats nephrotic
PAN aminonucleoside prevented inhibited acting induced rats nephrotic
angiotensin inhibited prevented glomerulosclerosis
puromycin aminonucleoside prevented inhibited hypertrophy
aminonucleoside prevented inhibited hypertrophy
PAN aminonucleoside prevented inhibited hypertrophy
Temocapril attenuate proteinuria
PAN group weeks % was index glomerulosclerosis
temocapril effective protected rats neprotic
folinic acid C treatment cancer gastric
folinic acid C treatment cancer
acid C treatment cancer gastric
acid C treatment cancer
5 dose High acid C treatment cancer gastric
5 dose High acid C treatment cancer
fluorouracil High acid C treatment cancer gastric
fluorouracil High acid C treatment cancer
mitomycin C treatment cancer gastric
mitomycin C treatment cancer
C treatment cancer gastric
C treatment cancer
folinic acid fluorouracil BACKGROUND shown effective toxicity
acid fluorouracil BACKGROUND shown effective toxicity
FA acid fluorouracil BACKGROUND shown effective toxicity
folinic acid part regimens cancer gastric
folinic acid part regimens cancer
acid part regimens cancer gastric
acid part regimens cancer
folinic acid fluorouracil BACKGROUND AGC
acid fluorouracil BACKGROUND AGC
FA acid part regimens cancer gastric
FA acid part regimens cancer
FA acid fluorouracil BACKGROUND AGC
5 infusion BACKGROUND fluorouracil acid part regimens cancer gastric
5 infusion BACKGROUND fluorouracil acid part regimens cancer
fluorouracil acid part regimens cancer gastric
fluorouracil acid part regimens cancer
5 infusion BACKGROUND AGC
fluorouracil BACKGROUND AGC
5 fluorouracil acid part regimens cancer gastric
5 fluorouracil acid part regimens cancer
FU 5 fluorouracil acid part regimens cancer gastric
FU 5 fluorouracil acid part regimens cancer
5 fluorouracil BACKGROUND AGC
FU 5 fluorouracil BACKGROUND AGC
5 infusion BACKGROUND shown effective toxicity
fluorouracil BACKGROUND shown effective toxicity
5 fluorouracil BACKGROUND shown effective toxicity
FU 5 fluorouracil BACKGROUND shown effective toxicity
FA FU study found rate toxicity
mitomycin C FU study found rate toxicity
C FU study found rate toxicity
MMC study found rate toxicity
5 bolus study found rate toxicity
FU study found rate toxicity
FA hour 2000 recruited AGC
5 preceded 2000 recruited AGC
FU mg preceded 2000 recruited AGC
FA CONCLUSIONS regimen AGC
5 dose High CONCLUSIONS regimen AGC
FU FA CONCLUSIONS regimen AGC
MMC regimen AGC
cisplatin alternative serve has considered occur HUS
galantamine disorder autistic
galantamine disorder
galantamine use assess treatment interfering children autism
galantamine trial METHODS children autism
galantamine was appeared beneficial treatment interfering children autism dyscontrol behavioral
galantamine was appeared beneficial treatment interfering children autism dyscontrol
galantamine was appeared beneficial treatment interfering children autism aggression
galantamine was appeared beneficial treatment interfering children autism inattention
galantamine was appeared beneficial treatment interfering children autism
Valproate induced encephalopathy
Valproate induced effect encephalopathy
valproate treatment effect encephalopathy
valproate due epilepsy
DSP pretreatment reduced induced hyperactivity
4 pretreatment reduced induced hyperactivity
DSP blocked rearings amphetamine stereotypies
4 DSP blocked rearings amphetamine stereotypies
amphetamine stereotypies
amphetamine hyperactivity reduction blocked noradrenaline uptake blocking agent prevents action neurotoxic
desipramine agent prevents action neurotoxic
noradrenaline blocked reduction hyperactivity
noradrenaline uptake blocking agent prevents action neurotoxic
DSP induced hyperactivity reduction blocked noradrenaline uptake blocking agent prevents action neurotoxic
4 DSP induced hyperactivity reduction blocked noradrenaline uptake blocking agent prevents action neurotoxic
DSP action neurotoxic
4 DSP action neurotoxic
DSP induced hyperactivity
4 DSP induced hyperactivity
DSP action prevents agent blocking uptake noradrenaline blocked reduction hyperactivity
4 DSP action prevents agent blocking uptake noradrenaline blocked reduction hyperactivity
amphetamine hyperactivity
desipramine agent blocking uptake noradrenaline blocked reduction hyperactivity
barium ingestion induced dysfunction hypersensitivity
chloride ingestion induced dysfunction hypersensitivity
barium ingestion induced dysfunction Cardiovascular
barium ingestion induced dysfunction
chloride ingestion induced dysfunction Cardiovascular
chloride ingestion induced dysfunction
sodium pentobarbital dysfunction hypersensitivity
pentobarbital dysfunction hypersensitivity
sodium pentobarbital dysfunction Cardiovascular
sodium pentobarbital dysfunction
pentobarbital dysfunction Cardiovascular
pentobarbital dysfunction
Barium hooded characterized hypertension
barium treatment month evident hypertension
barium induced disturbances
barium induced system within
barium induced system the
barium induced system cardiovascular
barium induced system
sodium pentobarbital system hypersensitivity
pentobarbital system hypersensitivity
barium effect aspect hypersensitivity
barium exposure induced disorder existence suggest contractility disturbances metabolic
barium exposure induced disorder existence suggest contractility disturbances
sodium pentobarbital system hypersensitivity contractility disturbances metabolic
sodium pentobarbital system hypersensitivity contractility disturbances
pentobarbital system hypersensitivity contractility disturbances metabolic
pentobarbital system hypersensitivity contractility disturbances
sodium pentobarbital system hypersensitivity
pentobarbital system hypersensitivity
barium exposure induced disorder cardiomyopathic
barium exposure induced disorder
sodium pentobarbital system hypersensitivity contractility suggest existence disorder cardiomyopathic
sodium pentobarbital system hypersensitivity contractility suggest existence disorder
pentobarbital system hypersensitivity contractility suggest existence disorder cardiomyopathic
pentobarbital system hypersensitivity contractility suggest existence disorder
barium exposure induced disorder existence suggest contractility hypersensitivity
Amiodarone mass glomerulonephritis disease patient valvular
Amiodarone mass glomerulonephritis disease heart
Amiodarone mass glomerulonephritis disease
Amiodarone is threatening tachycardia
Amiodarone is threatening anti drug arrhythmic
amiodarone developed mass proteinuria
amiodarone developed patient case disease valvular
amiodarone developed patient case disease heart
amiodarone developed patient case disease
amiodarone lesion indicating containing composed suspected cancer lung
amiodarone lesion indicating containing composed suspected cancer
amiodarone lesion neoplasm
amiodarone treatment complication suggests difficult diagnosis amiodarone lesion neoplasm
